DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for NA are 3814

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_0012	BHSA	NA	NA	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (45 %)	NA	29033372
DrugRepV_0015	Chlorogenic Acid	NA	Cancer	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (10 %)	Investigational	29033372
DrugRepV_0016	Tetrandrine	NA	Congestive circulatory disorder and inflammatory diseases	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (0 %)	Experimental	29033372
DrugRepV_0019	Delphinidin Chloride	NA	NA	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Increase (110 %)	NA	29033372
DrugRepV_0073	Sunitinib-Erlotinib	NA	NA	Ebola virus	rVSV-GP EBOV	NA	Flow cytometry	Decrease	NA	28240606
DrugRepV_0074	Sunitinib-Erlotinib	NA	NA	Ebola virus	Mouse adapted strain	NA	NA	Increase	NA	28240606
DrugRepV_0090	Imukin	NA	NA	Zika virus	Puerto Rico strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	28185815
DrugRepV_0091	Imukin	NA	NA	Zika virus	Puerto Rico strain PRVABC-59	NA	Real-time PCR	Decrease (>2 Log viral titer (copies/ml))	Approved, Investigational	28185815
DrugRepV_0092	Imukin	NA	NA	Zika virus	Puerto Rico strain PRVABC-59	NA	Plaque assay	Decrease (>90 %)	Approved, Investigational	28185815
DrugRepV_0097	Ki8751	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0100	GSK2656157	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect	NA	28099856
DrugRepV_0110	RGFP966	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0116	Methotrexate	NA	Gestational choriocarcinoma | Chorioadenoma destruens | Hydatidiform mole | Meningeal leukemia | Breast cancer | Epidermoid cancers of the head and neck | Lung cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Approved	28099856
DrugRepV_0117	PF-04691502	NA	Breast Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect	Investigational	28099856
DrugRepV_0120	Navitoclax	NA	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	28099856
DrugRepV_0123	GZD824	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect (No significant effect No significant effect)	NA	28099856
DrugRepV_0124	VE-822	NA	Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect (No significant effect No significant effect)	Investigational	28099856
DrugRepV_0125	Amuvatinib	NA	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect (No significant effect No significant effect)	Investigational	28099856
DrugRepV_0126	NVP-BHG712	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect (No significant effect No significant effect)	NA	28099856
DrugRepV_0127	WAY-600	NA	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0128	YM201636	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect	NA	28099856
DrugRepV_0129	RGFP966	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0130	QNZ	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0133	STF-118804	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0144	AMG-458	NA	Cancer	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (60 %)	NA	28099856
DrugRepV_0145	AMG-458	NA	Cancer	Zika virus	MR766	NA	Immunoflourescence assay	No significant effect (20 %)	NA	28099856
DrugRepV_0146	AMG-458	NA	Cancer	Zika virus	MR766	NA	Immunoflourescence assay	No significant effect (10 %)	NA	28099856
DrugRepV_0165	AMG-458	NA	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (60 %)	NA	28099856
DrugRepV_0166	AMG-458	NA	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (70 %)	NA	28099856
DrugRepV_0167	AMG-458	NA	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect (30 %)	NA	28099856
DrugRepV_0205	Toremifene-Clarithromycin-Posaconazole	NA	NA	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	NA	27890675
DrugRepV_0206	Toremifene-Mefloquine-Posaconazole	NA	NA	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	NA	27890675
DrugRepV_0207	Chloroquine-Maprotiline-Azithromycin	NA	Malaria and Depression	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27890675
DrugRepV_0213	Toremifene-Clarithromycin-Posaconazole	NA	NA	Ebola virus	EBOLA/Mayinga-eGFP	NA	Immunoflourescence assay	Decrease (>90 %)	NA	27890675
DrugRepV_0214	Toremifene-Mefloquine-Posaconazole	NA	NA	Ebola virus	EBOLA/Mayinga-eGFP	NA	Immunoflourescence assay	Decrease (74 %)	NA	27890675
DrugRepV_0217	Alvespimycin	NA	Cancer	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (3.72 ± 0.18 Ct)	Investigational	27801778
DrugRepV_0218	Alvespimycin	NA	Cancer	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?0.63 ± 1.39 Ct)	Investigational	27801778
DrugRepV_0231	JB1a	NA	NA	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?4.02 ± 0.13 Ct)	NA	27801778
DrugRepV_0232	JB1a	NA	NA	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?5.48 ± 0.50 Ct)	NA	27801778
DrugRepV_0239	Aimspro	NA	Multiple sclerosis	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?2.03 ± 0.95 Ct)	Phase II	27801778
DrugRepV_0240	Aimspro	NA	Multiple sclerosis	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?4.60 ± 1.15 Ct)	Phase II	27801778
DrugRepV_0241	NCK-8	NA	NA	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (>10 Ct)	NA	27801778
DrugRepV_0242	NCK-8	NA	NA	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (>10 Ct)	NA	27801778
DrugRepV_0252	Alvespimycin	NA	Cancer	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (0.44 ± 0.06 Ct)	Investigational	27801778
DrugRepV_0257	NCK-8	NA	NA	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Decrease (1.54 ± 0.44 Ct)	NA	27801778
DrugRepV_0259	Alvespimycin	NA	Cancer	Ebola virus	ME718-1976/Yambuku-Ecran	NA	NA	No significant effect	Investigational	27801778
DrugRepV_0261	NCK-8	NA	NA	Ebola virus	ME718-1976/Yambuku-Ecran	NA	NA	No significant effect	NA	27801778
DrugRepV_0302	PIK-75	NA	NA	Influenza virus	A/Anhui/1/ 2013		Immunoflourescence assay	Decrease (50 %)	NA	26192013
DrugRepV_0303	PIK-75	NA	NA	Influenza virus	A/California/04/09		Immunoflourescence assay	Decrease (50 %)	NA	26192013
DrugRepV_0304	PIK-75	NA	NA	Influenza virus	A/Philippines/2/82-X79		Immunoflourescence assay	Decrease (50 %)	NA	26192013
DrugRepV_0309	PIK-75	NA	NA	Influenza virus	A/Mississippi/3/01 wt		TCID50 assay	Decrease (~1 Log10 virus titer (TCID50/ml))	NA	26192013
DrugRepV_0310	PIK-75	NA	NA	Influenza virus	A/Mississippi/3/01 H275Y		TCID50 assay	Decrease (~1 Log10 virus titer (TCID50/ml))	NA	26192013
DrugRepV_0315	PIK-75	NA	NA	Influenza virus	A/Mississippi/3/01 wt		Immunoflourescence assay	Decrease (90 %)	NA	26192013
DrugRepV_0316	PIK-75	NA	NA	Influenza virus	A/Mississippi/3/01 H275Y		Immunoflourescence assay	Decrease (85 %)	NA	26192013
DrugRepV_0406	Quinacrine Dihydrochloride	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Investigational	26041706
DrugRepV_0441	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Investigational	26041706
DrugRepV_0469	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Investigational	26041706
DrugRepV_0498	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	EBOV-VLP	NA	Flow cytometry	No significant effect	Investigational	26041706
DrugRepV_0551	Tilorone	NA	Acquired immunodeficiency syndrome	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0559	Nitrovin	NA	NA	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	NA	26038505
DrugRepV_0564	Cyclomethycaine	NA	Anesthesia	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Withdrawn	26038505
DrugRepV_0567	Azaclorzine	NA	Anginal	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	NA	26038505
DrugRepV_0712	Aminoquinoline-13	NA	Malaria	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (50 %)	NA	23577127
DrugRepV_0716	Aminoquinoline-13	NA	Malaria	Marburg virus	Musoke	NA	Immunoflourescence assay	Decrease (50 %)	NA	23577127
DrugRepV_0720	Aminoquinoline-13	NA	Malaria	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (50 %)	NA	23577127
DrugRepV_0724	Aminoquinoline-13	NA	Malaria	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	Decrease (50 %)	NA	23577127
DrugRepV_0772	Dactinomycin	NA	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.435 %)	Approved	27476412
DrugRepV_0773	Methotrexate	NA	Gestational choriocarcinoma | Chorioadenoma destruens | Hydatidiform mole | Meningeal leukemia | Breast cancer | Epidermoid cancers of the head and neck | Lung cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (97.715 %)	Approved	27476412
DrugRepV_0896	Prilocaine Hydrochloride	NA	Anesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.97 %)	Approved	27476412
DrugRepV_0955	Guanfacine Hydrochloride	NA	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.975 %)	Approved, Investigational	27476412
DrugRepV_0985	Mestranol	NA	Contraception	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.56 %)	Approved	27476412
DrugRepV_0989	Ursodiol	NA	Gallstone and cholestatic forms of liver diseases including primary biliary cirrhosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.78 %)	Approved	27476412
DrugRepV_0997	Metaxalone	NA	Musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.445 %)	Approved	27476412
DrugRepV_1000	Beclomethasone Dipropionate	NA	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.25 %)	Approved	27476412
DrugRepV_1033	Zileuton	NA	Asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.355 %)	Approved, Withdrawn	27476412
DrugRepV_1039	Tiludronate Disodium	NA	Paget disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.63 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1067	Midodrine Hydrochloride	NA	Orthostatic Hypotension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.235 %)	Approved	27476412
DrugRepV_1115	Niacin	NA	Hyperlipidemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.67 %)	Approved, Investigational, Nutraceutical	27476412
DrugRepV_1149	Rizatriptan Benzoate	NA	Migraine disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.98 %)	Approved	27476412
DrugRepV_1205	Naringenin	NA	NA	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.34 %)	Experimental	27476412
DrugRepV_1224	Galantamine Hydrobromide	NA	Alzheimer's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.96 %)	Approved	27476412
DrugRepV_1269	Carglumic Acid	NA	Hyperammonaemia in patients with N-acetylglutamate synthase (NAGS) deficiency	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.855 %)	Approved	27476412
DrugRepV_1290	Gentamycin Sulfate	NA	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.715 %)	Approved	27476412
DrugRepV_1337	Phytonadione	NA	Haemorrhagic conditions in infants | Antidote for coumarin anticoagulants in hypoprothrombinaemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.655 %)	Approved, Investigational	27476412
DrugRepV_1353	Tetrahydrozoline Hydrochloride	NA	Discomfort and redness of the eye due to minor eye irritations	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.315 %)	Approved	27476412
DrugRepV_1394	Tinidazole	NA	Trichomonasis | Amebiasis | Giardiasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.3 %)	Approved	27476412
DrugRepV_1417	Difluprednate	NA	Anterior uveitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.575 %)	Approved	27476412
DrugRepV_1511	Acyclovir Zovirax	NA	Viral infections (Herpes simplex, Zoster and varicella zoster)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.46 %)	Approved	27476412
DrugRepV_1564	Desmethyl Erlotinib	NA	Cancer	Rift Valley fever virus	MP12-Luc	NA	Luciferase reporter assay	Decrease (65 %)	Approved, Investigational	26217313
DrugRepV_1615	Quinacrine Hydrochloride	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	Recombinant, infectious Ebola virus encoding green fluorescent protein	NA	Cell based assay	Decrease (50 %)	Investigational	26834994
DrugRepV_1617	Tilorone Dihydrochloride	NA	Viral infections	Ebola virus	Recombinant, infectious Ebola virus encoding green fluorescent protein	NA	Cell based assay	Decrease (50 %)	NA	26834994
DrugRepV_1623	Lavendustin A	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1628	D-serine	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Approved	24991006
DrugRepV_1632	2,2-Dipyridyl Disulfide	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Experimental	24991006
DrugRepV_1635	Pobilukast	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1636	PD-180970	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1637	Methylanthraniloyl guanosine triphosphate	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1638	Mastoparan	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1639	Hexadimethrine Bromide	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1640	Dideooxyforskolin	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1641	Compound 48/80	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1642	3-(N-methylanthraniloyl)-2-deoxy-ATP	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1643	3-Aminotriazole	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1644	2/3-O-N-methyanthraniloyl-ITP-gamma-S	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1645	2/3-O-N-methyanthraniloyl-GTP-gamma-S	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1646	2-(or3)-O-(N-methylanthranioyl)ATP	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1647	2-Aminopurine	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1648	1-cyclopropyl-3	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1649	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	MR766	NA	Cell viability assay	Decrease (98.7 %)	Investigational	27571349
DrugRepV_1652	Ensulizole	NA	Sunburn	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1654	Isoliquirtigenin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1658	Vidofludimus	NA	Crohn disease; Inflammatory bowel diseases and Rheumatoid arthritis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1659	SB-366791	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1660	Emodin	NA	Polycystic Kidney	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1661	Diphenyl isophthalate	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1662	Benzoylpas	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1663	Fenobam	NA	Fragile X Syndrome	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1665	Drometrizole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1666	PHA-690509	NA	Cancer	Zika virus	MR766	NA	Cell viability assay	Decrease (81.9 %)	NA	27571349
DrugRepV_1670	Cinanserin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1671	5-Nitro-2-(3-phenylpropylamino)benzoic Acid	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1672	Veliflapon	NA	Myocardial infarction (Heart attack)	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Phase III	27571349
DrugRepV_1676	Naringenin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1678	Fanetizole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1681	CAY10505	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1682	Hesperetin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1687	Piraxostat	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease (34.7 %)	NA	27571349
DrugRepV_1688	Albendazole oxide	NA	Parasitic infections	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1689	Tyrphostin AG 494	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1693	RITA	NA	Cancer	Zika virus	MR766	NA	Cell viability assay	Decrease (81.7 %)	NA	27571349
DrugRepV_1695	BF-170-hydrochloride	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease (65.8 %)	NA	27571349
DrugRepV_1697	Tribromsalan	NA	Bacterial infections	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1698	Pifexole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1699	Formononetin	NA	Postmenopausal Osteopenia	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1701	Tranilast	NA	Bronchial asthma | Keloid and hypertrophic scar | Allergic disorders such as asthma, allergic rhinitis | Atopic dermatitis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1702	Benzylparaben	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved, Experimental	27571349
DrugRepV_1703	2-Ethoxylethyl-p-methoxycinnamate	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1705	Nemorubicin	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease	NA	27571349
DrugRepV_1706	Rutaecarpine	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1707	MPEP	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1708	5,7-Dihydroxyflavone	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1711	2 Amino-6-nitrobenzothiazole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1713	Enfenamic Acid	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1714	Fenaminosulf	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1715	AS-252424	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1716	Phenserine	NA	Alzheimer's disease	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1718	Alizarin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1720	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	MR766	NA	Cell viability assay	Decrease	Investigational	27571349
DrugRepV_1723	Ensulizole	NA	Sunburn	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1725	Isoliquirtigenin	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease (36.3 %)	Experimental	27571349
DrugRepV_1729	Vidofludimus	NA	Crohn disease; Inflammatory bowel diseases and Rheumatoid arthritis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1730	SB-366791	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1731	Emodin	NA	Polycystic Kidney	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1732	Diphenyl isophthalate	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1733	Benzoylpas	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1734	Fenobam	NA	Fragile X Syndrome	Zika virus	MR766	NA	Cell viability assay	Decrease (60.5 %)	Investigational	27571349
DrugRepV_1736	Drometrizole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1737	PHA-690509	NA	Cancer	Zika virus	MR766	NA	Cell viability assay	Decrease	NA	27571349
DrugRepV_1741	Cinanserin	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease (56.9 %)	NA	27571349
DrugRepV_1742	5-Nitro-2-(3-phenylpropylamino)benzoic Acid	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1743	Veliflapon	NA	Myocardial infarction (Heart attack)	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Phase III	27571349
DrugRepV_1747	Naringenin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1749	Fanetizole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1752	CAY10505	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1753	Hesperetin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1758	Piraxostat	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease (60.3 %)	NA	27571349
DrugRepV_1759	Albendazole oxide	NA	Parasitic infections	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1760	Tyrphostin AG 494	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (45.6 %)	NA	27571349
DrugRepV_1764	RITA	NA	Cancer	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1766	BF-170-hydrochloride	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1768	Tribromsalan	NA	Bacterial infections	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1769	Pifexole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1770	Formononetin	NA	Postmenopausal Osteopenia	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1772	Tranilast	NA	Bronchial asthma | Keloid and hypertrophic scar | Allergic disorders such as asthma, allergic rhinitis | Atopic dermatitis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1773	Benzylparaben	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved, Experimental	27571349
DrugRepV_1774	2-Ethoxylethyl-p-methoxycinnamate	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1776	Nemorubicin	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease	NA	27571349
DrugRepV_1777	Rutaecarpine	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1778	MPEP	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1779	5,7-Dihydroxyflavone	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1782	2 Amino-6-nitrobenzothiazole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1784	Enfenamic Acid	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1785	Fenaminosulf	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease (36.7 %)	NA	27571349
DrugRepV_1786	AS-252424	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1787	Phenserine	NA	Alzheimer's disease	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1789	Alizarin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1791	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	MR766	NA	Cell viability assay	Decrease (54.4 %)	Investigational	27571349
DrugRepV_1794	Ensulizole	NA	Sunburn	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1796	Isoliquirtigenin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	Experimental	27571349
DrugRepV_1800	Vidofludimus	NA	Crohn disease; Inflammatory bowel diseases and Rheumatoid arthritis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1801	SB-366791	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1802	Emodin	NA	Polycystic Kidney	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1803	Diphenyl isophthalate	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1804	Benzoylpas	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1805	Fenobam	NA	Fragile X Syndrome	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1807	Drometrizole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1808	PHA-690509	NA	Cancer	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1812	Cinanserin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1813	5-Nitro-2-(3-phenylpropylamino)benzoic Acid	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1814	Veliflapon	NA	Myocardial infarction (Heart attack)	Zika virus	MR766	NA	Cell viability assay	No significant effect	Phase III	27571349
DrugRepV_1818	Naringenin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	Experimental	27571349
DrugRepV_1820	Fanetizole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1823	CAY10505	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1824	Hesperetin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	Experimental	27571349
DrugRepV_1829	Piraxostat	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1830	Albendazole oxide	NA	Parasitic infections	Zika virus	MR766	NA	Cell viability assay	No significant effect	Experimental	27571349
DrugRepV_1831	Tyrphostin AG 494	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1835	RITA	NA	Cancer	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1837	BF-170-hydrochloride	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1839	Tribromsalan	NA	Bacterial infections	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1840	Pifexole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1841	Formononetin	NA	Postmenopausal Osteopenia	Zika virus	MR766	NA	Cell viability assay	No significant effect	Investigational	27571349
DrugRepV_1843	Tranilast	NA	Bronchial asthma | Keloid and hypertrophic scar | Allergic disorders such as asthma, allergic rhinitis | Atopic dermatitis	Zika virus	MR766	NA	Cell viability assay	No significant effect	Investigational	27571349
DrugRepV_1844	Benzylparaben	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved, Experimental	27571349
DrugRepV_1845	2-Ethoxylethyl-p-methoxycinnamate	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1847	Nemorubicin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1848	Rutaecarpine	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1849	MPEP	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1850	5,7-Dihydroxyflavone	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1853	2 Amino-6-nitrobenzothiazole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1855	Enfenamic Acid	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease (58.5 %)	NA	27571349
DrugRepV_1856	Fenaminosulf	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1857	AS-252424	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1858	Phenserine	NA	Alzheimer's disease	Zika virus	MR766	NA	Cell viability assay	No significant effect	Investigational	27571349
DrugRepV_1860	Alizarin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1862	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	MR766 (1947 Ugandan strain)	NA	Cell viability assay	Decrease (50 %)	Investigational	27571349
DrugRepV_1863	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	FSS13025 (2010 Cambodian strain)	NA	Cell viability assay	Decrease (50 %)	Investigational	27571349
DrugRepV_1864	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Cell viability assay	Decrease (50 %)	Investigational	27571349
DrugRepV_1865	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	NA	NA	Cell viability assay	Decrease (50 %)	Investigational	27571349
DrugRepV_1866	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	NA	NA	Cell viability assay	Decrease (50 %)	Investigational	27571349
DrugRepV_1867	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	NA	NA	Cell viability assay	Decrease (50 %)	Investigational	27571349
DrugRepV_1870	PHA-690509	NA	Cancer	Zika virus	NA	NA	Cell viability assay	Decrease (50 %)	NA	27571349
DrugRepV_1871	PHA-690509	NA	Cancer	Zika virus	NA	NA	Cell viability assay	Decrease (50 %)	NA	27571349
DrugRepV_1872	PHA-690509	NA	Cancer	Zika virus	MR766 (1947 Ugandan strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1873	PHA-690509	NA	Cancer	Zika virus	FSS13025 (2010 Cambodian strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1874	PHA-690509	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1875	PHA-690509	NA	Cancer	Zika virus	MR766 (1947 Ugandan strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1876	PHA-690509	NA	Cancer	Zika virus	FSS13025 (2010 Cambodian strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1877	PHA-690509	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1880	PHA-690509	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Enzyme-linked immunosorbent assay	Decrease	NA	27571349
DrugRepV_1882	PHA-690509	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Plaque assay	Decrease (50 %)	NA	27571349
DrugRepV_1885	PHA-690509	NA	Cancer	Zika virus	FSS13026	NA	Real-time PCR	Decrease (50 %)	NA	27571349
DrugRepV_1887	PHA-690509	NA	Cancer	Zika virus	FSS13026	NA	Real-time PCR	Decrease	NA	27571349
DrugRepV_1890	PHA-690509	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1891	PHA-690509	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1893	SNS-032	NA	Cancer	Zika virus	FSS13026	NA	NA	Decrease (50 %)	Investigational	27571349
DrugRepV_1895	AT7519	NA	Cancer	Zika virus	FSS13026	NA	NA	Decrease (50 %)	NA	27571349
DrugRepV_1897	RGB-286147	NA	NA	Zika virus	FSS13026	NA	NA	Decrease (50 %)	NA	27571349
DrugRepV_1899	Alvocidib	NA	Cancer	Zika virus	FSS13026	NA	NA	Decrease (50 %)	Experimental	27571349
DrugRepV_1900	PHA-690509	NA	Cancer	Zika virus	FSS13026	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1901	Alvocidib	NA	Cancer	Zika virus	FSS13026	NA	Western blot	Decrease (Decrease Band intensity)	Experimental	27571349
DrugRepV_1905	PHA-690509	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1906	Alvocidib	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	Experimental	27571349
DrugRepV_1965	Fenretinide-Butylated Hydroxyanisole	NA	NA	Influenza virus	Strain A/PR8/ 34		Plaque assay	No significant effect	Investigational	25313218
DrugRepV_2029	Levonordefrin	NA	Dental disorders	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Approved	26585243
DrugRepV_2070	Phenothrin	NA	NA	Lassa virus	LASVpv	NA	Luciferase reporter assay	Decrease (50 %)	Experimental	29899092
DrugRepV_2079	Tiotidine	NA	NA	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	No significant decrease (50 %)	NA	29981374
DrugRepV_2080	Tiotidine	NA	NA	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	No significant decrease (50 %)	NA	29981374
DrugRepV_2081	Impentamine	NA	NA	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	No significant decrease (50 %)	NA	29981374
DrugRepV_2082	Impentamine	NA	NA	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	No significant decrease (50 %)	NA	29981374
DrugRepV_2085	Nordiphenhydramine	NA	NA	Ebola virus	HIV/EBOV	NA	Luciferase reporter assay	Decrease (50 %)	NA	29981374
DrugRepV_2086	Nordiphenhydramine	NA	NA	Marburg virus	HIV/MARV	NA	Luciferase reporter assay	Decrease (50 %)	NA	29981374
DrugRepV_2132	2-C-Methylcytidine	NA	Hepatitis C virus	Zika virus	MR766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	27163257
DrugRepV_2133	2-C-Methylcytidine	NA	Hepatitis C virus	Zika virus	MR766	NA	Virus yield reduction assay	Decrease (50 %)	Experimental	27163257
DrugRepV_2134	7-deaza-2-C-methyl-D-adenosine	NA	Viral infection	Zika virus	MR766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	27163257
DrugRepV_2135	7-deaza-2-C-methyl-D-adenosine	NA	Viral infection	Zika virus	MR766	NA	Virus yield reduction assay	Decrease (50 %)	NA	27163257
DrugRepV_2136	7-deaza-2-C-methyl-D-adenosine	NA	Viral infection	Zika virus	MR766	NA	Plaque assay	Decrease (50 %)	NA	27163257
DrugRepV_2137	7-deaza-2-C-methyl-D-adenosine	NA	Viral infection	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (50 %)	NA	27163257
DrugRepV_2138	7-deaza-2-C-methyl-D-adenosine	NA	Viral infection	Zika virus	MR766	NA	Survival assay	Increase	NA	27163257
DrugRepV_2139	7-deaza-2-C-methyl-D-adenosine	NA	Viral infection	Zika virus	MR766	NA	Real-time PCR	Decrease	NA	27163257
DrugRepV_2140	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Puerto Rican strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2141	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Puerto Rican strain PRVABC-59	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_2142	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Puerto Rican strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2143	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Puerto Rican strain PRVABC-59	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_2144	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Puerto Rican strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2145	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Puerto Rican strain PRVABC-59	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_2146	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2147	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_2148	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2149	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_2150	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2151	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_2152	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2153	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_2154	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2155	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_2177	Avobenzone	NA	Sunburn	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (16.643533 %)	Approved	27742486
DrugRepV_2215	Fudosteine	NA	Bronchial asthma | Chronic bronchitis | Pulmonary emphysema | Bronchiectasis | Pulmonary tuberculosis | Pneumoconiosis | Atypical mycobacterial disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.62256156 %)	NA	27742486
DrugRepV_2220	Tylosin tartrate	NA	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.36358127 %)	Vet Approved	27742486
DrugRepV_2235	Arbidol Hydrochloride	NA	Influenza	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.59070859 %)	NA	27742486
DrugRepV_2241	Novobiocin Sodium	NA	Staphylococci infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.24445866 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2244	Azacyclonol	NA	Psychosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.14203789 %)	NA	27742486
DrugRepV_2261	Azasetron Hydrochloride	NA	Nausea and vomiting induced by cancer chemotherapy	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.49334625 %)	NA	27742486
DrugRepV_2280	OSI-420	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.78127734 %)	NA	27742486
DrugRepV_2294	Daidzein	NA	Dietary supplement	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.45147852 %)	Experimental	27742486
DrugRepV_2296	Adenine Hydrochloride	NA	Nutritional supplement	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.42334798 %)	Approved	27742486
DrugRepV_2323	Geniposide	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.7860683 %)	NA	27742486
DrugRepV_2329	Chloroxine	NA	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.67704383 %)	Approved	27742486
DrugRepV_2337	Adiphenine Hydrochloride	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.4400476 %)	NA	27742486
DrugRepV_2357	Mecarbinate	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.00956049 %)	NA	27742486
DrugRepV_2370	Cytidine	NA	Biopolar Depression	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.69043453 %)	Experimental	27742486
DrugRepV_2381	Niacin	NA	Hyperlipidemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.44049164 %)	Approved, Investigational, Nutraceutical	27742486
DrugRepV_2388	Albendazole oxide	NA	Parasitic infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.36721682 %)	Experimental	27742486
DrugRepV_2392	Geniposidic Acid	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.33842957 %)	NA	27742486
DrugRepV_2399	Paeoniflorin	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.22636429 %)	NA	27742486
DrugRepV_2407	Adenine	NA	Nutritional supplement	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.12499687 %)	Approved	27742486
DrugRepV_2415	Adenine Sulfate	NA	Nutritional supplement	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.95953472 %)	Approved	27742486
DrugRepV_2465	Sodium Butyrate	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.80232337 %)	NA	27742486
DrugRepV_2471	Azelnidipine	NA	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.64469838 %)	Approved	27742486
DrugRepV_2477	Mestranol	NA	Contraception	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.44756785 %)	Approved	27742486
DrugRepV_2488	Aspartame	NA	Diet supplement and sugar substitute	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.28008959 %)	Approved	27742486
DrugRepV_2494	Curcumin	NA	Depressive disorder	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.21930657 %)	Approved	27742486
DrugRepV_2515	Talc	NA	Rashes	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.1085991 %)	Approved	27742486
DrugRepV_2521	Pregnenolone	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.2797662 %)	Approved, Experimental	27742486
DrugRepV_2533	Pimobendan	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.5850328 %)	Vet approved	27742486
DrugRepV_2538	Alibendol	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.6238122 %)	NA	27742486
DrugRepV_2539	Vicriviroc Malate	NA	AIDS	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.6325066 %)	Investigational	27742486
DrugRepV_2542	Sodium orthovanadate	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.6967088 %)	NA	27742486
DrugRepV_2545	Irsogladine	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.8011514 %)	Investigational	27742486
DrugRepV_2563	Detomidine Hydrochloride	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.086047 %)	Approved, Vet Approved	27742486
DrugRepV_2564	Hydroxyflutamide	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.1400626 %)	NA	27742486
DrugRepV_2570	Ursodiol	NA	Gallstone and cholestatic forms of liver diseases including primary biliary cirrhosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.242893 %)	Approved	27742486
DrugRepV_2596	Methacycline Hydrochloride	NA	Acute bacterial exacerbations of chronic bronchitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.5238499 %)	Approved, Investigational	27742486
DrugRepV_2610	2-Methoxyestradiol	NA	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.7014075 %)	Investigational	27742486
DrugRepV_2619	Nafamostat Mesylate	NA	Blood vessel coagulation | Hemorrhagic lesions	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.7795584 %)	Investigational	27742486
DrugRepV_2623	Liranaftate	NA	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.8068752 %)	NA	27742486
DrugRepV_2625	NAD	NA	Parkinson's disease | Chronic fatigue syndrome | Alzheimer's disease | Cardiovascular disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.8213385 %)	Approved	27742486
DrugRepV_2633	Zileuton	NA	Asthma	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.9379253 %)	Approved, Withdrawn	27742486
DrugRepV_2650	Bepotastine besilate	NA	Allergic rhinitis and uriticaria/puritus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.1704391 %)	Approved	27742486
DrugRepV_2668	Moguisteine	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.4037393 %)	NA	27742486
DrugRepV_2683	10-DAB	NA	Cancer	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.5981982 %)	NA	27742486
DrugRepV_2692	Dextrose	NA	Hypoglycemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.8688015 %)	Approved	27742486
DrugRepV_2709	Arecoline	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.0469253 %)	Experimental	27742486
DrugRepV_2746	Gabexate Mesylate	NA	Cancer | Ischemia-reperfusion injury | Pancreatitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.7539063 %)	Investigational	27742486
DrugRepV_2751	Marbofloxacin	NA	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.8874309 %)	Vet approved	27742486
DrugRepV_2763	Taurine	NA	Nutritional supplementation	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.1985759 %)	Approved	27742486
DrugRepV_2780	BIBR 953	NA	Hypertension	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.5344416 %)	Approved	27742486
DrugRepV_2811	Cefoselis Sulfate	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.3205301 %)	NA	27742486
DrugRepV_2813	Rizatriptan Benzoate	NA	Migraine disorders	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.3908172 %)	Approved	27742486
DrugRepV_2814	2-Thiouracil	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.4015713 %)	NA	27742486
DrugRepV_2818	Suplatast tosylate	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.4609451 %)	NA	27742486
DrugRepV_2831	Xylazine Hydrochloride	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.9275587 %)	Approved, Vet Approved	27742486
DrugRepV_2843	Danofloxacin Mesylate	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.3487008 %)	Experimental, Vet approved	27742486
DrugRepV_2856	Amidopyrine	NA	Pain	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.8828073 %)	NA	27742486
DrugRepV_2861	Ubenimex	NA	Acute myelocytic leukemia	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-7.1327673 %)	Approved	27742486
DrugRepV_2878	Betapar	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.1507562 %)	NA	27742486
DrugRepV_2889	Malotilate	NA	Liver disease	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.5901104 %)	NA	27742486
DrugRepV_2891	PMSF	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.6777643 %)	NA	27742486
DrugRepV_2907	Tranilast	NA	Bronchial asthma | Keloid and hypertrophic scar | Allergic disorders such as asthma, allergic rhinitis | Atopic dermatitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.5539143 %)	Investigational	27742486
DrugRepV_2913	Noradrenaline Bitartrate Monohydrate	NA	NA	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.8741533 %)	NA	27742486
DrugRepV_2961	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	25970853
DrugRepV_2964	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Enzyme-linked immunosorbent assay	Decrease (95 %)	Approved	25970853
DrugRepV_2967	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (91 %)	Approved	25970853
DrugRepV_2970	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (92 %)	Approved	25970853
DrugRepV_2973	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (91 %)	Approved	25970853
DrugRepV_2976	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	MTT assay	Decrease (88.2 %)	Approved	25970853
DrugRepV_2977	Apigenin	NA	NA	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	Experimental	22205980
DrugRepV_2979	Naringenin	NA	NA	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	Experimental	22205980
DrugRepV_2980	Silybin	NA	NA	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	Experimental, Investigational	22205980
DrugRepV_2984	6-Azauridine	NA	Cancer	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	NA	22205980
DrugRepV_2985	3-NH2-3-deoxyadenosine	NA	NA	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	NA	22205980
DrugRepV_2986	Apigenin	NA	NA	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	Experimental	22205980
DrugRepV_2988	Naringenin	NA	NA	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	Experimental	22205980
DrugRepV_2989	Silybin	NA	NA	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	Experimental, Investigational	22205980
DrugRepV_2993	6-Azauridine	NA	Cancer	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	NA	22205980
DrugRepV_2994	3-NH2-3-deoxyadenosine	NA	NA	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	NA	22205980
DrugRepV_2999	Sulfonyl Amidine	NA	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (10 %)	NA	25643977
DrugRepV_3000	Sulfonyl Amidine	NA	NA	Chikungunya virus	NA	NA	Plaque assay	Decrease (40 %)	NA	25643977
DrugRepV_3011	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Zika virus	HD78788	NA	Plaque assay	Decrease (75 %)	Approved	28343845
DrugRepV_3012	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Zika virus	HD78788	NA	Real-time PCR	Decrease	Approved	28343845
DrugRepV_3013	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Zika virus	HD78788	NA	Real-time PCR	Decrease (0.8 log)	Approved	28343845
DrugRepV_3014	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Real-time PCR	Decrease (1 log)	Approved	28343845
DrugRepV_3015	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Zika virus	HD78788	NA	Real-time PCR	Decrease (1 log)	Approved	28343845
DrugRepV_3016	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Zika virus	HD78788	NA	Real-time PCR	Decrease (1 log)	Approved	28343845
DrugRepV_3017	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Real-time PCR	Decrease (0.7 log)	Approved	28343845
DrugRepV_3018	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Real-time PCR	Decrease (0.8 log)	Approved	28343845
DrugRepV_3019	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Real-time PCR	Decrease (0.5 log)	Approved	28343845
DrugRepV_3020	Demethoxycurcumin	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease	Phase II	28343845
DrugRepV_3022	EF-24	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease	NA	28343845
DrugRepV_3023	FLLL31	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease	NA	28343845
DrugRepV_3024	Demethoxycurcumin	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease	Phase II	28343845
DrugRepV_3026	EF-24	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease	NA	28343845
DrugRepV_3027	FLLL31	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease	NA	28343845
DrugRepV_3028	Demethoxycurcumin	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease (50 %)	Phase II	28343845
DrugRepV_3030	EF-24	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease (50 %)	NA	28343845
DrugRepV_3031	FLLL31	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease (50 %)	NA	28343845
DrugRepV_3032	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Zika virus	HD78788	NA	Plaque assay	Decrease (50 %)	Approved	28343845
DrugRepV_3033	Demethoxycurcumin	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease (50 %)	Phase II	28343845
DrugRepV_3035	EF-24	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease (50 %)	NA	28343845
DrugRepV_3036	FLLL31	NA	NA	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease (50 %)	NA	28343845
DrugRepV_3037	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Chikungunya virus	La Reunion strain, 06-049 AM258994	NA	Plaque assay	Decrease (50 %)	Approved	28343845
DrugRepV_3038	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Approved	26752081
DrugRepV_3039	Abamectin	NA	Helmintic infection	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Terminated	26752081
DrugRepV_3043	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Approved	26752081
DrugRepV_3044	Abamectin	NA	Helmintic infection	Chikungunya virus	LR2006 OPY1	NA	Luciferase reporter assay	Decrease (50 %)	Terminated	26752081
DrugRepV_3048	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (100 %)	Terminated	26752081
DrugRepV_3050	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (87 %)	Approved	26752081
DrugRepV_3061	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Renilla luciferase assay	No significant effect (No significant effect %)	Terminated	26752081
DrugRepV_3063	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	CHIKV-Rluc	NA	Renilla luciferase assay	No significant effect (No significant effect %)	Approved	26752081
DrugRepV_3066	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Northern blot	Decrease	Terminated	26752081
DrugRepV_3068	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Western blot	Decrease	Terminated	26752081
DrugRepV_3069	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Western blot	Decrease	Terminated	26752081
DrugRepV_3072	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Western blot	Decrease	Terminated	26752081
DrugRepV_3073	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Western blot	Decrease	Terminated	26752081
DrugRepV_3076	Abamectin	NA	Helmintic infection	Chikungunya virus	CHIKV-Rluc	NA	Plaque assay	Decrease (3.5 Log)	Terminated	26752081
DrugRepV_3077	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	CHIKV-Rluc	NA	Plaque assay	Decrease (5.2 Log)	Approved	26752081
DrugRepV_3082	Abamectin	NA	Helmintic infection	Chikungunya virus	NA	NA	Plaque assay	Decrease (2 Log)	Terminated	26752081
DrugRepV_3083	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	NA	NA	Plaque assay	Decrease (3.3 Log)	Approved	26752081
DrugRepV_3085	Abamectin	NA	Helmintic infection	Chikungunya virus	NA	NA	Plaque assay	Decrease (0.3 Log)	Terminated	26752081
DrugRepV_3086	Berberine	NA	Parasitic and fungal infection	Chikungunya virus	NA	NA	Plaque assay	Decrease (1.2 Log)	Approved	26752081
DrugRepV_3089	Dipterocarpol	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (100 %)	NA	23275491
DrugRepV_3091	Aloe-emodin	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.89 %)	NA	23275491
DrugRepV_3092	Retrorsine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.84 %)	NA	23275491
DrugRepV_3094	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.76 %)	NA	23275491
DrugRepV_3096	Tunicamycin B	NA	Bacterial infections	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.7 %)	Experimental	23275491
DrugRepV_3097	Corydaline	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.69 %)	NA	23275491
DrugRepV_3100	Usnic Acid	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.54 %)	NA	23275491
DrugRepV_3101	Rhapontin	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.53 %)	NA	23275491
DrugRepV_3103	Ferutinin	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.43 %)	NA	23275491
DrugRepV_3104	Diacetoxyscirpenol	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.27 %)	NA	23275491
DrugRepV_3107	Acivicin	NA	Cancer	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (99.07 %)	Phase I	23275491
DrugRepV_3109	Jervine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (98.35 %)	NA	23275491
DrugRepV_3110	Hypocrellin B	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (98.08 %)	NA	23275491
DrugRepV_3111	Valinomycin	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (97.79 %)	Experimental	23275491
DrugRepV_3112	Hypocrellin A	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (97.64 %)	NA	23275491
DrugRepV_3114	E-64	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (95.94 %)	NA	23275491
DrugRepV_3115	Magnolol	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (95.74 %)	NA	23275491
DrugRepV_3117	Nonactin	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (95.31 %)	NA	23275491
DrugRepV_3119	Ochratoxin A	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (94.95 %)	NA	23275491
DrugRepV_3121	Parthenolide	NA	Allergic Contact Dermatitis	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (93.95 %)	Approved, Investigational	23275491
DrugRepV_3124	Rottlerin	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (92.81 %)	NA	23275491
DrugRepV_3125	Grayanotoxin III	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (91.39 %)	NA	23275491
DrugRepV_3126	Gossypol	NA	Non-small Cell Lung Cancer	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (90.89 %)	Investigational	23275491
DrugRepV_3127	Sanguinarine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (90.83 %)	NA	23275491
DrugRepV_3130	Cyclopiazonic Acid	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (79.93 %)	NA	23275491
DrugRepV_3131	Harmine Hydrochloride	NA	NA	Chikungunya virus	CHIKV-0708	NA	Immunoflourescence assay	Decrease (73.68 %)	NA	23275491
DrugRepV_3132	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (50 %)	NA	23275491
DrugRepV_3133	Hypocrellin A	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (50 %)	NA	23275491
DrugRepV_3134	Rottlerin	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (50 %)	NA	23275491
DrugRepV_3136	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Plaque assay	Decrease (4.3 Log)	NA	23275491
DrugRepV_3137	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (2.3 Log)	NA	23275491
DrugRepV_3140	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (3 Log)	NA	23275491
DrugRepV_3141	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Plaque assay	Decrease (3.5 Log)	NA	23275491
DrugRepV_3142	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (2.8 Log)	NA	23275491
DrugRepV_3143	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (7.8 Log)	NA	23275491
DrugRepV_3144	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Plaque assay	Decrease (6.4 Log)	NA	23275491
DrugRepV_3145	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Real-time PCR	Decrease (6 (Complete inhibition) Log)	NA	23275491
DrugRepV_3146	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Real-time PCR	Decrease (2 Log)	NA	23275491
DrugRepV_3147	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Real-time PCR	Decrease (2 Log)	NA	23275491
DrugRepV_3148	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Real-time PCR	Decrease (2.4 Log)	NA	23275491
DrugRepV_3149	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Real-time PCR	Decrease (3 Log)	NA	23275491
DrugRepV_3150	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Western blot	Decrease	NA	23275491
DrugRepV_3151	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Western blot	Decrease	NA	23275491
DrugRepV_3152	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Western blot	Decrease	NA	23275491
DrugRepV_3153	Harringtonine	NA	NA	Chikungunya virus	CHIKV-0708	NA	Western blot	Decrease	NA	23275491
DrugRepV_3154	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Western blot	Decrease	NA	23275491
DrugRepV_3155	Harringtonine	NA	NA	Chikungunya virus	CHIKV-122508	NA	Western blot	Decrease	NA	23275491
DrugRepV_3157	6-Azauridine	NA	Cancer	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	14670584
DrugRepV_3160	Fucoidan	NA	NA	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	14670584
DrugRepV_3165	6-Azauridine	NA	Cancer	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (1.8 Log)	NA	14670584
DrugRepV_3169	6-Azauridine	NA	Cancer	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (99 %)	NA	14670584
DrugRepV_3172	IFN-alpha2b-Ribavirin	NA	NA	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	14670584
DrugRepV_3181	Arbidol	NA	Viral infection	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3182	Arbidol	NA	Viral infection	Influenza virus	B/Beijing/184/93		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3183	Arbidol	NA	Viral infection	Influenza virus	A/Mem Bel		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3184	Arbidol	NA	Viral infection	Influenza virus	A/Queensland/6/72		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3185	Arbidol	NA	Viral infection	Influenza virus	A/Sydney/5/ 97		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3186	Arbidol	NA	Viral infection	Influenza virus	A/Moscow/16/98		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3187	Arbidol	NA	Viral infection	Influenza virus	A/PR/8/34		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3188	Arbidol	NA	Viral infection	Influenza virus	A/Moscow/17/98		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3191	Arbidol	NA	Viral infection	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (Decrease (0.5-1.0) log)	Investigational	22028179
DrugRepV_3194	Arbidol	NA	Viral infection	Influenza virus	A/Aichi/2/68		Quantal assay	Decrease (1.5 log)	Investigational	22028179
DrugRepV_3197	Arbidol	NA	Viral infection	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (2.5 log)	Investigational	22028179
DrugRepV_3198	Arbidol	NA	Viral infection	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (3.73 log)	Investigational	22028179
DrugRepV_3199	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	No significant effect (No significant reduction log)	Investigational	26384169
DrugRepV_3200	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Flow cytometry	Decrease (90 %)	Investigational	26384169
DrugRepV_3201	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (3 Log)	Investigational	26384169
DrugRepV_3202	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	Decrease (2 Log)	Investigational	26384169
DrugRepV_3203	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (50 %)	Investigational	26384169
DrugRepV_3204	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	Decrease (50 %)	Investigational	26384169
DrugRepV_3205	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Western blot	Decrease (Capsid protein Protein expression)	Investigational	26384169
DrugRepV_3206	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Western blot	Decrease (E1 protein Protein expression)	Investigational	26384169
DrugRepV_3207	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Western blot	Decrease (pE2 protein Protein expression)	Investigational	26384169
DrugRepV_3208	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Western blot	Decrease (E2 protein Protein expression)	Investigational	26384169
DrugRepV_3209	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Western blot	Decrease (nsP2 protein Protein expression)	Investigational	26384169
DrugRepV_3210	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Western blot	Decrease (nsP3 protein Protein expression)	Investigational	26384169
DrugRepV_3211	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Real-time PCR	Decrease (2 Log)	Investigational	26384169
DrugRepV_3212	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Real-time PCR	Decrease (2 Log)	Investigational	26384169
DrugRepV_3213	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Cell viability assay	Decrease (25 %)	Investigational	26384169
DrugRepV_3214	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Cell viability assay	Decrease (65 %)	Investigational	26384169
DrugRepV_3215	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Cell viability assay	Decrease (65 %)	Investigational	26384169
DrugRepV_3216	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	Decrease (1 Log)	Investigational	26384169
DrugRepV_3217	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	Decrease (2 Log)	Investigational	26384169
DrugRepV_3218	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VT	NA	Plaque assay	Decrease (1.8 Log)	Investigational	26384169
DrugRepV_3219	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	No significant effect (No significant reduction Log)	Investigational	26384169
DrugRepV_3220	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (1 Log)	Investigational	26384169
DrugRepV_3221	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (0.9 Log)	Investigational	26384169
DrugRepV_3222	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (No significant reduction Log)	Investigational	26384169
DrugRepV_3223	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (1.2 Log)	Investigational	26384169
DrugRepV_3224	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (1.2 Log)	Investigational	26384169
DrugRepV_3225	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VS	NA	Western blot	Decrease (pE2 protein expression Protein expression)	Investigational	26384169
DrugRepV_3226	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VS	NA	Western blot	Decrease (E2 protein expresion Protein expression)	Investigational	26384169
DrugRepV_3227	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Western blot	Decrease (pE2 protein expression Protein expression)	Investigational	26384169
DrugRepV_3228	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Western blot	Decrease (E2 protein expresion Protein expression)	Investigational	26384169
DrugRepV_3229	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226VS	NA	Plaque assay	Decrease (1.3 Log)	Investigational	26384169
DrugRepV_3230	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (2.5 Log)	Investigational	26384169
DrugRepV_3231	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (2 Log)	Investigational	26384169
DrugRepV_3232	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Real-time PCR	Decrease (2 Log)	Investigational	26384169
DrugRepV_3233	Andrographolide	NA	Ulcerative colitis and Upper respiratory tract infection	Chikungunya virus	E1:226AS	NA	Plaque assay	Decrease (50 %)	Investigational	26384169
DrugRepV_3240	T-1105	NA	Zika virus	Chikungunya virus	Indian Ocean strain 899	NA	Colorimetric method	Decrease (50 %)	NA	24951535
DrugRepV_3241	T-1105	NA	Zika virus	Chikungunya virus	Indian Ocean strain 899	NA	Colorimetric method	Decrease (50 %)	NA	24951535
DrugRepV_3248	T-1105	NA	Zika virus	Chikungunya virus	Indian Ocean strain 899	NA	Plaque assay	Decrease (50 %)	NA	24951535
DrugRepV_3249	T-1105	NA	Zika virus	Chikungunya virus	Indian Ocean strain 899	NA	Real-time PCR	Decrease (50 %)	NA	24951535
DrugRepV_3250	T-1105	NA	Zika virus	Chikungunya virus	LR2006 OPY1	NA	Real-time PCR	Decrease (50 %)	NA	24951535
DrugRepV_3251	T-1105	NA	Zika virus	Chikungunya virus	Venturini (Italy 2008)	NA	Real-time PCR	Decrease (50 %)	NA	24951535
DrugRepV_3252	T-1105	NA	Zika virus	Chikungunya virus	Bianchi (Italy 2008)	NA	Real-time PCR	Decrease (50 %)	NA	24951535
DrugRepV_3253	T-1105	NA	Zika virus	Chikungunya virus	Congo 95 (2011)	NA	Real-time PCR	Decrease (50 %)	NA	24951535
DrugRepV_3264	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res C1-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3265	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res C2-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3266	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res C3-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3270	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res_p7 C1-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3271	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res_p7 C2-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3272	T-1105	NA	Zika virus	Chikungunya virus	Favipiravir_res_p7 C3-CHIKV 899	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	24951535
DrugRepV_3273	5-Tetradecyloxy-2-furoic Acid	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3275	Cerulenin	NA	Fungal infection	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved	27177310
DrugRepV_3277	AnnH18	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3278	AnnH14	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3279	KH-CB19	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3280	Anacardic Acid	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3281	TAE684	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3284	6-Hydroxyflavone	NA	Anxiety-like disorders	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3287	Alsterpaullone	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Experimental	27177310
DrugRepV_3290	Tivozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	Investigational	27177310
DrugRepV_3292	Linifanib	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (50 %)	NA	27177310
DrugRepV_3293	5-Tetradecyloxy-2-furoic Acid	NA	NA	Influenza virus	NA		Flow cytometry	Decrease (100 %)	NA	27177310
DrugRepV_3294	Cerulenin	NA	Fungal infection	Influenza virus	NA		Flow cytometry	Decrease (100 %)	Approved	27177310
DrugRepV_3297	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Influenza virus	NA		Flow cytometry	Decrease (100 %)	Investigational	27177310
DrugRepV_3298	Anacardic Acid	NA	NA	Chikungunya virus	NA	NA	Flow cytometry	Decrease (75 %)	NA	27177310
DrugRepV_3300	Cerulenin	NA	Fungal infection	Chikungunya virus	NA	NA	Flow cytometry	Decrease (75 %)	Approved	27177310
DrugRepV_3302	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	NA	NA	Flow cytometry	Decrease (90 %)	Investigational	27177310
DrugRepV_3303	Cerulenin	NA	Fungal infection	Chikungunya virus	NA	NA	Real-time PCR	Decrease (100 %)	Approved	27177310
DrugRepV_3304	5-Tetradecyloxy-2-furoic Acid	NA	NA	Chikungunya virus	NA	NA	Real-time PCR	Decrease (100 %)	NA	27177310
DrugRepV_3306	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	NA	NA	Real-time PCR	Decrease (50 %)	Investigational	27177310
DrugRepV_3307	Cerulenin	NA	Fungal infection	Chikungunya virus	NA	NA	Real-time PCR	Decrease (100 %)	Approved	27177310
DrugRepV_3308	5-Tetradecyloxy-2-furoic Acid	NA	NA	Chikungunya virus	NA	NA	Real-time PCR	Decrease (100 %)	NA	27177310
DrugRepV_3310	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	NA	NA	Real-time PCR	Decrease (80 %)	Investigational	27177310
DrugRepV_3311	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	C21	NA	Survival assay	NA	Investigational	27177310
DrugRepV_3312	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	C21	NA	Plaque assay	No significant reduction (0.9 Log)	Investigational	27177310
DrugRepV_3313	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	C21	NA	Plaque assay	Decrease (1.2 Log)	Investigational	27177310
DrugRepV_3314	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Chikungunya virus	C21	NA	Plaque assay	No significant reduction (0.8 Log)	Investigational	27177310
DrugRepV_3316	5-Tetradecyloxy-2-furoic Acid	NA	NA	Chikungunya virus	C21	NA	Plaque assay	No significant reduction (0.2 Log)	NA	27177310
DrugRepV_3350	Trametinib-Oseltamivir	NA	NA	Influenza virus	WSN/H1N1		Plaque assay	Decrease (95 %)	Approved	29990517
DrugRepV_3352	Trametinib-Oseltamivir	NA	NA	Influenza virus	WSN/H1N1		Plaque assay	Decrease (3.5 Log)	Approved	29990517
DrugRepV_3376	Mycophenolic Acid-Betaferon	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (50 %)	NA	24096239
DrugRepV_3382	Betaferon	NA	Multiple sclerosis	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (50 %)	Approved	24096239
DrugRepV_3407	SSYA10-001	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (50 %)	NA	24841268
DrugRepV_3408	SSYA10-001	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (50 %)	NA	24841268
DrugRepV_3409	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3413	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	B/Bris/60/2008 (Victoria)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3416	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/California/7/2009 (H1N1)		Plaque assay	Decrease (2.1 Log)	Investigational	28778830
DrugRepV_3417	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/California/7/2009 (H1N1)		Plaque assay	Decrease (2.9 Log)	Investigational	28778830
DrugRepV_3420	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/WSN/1933 (H1N1)		Plaque assay	Decrease (1.7 Log)	Investigational	28778830
DrugRepV_3422	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/DM/528/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3423	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Texas/4/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3424	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/North Carolina/39/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3425	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Washington/29/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3426	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/WSN/1933 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3427	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3428	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/DM/524/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3429	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Switzerland/9715293/2013 (H3N2)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3430	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Switzerland/9715293/2013 X-247 (H3N2)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3431	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Hongkong/4801/2014 (H3N2)		Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3432	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/California/2/2014 (H3N2)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3433	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Udorn/1972 (H3N2)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3434	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Soloman Islands/3/2006 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3435	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	B/Wisconsin/1/2010 (Yamagata)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3436	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	B/Bris/60/2008 (Victoria)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3439	Saliphenylhalamide	NA	NA	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	NA	22910914
DrugRepV_3442	NVP-AUY922	NA	NA	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	NA	22910914
DrugRepV_3443	Alvespimycin	NA	Cancer	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Investigational	22910914
DrugRepV_3444	Tanespimycin	NA	Cancer	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Investigational	22910914
DrugRepV_3447	Saliphenylhalamide	NA	NA	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	NA	22910914
DrugRepV_3450	NVP-AUY922	NA	NA	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	NA	22910914
DrugRepV_3451	Alvespimycin	NA	Cancer	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Investigational	22910914
DrugRepV_3452	Tanespimycin	NA	Cancer	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Investigational	22910914
DrugRepV_3470	Pyrrolopyridinamine PPA-7	NA	NA	Influenza virus	CA/09 (H1N1)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3471	Aminothiadiazole ATD-1	NA	NA	Influenza virus	CA/09 (H1N1)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3472	Dihydrofuropyridine carboxamide HPC-2	NA	NA	Influenza virus	CA/09 (H1N1)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3473	Pyrrolopyridinamine PPA-7	NA	NA	Influenza virus	PE/09 (H3N2)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3474	Aminothiadiazole ATD-1	NA	NA	Influenza virus	PE/09 (H3N2)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3475	Dihydrofuropyridine carboxamide HPC-2	NA	NA	Influenza virus	PE/09 (H3N2)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3476	Pyrrolopyridinamine PPA-7	NA	NA	Influenza virus	B/Florida/04/2006 (B/FL/06)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3477	Aminothiadiazole ATD-1	NA	NA	Influenza virus	B/Florida/04/2006 (B/FL/06)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3478	Dihydrofuropyridine carboxamide HPC-2	NA	NA	Influenza virus	B/Florida/04/2006 (B/FL/06)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3479	Pyrrolopyridinamine PPA-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3480	Pyrrolopyridinamine PPA-2	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3481	Pyrrolopyridinamine PPA-3	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3482	Pyrrolopyridinamine PPA-4	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3483	Pyrrolopyridinamine PPA-5	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3484	Pyrrolopyridinamine PPA-6	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3485	Pyrrolopyridinamine PPA-7	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3486	Pyrrolopyridinamine PPA-8	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3487	Pyrrolopyridinamine PPA-9	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3488	Pyrrolopyridinamine PPA-10	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3489	Pyrrolopyridinamine PPA-11	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3490	Pyrrolopyridinamine PPA-12	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3491	Pyrrolopyridinamine PPA-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3492	Pyrrolopyridinamine PPA-2	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3493	Pyrrolopyridinamine PPA-3	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3494	Pyrrolopyridinamine PPA-4	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3495	Pyrrolopyridinamine PPA-5	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3496	Pyrrolopyridinamine PPA-6	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3497	Pyrrolopyridinamine PPA-7	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3498	Pyrrolopyridinamine PPA-8	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3499	Pyrrolopyridinamine PPA-9	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3500	Pyrrolopyridinamine PPA-10	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3501	Pyrrolopyridinamine PPA-11	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3502	Pyrrolopyridinamine PPA-12	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3503	Aminothiadiazole ATD-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3504	Aminothiadiazole ATD-2	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3505	Aminothiadiazole ATD-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3506	Aminothiadiazole ATD-2	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3507	Dihydrofuropyridine carboxamide HPC-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3508	Dihydrofuropyridine carboxamide HPC-2	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3509	Dihydrofuropyridine carboxamide HPC-3	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3510	Dihydrofuropyridine carboxamide HPC-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3511	Dihydrofuropyridine carboxamide HPC-2	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3512	Dihydrofuropyridine carboxamide HPC-3	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3513	Imidazopyridinamine IPA-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3514	Imidazopyridinamine IPA-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3578	AY9944	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3581	GBR-12783	NA	Psychosis	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3582	Tabimorelin	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3584	Camylofine	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3587	ML9	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3593	Iminodyn 17	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3594	Nobiletin	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3596	N-Acetyl-L-leucyl- L- leucyl-L- methional	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3597	Calpeptin	NA	NA	Ebola virus	EBOV trVLP	NA	Luciferase reporter assay	Decrease (50 %)	NA	30149038
DrugRepV_3599	Gentian Violet	NA	Bacterial infection | Fungal infections (mouth (thrush) and skin)	Nipah virus	NA	NA	Taqman PCR	Decrease (50 %)	Approved	19889218
DrugRepV_3600	Gliotoxin	NA	NA	Nipah virus	NA	NA	Taqman PCR	Decrease (50 %)	NA	19889218
DrugRepV_3602	Gentian Violet	NA	Bacterial infection | Fungal infections (mouth (thrush) and skin)	Hendra virus	NA	NA	Taqman PCR	Decrease (50 %)	Approved	19889218
DrugRepV_3603	Gliotoxin	NA	NA	Hendra virus	NA	NA	Taqman PCR	Decrease (50 %)	NA	19889218
DrugRepV_3605	Gentian Violet	NA	Bacterial infection | Fungal infections (mouth (thrush) and skin)	Nipah virus	NA	NA	Taqman PCR	Decrease (50 %)	Approved	19889218
DrugRepV_3606	Gliotoxin	NA	NA	Nipah virus	NA	NA	Taqman PCR	Decrease (50 %)	NA	19889218
DrugRepV_3608	Gentian Violet	NA	Bacterial infection | Fungal infections (mouth (thrush) and skin)	Hendra virus	NA	NA	Taqman PCR	Decrease (50 %)	Approved	19889218
DrugRepV_3609	Gliotoxin	NA	NA	Hendra virus	NA	NA	Taqman PCR	Decrease (50 %)	NA	19889218
DrugRepV_3610	Gliotoxin	NA	NA	Influenza virus	A/ swine/Rachaburi/2000 (H1N1)		Taqman PCR	Decrease (50 %)	NA	19889218
DrugRepV_3611	C-c3 Ado	NA	NA	Nipah virus	NA	NA	RT-PCR	Decrease	NA	16641448
DrugRepV_3612	5 Noraristeromycin	NA	NA	Nipah virus	NA	NA	RT-PCR	Decrease	NA	16641448
DrugRepV_3613	DHCaA	NA	NA	Nipah virus	NA	NA	RT-PCR	Decrease	NA	16641448
DrugRepV_3615	EICAR	NA	NA	Nipah virus	NA	NA	RT-PCR	Decrease	NA	16641448
DrugRepV_3616	Pyrazofurin	NA	NA	Nipah virus	NA	NA	RT-PCR	Decrease	NA	16641448
DrugRepV_3617	Carbodine	NA	NA	Nipah virus	NA	NA	RT-PCR	Decrease	NA	16641448
DrugRepV_3618	6-Azauridine	NA	Cancer	Nipah virus	NA	NA	RT-PCR	Decrease	NA	16641448
DrugRepV_3619	Poly(I)-poly(C12U)	NA	NA	Nipah virus	NA	NA	RT-PCR	Decrease	NA	16641448
DrugRepV_3621	6-Azauridine	NA	Cancer	Nipah virus	NA	NA	RT-PCR	Decrease	NA	16641448
DrugRepV_3627	Cyanovirin-N	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	15073681
DrugRepV_3628	Cyanovirin-N	NA	NA	Marburg virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	15073681
DrugRepV_3629	Cyanovirin-N	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	15073681
DrugRepV_3630	N-methyl-5,7-dinitro-N-propylquinolin-8-amine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3631	2-[3-(4-chlorophenyl)-1-(3-methoxyphenyl)-3-oxopropyl]propanedinitrile	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3632	(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,9,15(20)-pentaene-14,18-dione	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3633	2-[(1E)-2-(5-nitrofuran-2-yl)ethenyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-one	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3634	N-(3,4-dichlorophenyl)-5-nitrofuran-2-carboxamide	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3635	7-[(furan-2-yl)methyl]-3-[3-(1H-imidazol-1-yl)propyl]-5,6-diphenyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-imine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3636	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3637	N,N-bis(4-methylphenyl)pyridin-3-amine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3638	N-methyl-5,7-dinitro-N-propylquinolin-8-amine	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3639	2-[3-(4-chlorophenyl)-1-(3-methoxyphenyl)-3-oxopropyl]propanedinitrile	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3640	(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,9,15(20)-pentaene-14,18-dione	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3641	2-[(1E)-2-(5-nitrofuran-2-yl)ethenyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-one	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3642	N-(3,4-dichlorophenyl)-5-nitrofuran-2-carboxamide	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3643	7-[(furan-2-yl)methyl]-3-[3-(1H-imidazol-1-yl)propyl]-5,6-diphenyl-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-4-imine	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3644	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3645	N,N-bis(4-methylphenyl)pyridin-3-amine	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3646	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	Zaire	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3647	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Marburg virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3648	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Rift Valley fever virus	MP12	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3649	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Influenza virus	California/07/2009		Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3650	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Influenza virus	Brisbane/10/2007		Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3651	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3652	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3653	2-methyl-4-phenyl-1H-naphtho[2,3-b][1,4]diazepine hydrochloride	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3654	2-(4-chlorophenyl)-7,8-dimethyl-4-(trifluoromethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3655	2-(1,1,2,2,2-pentafluoroethyl)-4-phenyl-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3656	7,8-dichloro-2-(1,1,2,2,2-pentafluoroethyl)-4-phenyl-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3657	2-[4-(trifluoromethyl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3658	2-(4-methylphenyl)-4-(trifluoromethyl)-3H-1,5-benzodiazepine	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3659	4-methoxy-2-[4-(trifluoromethyl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3660	2-[4-(thiophen-2-yl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3661	4-chloro-2-[4-(furan-2-yl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3662	4-methoxy-2-[4-(thiophen-2-yl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3663	2-[4-(furan-2-yl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3664	2-[4-(3-nitrophenyl)-3H-1,5-benzodiazepin-2-yl]phenol	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (90 %)	NA	21270170
DrugRepV_3665	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Marburg virus	Lake Victoria	NA	Luciferase reporter assay	Decrease (90 %)	NA	21270170
DrugRepV_3666	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Marburg virus	Lake Victoria	NA	Luciferase reporter assay	Decrease (50 %)	NA	21270170
DrugRepV_3667	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Marburg virus	Lake Victoria	NA	Luciferase reporter assay	Decrease (100 %)	NA	21270170
DrugRepV_3668	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Marburg virus	Lake Victoria	NA	Luciferase reporter assay	Decrease (98 %)	NA	21270170
DrugRepV_3669	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Lassa virus	NA	NA	Luciferase reporter assay	Decrease (40 %)	NA	21270170
DrugRepV_3670	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Influenza virus	Goose/Qinghai/59/05		Luciferase reporter assay	Decrease (15 %)	NA	21270170
DrugRepV_3671	2,6-bis[(3-tert-butyl-2-hydroxy-5-methylphenyl)methyl]-4-methylphenol	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (100 %)	NA	22027648
DrugRepV_3672	NSC 62914	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease	NA	22027648
DrugRepV_3673	NSC 62914	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	NA	22027648
DrugRepV_3674	Trolox	NA	NA	Ebola virus	Zaire	NA	RT-PCR	Decrease (45 %)	NA	22027648
DrugRepV_3675	Trolox	NA	NA	Marburg virus	NA	NA	RT-PCR	Decrease (70 %)	NA	22027648
DrugRepV_3676	NSC 62914	NA	NA	Marburg virus	Ci67	NA	RT-PCR	Decrease (98 %)	NA	22027648
DrugRepV_3677	NSC 62914	NA	NA	Lassa virus	Josiah	NA	RT-PCR	Decrease (98 %)	NA	22027648
DrugRepV_3678	NSC 62914	NA	NA	Rift Valley fever virus	MP12	NA	RT-PCR	Decrease (97 %)	NA	22027648
DrugRepV_3679	NSC 62914	NA	NA	Ebola virus	NA	NA	NA	Decrease	NA	22027648
DrugRepV_3680	NSC 62914	NA	NA	Marburg virus	NA	NA	NA	Decrease	NA	22027648
DrugRepV_3681	N3,N12-bis[2-(morpholin-4-yl)ethyl]-6,15-diazatetracyclo[8.8.0.02,7.011,16]octadeca-1(10),2,4,6,8,11(16),12,14,17-nonaene-3,12-diamine tetrahydrochloride	NA	NA	Ebola virus	Zaire-95	NA	NA	Decrease (50 %)	NA	23012625
DrugRepV_3682	N5,N14-bis[2-(morpholin-4-yl)ethyl]-3,12-bis({[2-(morpholin-4-yl)ethyl]amino})-6,15-diazatetracyclo[8.8.0.02,7.011,16]octadeca-1(10),2,4,6,8,11(16),12,14,17-nonaene-5,14-dicarboxamide; hexakis(trifluoroacet	NA	NA	Ebola virus	Zaire-95	NA	NA	Decrease (50 %)	NA	23012625
DrugRepV_3683	N3,N12-bis[2-(morpholin-4-yl)ethyl]-6,15-diazatetracyclo[8.8.0.02,7.011,16]octadeca-1(10),2,4,6,8,11(16),12,14,17-nonaene-3,12-diamine	NA	NA	Ebola virus	Zaire-95	NA	NA	Decrease (50 %)	NA	23012625
DrugRepV_3684	N3,N12-bis[2-(morpholin-4-yl)ethyl]-6,15-diazatetracyclo[8.8.0.02,7.011,16]octadeca-1(10),2,4,6,8,11(16),12,14,17-nonaene-3,12-diamine tetrahydrochloride	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	23012625
DrugRepV_3685	N3,N12-bis[2-(morpholin-4-yl)ethyl]-6,15-diazatetracyclo[8.8.0.02,7.011,16]octadeca-1(10),2,4,6,8,11(16),12,14,17-nonaene-3,12-diamine	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	23012625
DrugRepV_3686	BCX4430	NA	Ebola virus	Marburg virus	Musoke	NA	RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_3687	BCX4430	NA	Ebola virus	Marburg virus	Ci67	NA	RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_3688	BCX4430	NA	Ebola virus	Marburg virus	Angola	NA	RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_3689	BCX4430	NA	Ebola virus	Ebola virus	Kikwit	NA	RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_3690	BCX4430	NA	Ebola virus	Chikungunya virus	AF 15561	NA	RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_3691	BCX4430	NA	Ebola virus	Rift Valley fever virus	ZH5018	NA	RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_3692	BCX4430	NA	Ebola virus	Lassa virus	Josiah	NA	RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_3693	BCX4430	NA	Ebola virus	Nipah virus	Malaysia	NA	RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_3694	BCX4430	NA	Ebola virus	Middle East respiratory syndrome coronavirus	Jordan N3	NA	RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_3695	BCX4430	NA	Ebola virus	Severe acute respiratory syndrome coronavirus	Urbani	NA	RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_3696	BCX4430	NA	Ebola virus	Influenza virus	pH1N1		RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_3698	6-Azauridine	NA	Cancer	Marburg virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	24713118
DrugRepV_3699	2-C-Methylcytidine	NA	Hepatitis C virus	Marburg virus	NA	NA	Luciferase assay	Decrease (50 %)	Experimental	24713118
DrugRepV_3701	6-Azauridine	NA	Cancer	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	24713118
DrugRepV_3702	2-C-Methylcytidine	NA	Hepatitis C virus	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Experimental	24713118
DrugRepV_3704	6-Azauridine	NA	Cancer	Marburg virus	NA	NA	NA	Decrease (98 %)	NA	24713118
DrugRepV_3708	6-Azauridine	NA	Cancer	Ebola virus	NA	NA	NA	Decrease (99 %)	NA	24713118
DrugRepV_3711	C795-0925	NA	NA	Rift Valley fever virus	ZH548/MP-12	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3712	D011-2120	NA	NA	Rift Valley fever virus	ZH548/MP-12	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3713	F694-1532	NA	NA	Rift Valley fever virus	ZH548/MP-12	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3714	G202-0362	NA	NA	Rift Valley fever virus	ZH548/MP-12	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3715	C795-0925	NA	NA	Ebola virus	Zaire	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3716	D011-2120	NA	NA	Ebola virus	Zaire	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3717	F694-1532	NA	NA	Ebola virus	Zaire	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3718	G202-0362	NA	NA	Ebola virus	Zaire	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3719	C795-0925	NA	NA	Marburg virus	Ci67	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3720	D011-2120	NA	NA	Marburg virus	Ci67	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3721	F694-1532	NA	NA	Marburg virus	Ci67	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3722	G202-0362	NA	NA	Marburg virus	Ci67	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3723	C795-0925	NA	NA	Lassa virus	Josiah	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3724	D011-2120	NA	NA	Lassa virus	Josiah	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3725	F694-1532	NA	NA	Lassa virus	Josiah	NA	RT-PCR	Decrease (50 %)	NA	25144302
DrugRepV_3727	AZD8055	NA	Cancer	Lassa virus	NA	NA	NA	Decrease	Investigational	25986249
DrugRepV_3728	TWS119	NA	NA	Lassa virus	NA	NA	NA	Decrease	NA	25986249
DrugRepV_3729	SU 4312	NA	NA	Lassa virus	NA	NA	NA	Decrease	NA	25986249
DrugRepV_3730	Falnidamol dihydrochloride	NA	Solid Tumor	Lassa virus	NA	NA	NA	Decrease	Investigational	25986249
DrugRepV_3731	Ki 8751	NA	NA	Lassa virus	NA	NA	NA	Decrease	NA	25986249
DrugRepV_3732	10-DEBC hydrochloride	NA	NA	Lassa virus	NA	NA	NA	Decrease	NA	25986249
DrugRepV_3738	Falnidamol dihydrochloride	NA	Solid Tumor	Lassa virus	NA	NA	RT-PCR	Decrease (50 %)	Investigational	25986249
DrugRepV_3739	Falnidamol dihydrochloride	NA	Solid Tumor	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	Investigational	25986249
DrugRepV_3740	Falnidamol dihydrochloride	NA	Solid Tumor	Marburg virus	NA	NA	RT-PCR	Decrease (50 %)	Investigational	25986249
DrugRepV_3742	Falnidamol	NA	Solid Tumor	Lassa virus	NA	NA	RT-PCR	Decrease (50 %)	Investigational	25986249
DrugRepV_3744	Falnidamol	NA	Solid Tumor	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	Investigational	25986249
DrugRepV_3745	Falnidamol	NA	Solid Tumor	Ebola virus	1976	NA	Firefly luciferase assay	Decrease (50 %)	Investigational	25986249
DrugRepV_3746	Falnidamol	NA	Solid Tumor	Ebola virus	2014	NA	Firefly luciferase assay	Decrease (50 %)	Investigational	25986249
DrugRepV_3747	Falnidamol	NA	Solid Tumor	Lassa virus	NA	NA	Firefly luciferase assay	Decrease (50 %)	Investigational	25986249
DrugRepV_3751	MLS000078751	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3752	MLS000394177	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3753	MLS000534476	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3754	MLS000554255	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3755	MLS000555232	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3756	MLS000730532	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3757	MLS000733230	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3758	MLS000762907	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3759	MLS001101371	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3760	MLS000078751	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3761	MLS000394177	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3762	MLS000534476	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3763	MLS000554255	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3764	MLS000555232	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3765	MLS000730532	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3766	MLS000733230	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3767	MLS000762907	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3768	MLS001101371	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3769	MLS001239325	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3770	MLS001239325	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3771	MLS001030162	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3772	MLS001030162	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3773	MLS000666802	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3774	MLS000666802	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3775	MLS000999960	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3776	MLS000999960	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3777	MLS001173370	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3778	MLS001173370	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3779	MLS001174896	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3780	MLS001174896	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3781	MLS001196083	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3782	MLS001196083	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3783	MLS001239358	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3784	MLS001239358	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3785	MLS001177927	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3786	MLS001177927	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3787	MLS001209453	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3788	MLS001209453	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3789	MLS000580080	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3790	MLS000580080	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3791	MLS000106706	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3792	MLS000106706	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3793	MLS001175455	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3794	MLS001175455	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3795	MLS000772389	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3796	MLS000772389	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3797	MLS000042810	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3798	MLS000042810	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3799	MLS001162808	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3800	MLS001162808	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3801	MLS000684231	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3802	MLS000684231	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3803	MLS000556387	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3804	MLS000556387	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3805	MLS001179278	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3806	MLS001179278	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3807	MLS000567464	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3808	MLS000567464	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3809	MLS000583959	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3810	MLS000583959	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3811	MLS001018888	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3812	MLS001018888	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3813	MLS001047402	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3814	MLS001047402	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3815	MLS001029946	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3816	MLS001029946	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3817	MLS000332573	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3818	MLS000332573	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3819	MLS000936259	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3820	MLS000936259	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3821	MLS000718690	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3822	MLS000718690	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3823	MLS000880330	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3824	MLS000880330	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3825	MLS001207131	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3826	MLS001207131	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3827	MLS000673118	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3828	MLS000673118	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3829	MLS000689481	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3830	MLS000689481	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3831	MLS001179272	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3832	MLS001179272	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3833	MLS002702500	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3834	MLS002702500	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3835	MLS001180408	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3836	MLS000737975	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3837	MLS001237534	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3838	MLS000336293	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3839	MLS000780111	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3840	MLS001179997	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3841	MLS000418057	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3842	MLS000936795	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3843	MLS000092187	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3844	MLS000391391	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3845	MLS000569139	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3846	MLS001045935	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3847	MLS001181479	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3848	MLS000391984	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3849	MLS000063146	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3850	MLS000768081	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3851	MLS000091920	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3852	MLS001150589	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3853	MLS000736237	NA	NA	Marburg virus	Musoke	NA	NA	Decrease (50 %)	NA	27161622
DrugRepV_3855	Enclomiphene	NA	Male hypogonadism	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	Investigational	27490565
DrugRepV_3856	Zuclomiphene	NA	NA	Ebola virus	Mayinga	NA	NA	Decrease (50 %)	NA	27490565
DrugRepV_3858	Enclomiphene	NA	Male hypogonadism	Ebola virus	Mayinga	NA	Renilla luciferase assay	Decrease (100 %)	Investigational	27490565
DrugRepV_3859	Zuclomiphene	NA	NA	Ebola virus	Mayinga	NA	Renilla luciferase assay	Decrease (100 %)	NA	27490565
DrugRepV_3867	BCX4430	NA	Ebola virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3868	BCX4430	NA	Ebola virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3869	BCX4430	NA	Ebola virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3870	BCX4430	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3871	BCX4430	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3872	BCX4430	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3873	BCX4430	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3874	BCX4430	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3883	UV-1	NA	NA	Ebola virus	Zaire-Kikwit	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3884	UV-2	NA	NA	Ebola virus	Zaire-Kikwit	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3885	UV-3	NA	NA	Ebola virus	Zaire-Kikwit	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3886	UV-4	NA	NA	Ebola virus	Zaire-Kikwit	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3887	UV-5	NA	NA	Ebola virus	Zaire-Kikwit	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3888	UV-1	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3889	UV-2	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3890	UV-3	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3891	UV-4	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3892	UV-5	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (50 %)	NA	27908828
DrugRepV_3893	cp15	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3894	cp15	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3895	cp15	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3896	cp15	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3897	cp19	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3898	cp19	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3899	cp19	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3900	cp19	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3901	cp3	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3902	cp5	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3903	cp11	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3904	cp13	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3905	cp15	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3906	cp16	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3907	cp19	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3908	cp3	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3909	cp5	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3910	cp11	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3911	cp13	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3912	cp15	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3913	cp16	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3914	cp19	NA	NA	Marburg virus	Ci67	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3915	cp3	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3916	cp5	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3917	cp11	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3918	cp13	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3919	cp15	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3920	cp16	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3921	cp19	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3922	CBS1129	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3923	CBS1130	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3924	CBS1131	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3925	CBS1132	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3926	CBS1133	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3927	CBS1134	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3928	CBS1135	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3929	CBS1136	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3930	CBS1137	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3931	CBS1138	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3932	CBS1139	NA	NA	Ebola virus	Kikwit	NA	NA	Decrease (50 %)	NA	28645623
DrugRepV_3933	IHVR-19029	NA	NA	Zika virus	PRVABC-59	NA	qRT-PCR	Decrease (50 %)	NA	29253498
DrugRepV_3934	IHVR-19029	NA	NA	Ebola virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	29253498
DrugRepV_3938	GSK983	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3939	Angelicin	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3940	Benzoquinoline	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3941	SW539	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3942	SW320	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3943	SW351	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3944	SW491	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3945	SW490	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3946	SW388	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3947	SW386	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3948	SW349	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3949	SW991	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3950	SW456	NA	NA	Ebola virus	NA	NA	Plaque assay	Decrease (50 %)	NA	29294299
DrugRepV_3953	12N-p-dichlorobenzyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3954	12N-o-methylbenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3955	12N-2,4-dichlorobenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3956	12N-3,5 -dichlorobenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3957	12N-3,4-dichlorobenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3958	12N-m-methoxybenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3959	12N-benzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3960	12N-p-trifluoromethoxylbenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3961	12N-p-fluorobenzyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3962	12N-3,5-dichlorobenzoyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3963	12N-p-chlorobenzoyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3964	12N-3,4-dichlorobenzoyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3965	12N-3,4-dichlorobenzenesulfonyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3966	12N-3,5-dichlorobenzenesulfonyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3967	12N-o-thiophenesulfonyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3968	12N-m-cyanobenzenesulfonyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3969	12N-p-chlorobenzenesulfonyl aloperine	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3970	12N-p-chlorophenylethyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3971	12N-3,4-dichlorophenylethyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3972	12N-3,5-dichlorophenylethyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3973	12N-3,4-dichlorohydrocinnamyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3974	12N-3,5-dichlorohydrocinnamyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3975	12N-p-chlorohydrocinnamyl aloperine dihydrochloride	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3976	12N-p-dichlorobenzyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3977	12N-o-methylbenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3978	12N-2,4-dichlorobenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3979	12N-3,5 -dichlorobenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3980	12N-3,4-dichlorobenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3981	12N-m-methoxybenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3982	12N-benzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3983	12N-p-trifluoromethoxylbenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3984	12N-p-fluorobenzyl aloperine dihydrochloride	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3985	12N-3,5-dichlorobenzoyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3986	12N-p-chlorobenzoyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3987	12N-3,4-dichlorobenzoyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3988	12N-3,4-dichlorobenzenesulfonyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3989	12N-3,5-dichlorobenzenesulfonyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3990	12N-o-thiophenesulfonyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3991	12N-m-cyanobenzenesulfonyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3992	12N-p-chlorobenzenesulfonyl aloperine	NA	NA	Marburg virus	NA	NA	NA	Decrease (50 %)	NA	29494844
DrugRepV_3996	Tyrphostin AG1478	NA	NA	Lassa virus	NA	NA	Luciferase assay	Decrease (100 %)	NA	21947546
DrugRepV_3997	Tyrphostin AG1478	NA	NA	Marburg virus	NA	NA	Luciferase assay	Decrease (100 %)	NA	21947546
DrugRepV_3998	Tyrphostin AG1478	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (100 %)	NA	21947546
DrugRepV_3999	Genistein-Tyrphostin AG1478	NA	NA	Lassa virus	NA	NA	Luciferase assay	Decrease (99 %)	NA	21947546
DrugRepV_4000	Genistein-Tyrphostin AG1478	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (99 %)	NA	21947546
DrugRepV_4001	FGI-103	NA	NA	Ebola virus	Zaire	NA	Plaque assay	Decrease (50 %)	NA	20211898
DrugRepV_4002	FGI-103	NA	NA	Ebola virus	Sudan	NA	Plaque assay	Decrease (50 %)	NA	20211898
DrugRepV_4003	FGI-103	NA	NA	Marburg virus	Ravn	NA	Plaque assay	Decrease (50 %)	NA	20211898
DrugRepV_4004	FGI-103	NA	NA	Marburg virus	Ci67	NA	Plaque assay	Decrease (95 %)	NA	20211898
DrugRepV_4005	FGI-103	NA	NA	Ebola virus	Zaire	NA	NA	Decrease	NA	20211898
DrugRepV_4006	2-APB	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4007	A23187	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4008	Di-Tert-Butylhydroquinone	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4009	CA1001	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4011	Ionomycin	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4012	Ryanodine	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4013	Thapsigargin	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4014	Xestospongin C	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4015	2-APB	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4016	A23187	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4017	Di-Tert-Butylhydroquinone	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4018	CA1001	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4020	Ionomycin	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4021	Ryanodine	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4022	Thapsigargin	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4023	Xestospongin C	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4024	Agatoxin	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4026	Conotoxin	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Investigational	20668647
DrugRepV_4028	Lanthanum Chloride	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4032	Tetrandrine	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Experimental	20668647
DrugRepV_4034	5-N-ethyl isopropyl amiloride	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4036	Benzamil	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4039	Agatoxin	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4041	Conotoxin	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Investigational	20668647
DrugRepV_4043	Lanthanum Chloride	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4047	Tetrandrine	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Experimental	20668647
DrugRepV_4049	5-N-ethyl isopropyl amiloride	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4051	Benzamil	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4054	7-octyl-indolactam	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4056	Gliotoxin	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4057	Oleic Acid	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Approved, Investigational, Vet approved	20668647
DrugRepV_4059	PKC Inhibitor	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4060	PMA	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4061	Rottlerin	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4062	U73122	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4063	7-octyl-indolactam	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4065	Gliotoxin	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4066	Oleic Acid	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Approved, Investigational, Vet approved	20668647
DrugRepV_4068	PKC Inhibitor	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4069	PMA	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4070	Rottlerin	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4071	U73122	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	NA	20668647
DrugRepV_4072	25-OH-cholecalciferol	NA	NA	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Approved, Nutraceutical	20668647
DrugRepV_4073	4-OH-tamoxifen	NA	Breast cancer	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Investigational	20668647
DrugRepV_4074	Arg-vasopressin	NA	Enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Approved	20668647
DrugRepV_4075	Bradykinin	NA	Hypertension and Diabetes Type 2	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Investigational	20668647
DrugRepV_4077	Cholecalciferol	NA	Vitamin D resistant rickets), hypoparathyroidism, and familial hypophosphatemia	Hendra virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Approved	20668647
DrugRepV_4080	25-OH-cholecalciferol	NA	NA	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Approved, Nutraceutical	20668647
DrugRepV_4081	4-OH-tamoxifen	NA	Breast cancer	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Investigational	20668647
DrugRepV_4082	Arg-vasopressin	NA	Enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Approved	20668647
DrugRepV_4083	Bradykinin	NA	Hypertension and Diabetes Type 3	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Investigational	20668647
DrugRepV_4085	Cholecalciferol	NA	Vitamin D resistant rickets), hypoparathyroidism, and familial hypophosphatemia	Nipah virus	NA	NA	Immunolabeling assay	Decrease (50 %)	Approved	20668647
DrugRepV_4103	2-(4-tert-butylphenyl)-N-[(E)-(3,4-diethoxyphenyl)methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4104	2-(4-tert-butylphenyl)-N-[(E)-(3,5-dibromo-4-methoxyphenyl)methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4105	2-(4-tert-butylphenyl)-N-[(E)-[4-(diethylamino)-2-hydroxyphenyl]methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4106	2-(4-tert-butylphenyl)-N-[(E)-[4-(trifluoromethyl)phenyl]methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4107	2-(4-tert-butylphenyl)-N-[(E)-[4-(methylsulfanyl)phenyl]methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4108	2-(4-tert-butylphenyl)-N-[(E)-(4-methylphenyl)methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4109	2-(4-tert-butylphenyl)-N-[(1E)-2-[(1-methylnaphthalen-2-yl)oxy]ethylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4110	2-(4-tert-butylphenyl)-N-[(E)-[4-(propan-2-yl)phenyl]methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4111	2-(4-tert-butylphenyl)-N-[(1E)-1-phenylpropylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4112	N-[(E)-(4-bromophenyl)methylidene]-2-phenylcyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4113	N-[(E)-(4-hydroxyphenyl)methylidene]-2-phenylcyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4114	N-[(E)-(4-cyclohexylphenyl)methylidene]-2-phenylcyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4115	N-[(1E)-1-(4-methoxyphenyl)ethylidene]-2-phenylcyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4116	(2E)-3-(4-tert-butylphenyl)-N-[(E)-(3,4-diethoxyphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	NA	NA	CPE reduction assay	Decrease (50 %)	NA	23380636
DrugRepV_4117	Coumarin A	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (50 %)	NA	28100218
DrugRepV_4118	Coumarin B	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (50 %)	NA	28100218
DrugRepV_4119	Lupeol Acetate 26SK001	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (50 %)	NA	28100218
DrugRepV_4120	Voacangine 26SK002	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (50 %)	NA	28100218
DrugRepV_4121	Coumarin A	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (44 %)	NA	28100218
DrugRepV_4122	Coumarin B	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (92.5 %)	NA	28100218
DrugRepV_4123	Lupeol Acetate 26SK001	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (4.1 %)	NA	28100218
DrugRepV_4124	Voacangine 26SK002	NA	NA	Chikungunya virus	Acol	NA	Plating method	Decrease (0.4 %)	NA	28100218
DrugRepV_4125	3-{3-[(1E)-1-(hydroxyimino)ethyl]phenyl}-5-methyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4126	3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-5-methyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4127	5-ethyl-3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4128	3-(3-acetylphenyl)-5-ethyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4129	5-(aminomethyl)-3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4130	3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-5-sulfanyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4131	3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-5-(methylsulfanyl)-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4132	3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-5-(methylamino)-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4133	5-ethyl-3-{3-[(1E)-1-{[2-(4-methylpiperazin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4134	5-ethyl-3-{3-[(1E)-1-{[2-(morpholin-4-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4135	5-ethyl-3-{3-[(1E)-1-{[2-(thiomorpholin-4-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4136	3-{3-[(1E)-1-{[2-(diethylamino)ethoxy]imino}ethyl]phenyl}-5-ethyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4137	3-{3-[(1E)-1-{[2-(cyclohexylamino)ethoxy]imino}ethyl]phenyl}-5-ethyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4138	5-ethyl-3-{3-[(1E)-1-{[2-(piperidin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4139	5-ethyl-3-{3-[(1E)-1-{[2-(pyrrolidin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4140	3-{3-[(1E)-1-({2-[4-(dimethylamino)piperidin-1-yl]ethoxy}imino)ethyl]phenyl}-5-ethyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4141	5-ethyl-3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Venturini	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4142	5-ethyl-3-{3-[(1E)-1-{[2-(morpholin-4-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Venturini	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4143	5-ethyl-3-{3-[(1E)-1-{[2-(piperidin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Venturini	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4144	5-ethyl-3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Congo 95	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4145	5-ethyl-3-{3-[(1E)-1-{[2-(morpholin-4-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Congo 95	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4146	5-ethyl-3-{3-[(1E)-1-{[2-(piperidin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	Congo 95	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4147	5-ethyl-3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	St. Martin 20235	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4148	5-ethyl-3-{3-[(1E)-1-{[2-(piperidin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	St. Martin 20235	NA	qRT-PCR	Decrease (50 %)	NA	28619679
DrugRepV_4149	2-(4-tert-butylphenyl)-N-[(E)-(4-ethoxyphenyl)methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4150	2-(4-tert-butylphenyl)-N-[(E)-[4-(trifluoromethyl)phenyl]methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4151	N-[(E)-(4-hydroxyphenyl)methylidene]-2-phenylcyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4152	N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]-2-phenylcyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4153	N-[(1E)-1-(4-methoxyphenyl)ethylidene]-2-phenylcyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4154	(2E)-3-(4-tert-butylphenyl)-N-[(E)-(3,4-diethoxyphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4155	2-(4-tert-butylphenyl)-N-[(E)-(4-ethoxyphenyl)methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4156	2-(4-tert-butylphenyl)-N-[(E)-(4-hydroxyphenyl)methylidene]cyclopropane-1-carbohydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4157	(2E)-3-(4-tert-butylphenyl)-N-[(E)-(4-ethoxyphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4158	(2E)-3-(4-tert-butylphenyl)-N-[(E)-(4-methylphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4159	(2E)-3-(4-methylphenyl)-N-[(E)-(4-methylphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4160	(2E)-N-[(E)-(4-methylphenyl)methylidene]-3-phenylprop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4161	(2E)-3-(4-tert-butylphenyl)-N-[(E)-[4-(propan-2-yl)phenyl]methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4162	(2E)-3-(4-tert-butylphenyl)-N-[(E)-(4-tert-butylphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4163	(2E)-3-(4-tert-butylphenyl)-N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4164	(2E)-N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]-3-phenylprop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4165	(2E)-3-(4-tert-butylphenyl)-N-[(E)-phenylmethylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4166	(2E)-3-(4-tert-butylphenyl)-N-[(E)-(4-nitrophenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4167	(2E)-3-(4-tert-butylphenyl)-N-[(1E)-1-(4-chlorophenyl)ethylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4168	(2E)-3-(4-tert-butylphenyl)-N-[(1E)-1-(pyrazin-2-yl)ethylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4169	(2E)-3-(4-tert-butylphenyl)-N-[(1E)-1-(4-ethoxyphenyl)ethylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4170	(2E)-N-[(1E)-1-{[1,1-biphenyl]-4-yl}ethylidene]-3-(4-tert-butylphenyl)prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4171	(2E)-N-[(E)-(4-ethoxyphenyl)methylidene]-3-(4-methylphenyl)prop-2-enehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4172	(2E)-3-(4-tert-butylphenyl)-N-{[4-(trifluoromethyl)phenyl]methyl}prop-2-enamide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4173	(2E)-3-phenyl-N-{[4-(trifluoromethyl)phenyl]methyl}prop-2-enamide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4174	(2E)-N-({[1,1-biphenyl]-4-yl}methyl)-3-(4-tert-butylphenyl)prop-2-enamide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4175	(2E)-N-({[1,1-biphenyl]-4-yl}methyl)-3-phenylprop-2-enamide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4176	3-(4-tert-butylphenyl)-N-[(E)-(4-ethoxyphenyl)methylidene]propanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4177	N-[(E)-(4-ethoxyphenyl)methylidene]-3-phenylpropanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4178	3-(4-tert-butylphenyl)-N-[(E)-(4-methylphenyl)methylidene]propanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4179	N-[(E)-(4-methylphenyl)methylidene]-3-phenylpropanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4180	3-(4-tert-butylphenyl)-N-[(E)-(4-hydroxyphenyl)methylidene]propanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4181	N-[(E)-(4-methylphenyl)methylidene]-3-phenylpropanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4182	3-(4-tert-butylphenyl)-N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]propanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4183	N-[(E)-(4-cyclohexylphenyl)methylidene]-3-phenylpropanehydrazide	NA	NA	Chikungunya virus	889	NA	CPE reduction assay	Decrease (50 %)	NA	29336951
DrugRepV_4184	1-(4-{2-[1-cyclohexyl-2-(furan-3-yl)-1H-1,3-benzodiazol-5-yl]-1,3-oxazol-5-yl}phenyl)pyrrolidin-2-one	NA	NA	Chikungunya virus	SL10571	NA	MTT assay	Decrease (50 %)	NA	28236746
DrugRepV_4186	1-(4-{2-[1-cyclohexyl-2-(furan-3-yl)-1H-1,3-benzodiazol-5-yl]-1,3-oxazol-5-yl}phenyl)pyrrolidin-2-one	NA	NA	Chikungunya virus	S27	NA	MTT assay	Decrease (50 %)	NA	28236746
DrugRepV_4188	1-(4-{2-[1-cyclohexyl-2-(furan-3-yl)-1H-1,3-benzodiazol-5-yl]-1,3-oxazol-5-yl}phenyl)pyrrolidin-2-one	NA	NA	Chikungunya virus	BaH306	NA	MTT assay	Decrease (50 %)	NA	28236746
DrugRepV_4190	Phorbol	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4191	Phorbol-12-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	25970561
DrugRepV_4192	Phorbol-12-decanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4193	Phorbol-13-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4194	Phorbol-13-butyrate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4195	Pphorbol-13-decanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4196	Phorbol-13-tetradecanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4197	Phorbol-12,13-diacetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4198	Phorbol-12,13-dibutyrate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4199	Phorbol-12,13- dihexanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4200	Phorbol-12,13-didecanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4201	4α-phorbol-12,13-didecanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4202	12-O-tetradecanoylphorbol-13-acetate	NA	Cancer	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase II	25970561
DrugRepV_4203	12-O-tetradecanoyl-4?-phorbol-13-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4204	12-O- tiglylphorbol-13-decanoate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4205	12-O-(N-methylanthranilate) phorbol-13-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4206	Phorbol-13,20-diacetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4207	12,13-O,O-dinonanoylphorbol-20-homovanillate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4208	12-O-phenylacetyl-13-O-acetylphorbol-20-homovanillate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4209	Phorbol-12,13,20-triacetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4210	20-oxo-20-deoxyphorbol-12,13-dibutyrate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4211	12-O-tetradecanoyl-20-oxo-20-deoxyphorbol-13-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4212	12-deoxyphorbol-13-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4213	13-O-isobutyryl-12-deoxyphorbol-20-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4214	13-O-phenylacetyl-12-deoxyphorbol-20-acetate	NA	NA	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	25970561
DrugRepV_4218	Resiniferatoxin	NA	Interstitial cystitis and urinary incontinence	Chikungunya virus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	25970561
DrugRepV_4220	Arbidol	NA	NA	Chikungunya virus	LR2006 OPY1	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	21440006
DrugRepV_4221	HZ2a	NA	NA	Chikungunya virus	LR2006 OPY1	NA	Immunoflourescence assay	Decrease (50 %)	NA	21440006
DrugRepV_4222	6-bromo-4-(dimethylaminomethyl)-5-hydroxy-1-methyl-2-(phe- nylsulphonylmethyl)-1H-indole-3-carboxylate	NA	NA	Chikungunya virus	LR2006 OPY1	NA	Immunoflourescence assay	Decrease (50 %)	NA	21440006
DrugRepV_4223	6-bromo- 4-(dimethylaminomethyl)-5-hydroxy-1-methyl-2-(methylphenyl- sulphoxyde)-1H-indole-3-carboxylate	NA	NA	Chikungunya virus	LR2006 OPY1	NA	Immunoflourescence assay	Decrease (50 %)	NA	21440006
DrugRepV_4224	(2E)-3-(4-tert-butylphenyl)-N-[(E)-(4-ethoxyphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4225	3-[(E)-{[2-(4-methylphenyl)-1H-indol-3-yl]methylidene}amino]-1-(2-phenylethyl)thiourea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4226	(2E)-N-[(E)-(4-ethoxyphenyl)methylidene]-3-[4-(propan-2-yl)phenyl]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4227	(2E)-N-[(E)-(4-ethoxyphenyl)methylidene]-3-[4-(trifluoromethyl)phenyl]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4228	(2E)-N-[(E)-(4-ethoxyphenyl)methylidene]-3-(4-methoxyphenyl)prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4229	(2E)-3-{[1,1-biphenyl]-4-yl}-N-[(E)-(4-ethoxyphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4230	(2E)-N-[(E)-(4-methylphenyl)methylidene]-3-[4-(propan-2-yl)phenyl]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4231	(2E)-N-[(E)-(4-methylphenyl)methylidene]-3-[4-(trifluoromethyl)phenyl]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4232	(2E)-3-(4-methoxyphenyl)-N-[(E)-(4-methylphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4233	(2E)-3-{[1,1-biphenyl]-4-yl}-N-[(E)-(4-methylphenyl)methylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4234	(2E)-N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]-3-[4-(propan-2-yl)phenyl]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4235	(2E)-N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]-3-[4-(trifluoromethyl)phenyl]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4236	(2E)-N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]-3-(4-methoxyphenyl)prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4237	(2E)-3-{[1,1-biphenyl]-4-yl}-N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4238	(2E)-N-[(E)-(4-hydroxyphenyl)methylidene]-3-[4-(propan-2-yl)phenyl]prop-2-enehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4239	N-[(E)-(4-ethoxyphenyl)methylidene]naphthalene-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4240	N-[(E)-(4-ethoxyphenyl)methylidene]quinoline-3-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4241	N-[(E)-(4-ethoxyphenyl)methylidene]quinoline-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4242	N-[(E)-(4-ethoxyphenyl)methylidene]-1H-indole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4243	N-[(E)-(4-ethoxyphenyl)methylidene]-1H-1,3-benzodiazole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4244	N-[(E)-(4-methylphenyl)methylidene]naphthalene-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4245	N-[(E)-(4-methylphenyl)methylidene]quinoline-3-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4246	N-[(E)-(4-methylphenyl)methylidene]quinoline-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4247	N-[(E)-(4-methylphenyl)methylidene]-1H-indole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4248	N-[(E)-(4-methylphenyl)methylidene]-1H-1,3-benzodiazole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4249	N-[(E)-(4-hydroxyphenyl)methylidene]naphthalene-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4250	N-[(E)-(4-hydroxyphenyl)methylidene]quinoline-3-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4251	N-[(E)-(4-hydroxyphenyl)methylidene]quinoline-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4252	N-[(E)-(4-hydroxyphenyl)methylidene]-1H-indole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4253	N-[(E)-(4-hydroxyphenyl)methylidene]-1H-1,3-benzodiazole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4254	N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]naphthalene-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4255	N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]quinoline-3-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4256	N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]quinoline-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4257	N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]-1H-indole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4258	N-[(1E)-1-(4-cyclohexylphenyl)ethylidene]-1H-1,3-benzodiazole-2-carbohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4259	3-(4-tert-butylphenyl)-N-[(E)-(4-ethoxyphenyl)methylidene]-3-oxopropanehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4260	3-(4-tert-butylphenyl)-N-[(E)-(4-methylphenyl)methylidene]-3-oxopropanehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4261	3-(4-tert-butylphenyl)-N-[(E)-(4-hydroxyphenyl)methylidene]-3-oxopropanehydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4262	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-[(E)-[(4-ethoxyphenyl)methylidene]amino]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4263	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-[(E)-[(4-methylphenyl)methylidene]amino]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4264	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-[(E)-[(4-hydroxyphenyl)methylidene]amino]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4265	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-[(E)-[1-(4-cyclohexylphenyl)ethylidene]amino]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4266	1-[(E)-[(4-ethoxyphenyl)methylidene]amino]-3-(2-phenylethyl)thiourea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4267	1-[(E)-[(4-methylphenyl)methylidene]amino]-3-(2-phenylethyl)thiourea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4268	1-[(E)-[(4-hydroxyphenyl)methylidene]amino]-3-(2-phenylethyl)thiourea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4269	1-[(E)-[1-(4-cyclohexylphenyl)ethylidene]amino]-3-(2-phenylethyl)thiourea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4270	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-[(4-ethoxyphenyl)methyl]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4271	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-[(4-methylphenyl)methyl]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4272	1-benzyl-3-[(1E)-2-(4-tert-butylphenyl)ethenyl]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4273	1-[(4-methoxyphenyl)methyl]-3-[(1E)-2-phenylethenyl]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4274	1-[(4-methylphenyl)methyl]-3-[(1E)-2-phenylethenyl]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4275	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-(4-methylphenyl)urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4276	3-[(1E)-2-(4-tert-butylphenyl)ethenyl]-1-(4-hydroxyphenyl)urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4277	1-(4-methylphenyl)-3-[(1E)-2-phenylethenyl]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4278	1-(4-hydroxyphenyl)-3-[(1E)-2-phenylethenyl]urea	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4279	N-[(2E)-3-(4-tert-butylphenyl)prop-2-enoyl]-4-ethoxybenzohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4280	N-[(2E)-3-(4-tert-butylphenyl)prop-2-enoyl]-4-methylbenzohydrazide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4281	2-[(1E)-2-(4-tert-butylphenyl)ethenyl]-5-(4-ethoxyphenyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4282	2-[(1E)-2-(4-tert-butylphenyl)ethenyl]-5-(4-methylphenyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4283	2-[2-(4-tert-butylphenyl)ethyl]-5-(4-ethoxyphenyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4284	2-[2-(4-tert-butylphenyl)ethyl]-5-(4-methylphenyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4285	2-(4-ethoxyphenyl)-5-(2-phenylethyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4286	2-(4-methylphenyl)-5-(2-phenylethyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4287	4-{5-[2-(4-tert-butylphenyl)ethyl]-1,3,4-oxadiazol-2-yl}phenol	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4288	2-[(4-tert-butylphenyl)methyl]-5-(4-ethoxyphenyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4289	2-[(4-tert-butylphenyl)methyl]-5-(4-methylphenyl)-1,3,4-oxadiazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4290	4-(4-methylphenyl)-1-(2-phenylethyl)-1H-1,2,3-triazole	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4291	(2E)-3-(4-tert-butylphenyl)-N-(5-methyl-1H-1,3-benzodiazol-2-yl)prop-2-enamide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4292	(2E)-N-(1H-1,3-benzodiazol-2-yl)-3-(4-tert-butylphenyl)prop-2-enamide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4293	3-(4-tert-butylphenyl)-N-(5-methyl-1H-1,3-benzodiazol-2-yl)propanamide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4294	N-(1H-1,3-benzodiazol-2-yl)-3-(4-tert-butylphenyl)propanamide	NA	NA	Chikungunya virus	899	NA	CPE reduction assay	Decrease (50 %)	NA	29499487
DrugRepV_4299	Fisetin	NA	Frail Elderly Syndrome	Chikungunya virus	NA	NA	NA	Decrease (50 %)	Experimental	27460167
DrugRepV_4300	Quercetagetin	NA	NA	Chikungunya virus	NA	NA	NA	Decrease (50 %)	NA	27460167
DrugRepV_4302	Carbocyclic adenosine	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4303	Carbocyclic 3-deazaadenosine	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4304	9-[trans- 2,trans - 3 - dihydroxy - 4 - (methyl) - cyclopent - 4 - enyl] - 3 - deazaadenine	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4305	9-[trans-2,trans-3-dihydroxy-4-hydroxymethyl-cyclopent-4-enyl]-adenine	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4306	9-[trans-2,trans-3-dihydroxy-4-hydroxymethyl-cyclopent-4-enyl]-3-deazaadenine	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4307	9-[trans-2,trans-3-dihydroxycyclopent-4-enyl]- adenine (DHCpAdo)	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4308	9-[trans-2,trans-3-dihydroxycyclopent- 4-enyl]-3-deazaadenine (DHCp-c3Ado)	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4309	4,5- didehydro-5-deoxy-5-fluoroadenosine (DDFA)	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4311	Guanosine Dialdehyde	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4312	Adenosine Dialdehyde	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	Approved, Investigational	9988190
DrugRepV_4314	Carbocyclic 3-deazaadenosine	NA	NA	Ebola virus	Sudan (Boneface strain)	NA	Plaque reduction assay	Decrease (50 %)	NA	9988190
DrugRepV_4315	9-[trans-2,trans-3-dihydroxy-4-hydroxymethyl-cyclopent-4-enyl]-adenine	NA	NA	Ebola virus	Sudan (Boneface strain)	NA	Plaque reduction assay	Decrease (50 %)	NA	9988190
DrugRepV_4316	9-[trans-2,trans-3-dihydroxy-4-hydroxymethyl-cyclopent-4-enyl]-3-deazaadenine	NA	NA	Ebola virus	Sudan (Boneface strain)	NA	Plaque reduction assay	Decrease (50 %)	NA	9988190
DrugRepV_4317	Carbocyclic 3-deazaadenosine	NA	NA	Ebola virus	EBO-Z	NA	Survival assay	Increase	NA	9988190
DrugRepV_4318	FGI-106	NA	NA	Ebola virus	Zaire	NA	Plaque assay	Decrease (50 %)	NA	19523489
DrugRepV_4319	FGI-106	NA	NA	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (50 %)	NA	19523489
DrugRepV_4320	FGI-106	NA	NA	Ebola virus	Zaire	NA	Survival assay	Increase	NA	19523489
DrugRepV_4321	N-(1,3-benzodioxol-5-ylmethyl)-2-(3-cyano-2-methyl-1H-indol-1-yl)acetamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (44.6 %)	NA	24501399
DrugRepV_4322	N-benzyl-6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (32.6 %)	NA	24501399
DrugRepV_4323	9H-carbazol-3-amine	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (6.1 %)	NA	24501399
DrugRepV_4324	7-(1H-benzimidazol-2-ylthio)-8-methyl[1,3]dioxolo[4,5-g]quinolin-6(5H)-one	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-3.8 %)	NA	24501399
DrugRepV_4325	N-[2-(2-methoxyethyl)-1,2,3,4-tetrahydropyrazino[1,2-a]benzimidazol-8-yl]benzamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-16 %)	NA	24501399
DrugRepV_4326	tris[4-(dimethylamino)phenyl]methanol	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (31.8 %)	NA	24501399
DrugRepV_4327	6-chloro-N-[3-(4-methyl-1H-pyrazol-1-yl)propyl]-2-(3-pyridinyl)-4-quinolinecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (31.8 %)	NA	24501399
DrugRepV_4328	1-(2-furoyl)-5-(2-furyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-1.6 %)	NA	24501399
DrugRepV_4329	2-[(1H-benzimidazol-2-ylmethyl)thio]-1-[2-(4-methylphenoxy)ethyl]-1H-benzimidazole	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-1.8 %)	NA	24501399
DrugRepV_4330	N-(3-chloro-4-fluorophenyl)-N-[4-(4-morpholinylsulfonyl)phenyl]urea	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (66.3 %)	NA	24501399
DrugRepV_4331	4-{[(5-methyl-2-thienyl)methyl]amino}phenol	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-12.6 %)	NA	24501399
DrugRepV_4332	N-[5-(1H-benzimidazol-2-yl)-2-methylphenyl]-1,3-benzodioxole-5-carboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-3.4 %)	NA	24501399
DrugRepV_4333	N-[1-benzyl-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]benzamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (10.2 %)	NA	24501399
DrugRepV_4334	2-methoxy-N-[1-methyl-2-(1-pyrrolidinylmethyl)-1H-benzimidazol-5-yl]benzamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (8.6 %)	NA	24501399
DrugRepV_4335	N-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-2-(2-naphthyloxy)acetamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (66.9 %)	NA	24501399
DrugRepV_4336	N-(2,5-dimethoxyphenyl)-N-[4-(trifluoromethyl)phenyl]urea	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (9.6 %)	NA	24501399
DrugRepV_4337	4-{[(1H-benzimidazol-2-ylthio)acetyl]amino}phenyl thiocyanate	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (34 %)	NA	24501399
DrugRepV_4338	N-(3,4-dichlorophenyl)-N-[3-(trifluoromethyl)phenyl]urea	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (11.6 %)	NA	24501399
DrugRepV_4339	N-1,3-benzodioxol-5-yl-6-chloro-2-(3-pyridinyl)-4-quinolinecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (45.7 %)	NA	24501399
DrugRepV_4340	N-(3-chlorophenyl)-N-(4-cyanophenyl)urea	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (10.1 %)	NA	24501399
DrugRepV_4341	N-[4-(1H-benzimidazol-2-yl)phenyl]-2-chloro-5-(4H-1,2,4-triazol-4-yl)benzamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-3.4 %)	NA	24501399
DrugRepV_4342	N-[3-(aminocarbonyl)-5-benzyl-2-thienyl]-2-methyl-3-furamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (5.7 %)	NA	24501399
DrugRepV_4343	4,5-dimethyl-2-{[(5-propyl-3-thienyl)carbonyl]amino}-N-(3-pyridinylmethyl)-3-thiophenecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-24.6 %)	NA	24501399
DrugRepV_4344	1-(isopropylamino)-3-(3-phenyl-4,5-dihydropyrazolo[4,3-a]carbazol-10(3H)-yl)-2-propanol	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (13.1 %)	NA	24501399
DrugRepV_4345	2-[(4-tert-butyl-1,3-thiazol-2-yl)amino]-8-quinolinol	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (6.4 %)	NA	24501399
DrugRepV_4346	N-(aminocarbonyl)-2-{[(5-methyl-3-thienyl)carbonyl]amino}-3-thiophenecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (6.2 %)	NA	24501399
DrugRepV_4347	2-chloro-N-(4-phenyl-1,3-thiazol-2-yl)-5-(4H-1,2,4-triazol-4-yl)benzamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (10.7 %)	NA	24501399
DrugRepV_4348	N-[3-(2-oxo-2H-chromen-3-yl)phenyl]-1,3-benzodioxole-5-carboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (2.1 %)	NA	24501399
DrugRepV_4349	4,5-dimethyl-2-[(phenoxyacetyl)amino]-N-(3-pyridinylmethyl)-3-thiophenecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-0.6 %)	NA	24501399
DrugRepV_4350	N-(4-{[(5-methyl-3-isoxazolyl)amino]sulfonyl}phenyl)-1-benzothiophene-3-carboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-2.6 %)	NA	24501399
DrugRepV_4351	3-[(1H-benzimidazol-2-ylmethyl)thio]-9-benzyl-9H-[1,2,4]triazolo[4,3-a]benzimidazole	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-6.1 %)	NA	24501399
DrugRepV_4352	methyl N-[4,6-bis(isopropylamino)-1,3,5-triazin-2-yl]-N-cyanoglycinate	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (82.4 %)	NA	24501399
DrugRepV_4353	N-(3,4-dichlorophenyl)-2-oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (33.4 %)	NA	24501399
DrugRepV_4354	N-(3-pyridinylmethyl)dibenzo[b,d]furan-3-amine	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (25.4 %)	NA	24501399
DrugRepV_4355	(1,3-benzodioxol-5-ylmethyl)[4-(1-pyrrolidinyl)phenyl]amine	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (10.5 %)	NA	24501399
DrugRepV_4356	4-methyl-5-phenyl-N-3-pyridinyl-2-thiophenecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (25.2 %)	NA	24501399
DrugRepV_4357	N-(2,5-dimethoxyphenyl)-2-(2-oxo-1,3-benzoxazol-3(2H)-yl)acetamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (17.4 %)	NA	24501399
DrugRepV_4358	3-[(2,4-dichlorophenoxy)methyl]-N-(3-pyridinylmethyl)benzamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (26.8 %)	NA	24501399
DrugRepV_4359	5-phenyl-2-(2-phenylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-6.6 %)	NA	24501399
DrugRepV_4360	6-bromo-2-oxo-N-3-pyridinyl-2H-chromene-3-carboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (20.9 %)	NA	24501399
DrugRepV_4361	2-[(2-methyl-8-quinolinyl)amino]-4H-pyrido[3,2-e][1,3]thiazin-4-one	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-12.1 %)	NA	24501399
DrugRepV_4362	N-(3-chloro-4-fluorophenyl)-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]urea	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (12.3 %)	NA	24501399
DrugRepV_4363	4-({[(3-chloro-4-fluorophenyl)amino]carbonyl}amino)-N-methylbenzenesulfonamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (1.8 %)	NA	24501399
DrugRepV_4364	2-(4-fluorophenyl)-N-(4-{[(4-methylphenyl)amino]sulfonyl}phenyl)acetamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (1.1 %)	NA	24501399
DrugRepV_4365	5-methyl-N-[4-(1-pyrrolidinylsulfonyl)phenyl]-3-thiophenecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-0.3 %)	NA	24501399
DrugRepV_4366	2-amino-N-(3-chlorophenyl)-3-quinolinecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-1.5 %)	NA	24501399
DrugRepV_4367	2-(1,3-benzodioxol-5-yl)-1-(1,3-benzodioxol-5-ylmethyl)-1H-benzimidazole	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-15.9 %)	NA	24501399
DrugRepV_4368	N-{3-[(benzylamino)carbonyl]phenyl}-5-methyl-3-thiophenecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-11.5 %)	NA	24501399
DrugRepV_4369	8-chloro-N-[3-(3-methyl-1H-pyrazol-1-yl)propyl]-2-(2-pyridinyl)-4-quinolinecarboxamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (-11.7 %)	NA	24501399
DrugRepV_4370	N-[4-(2,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(2-thienyl)acetamide	NA	NA	Ebola virus	GP, amino acids 196 to 205	NA	CatL-Peptide cleavage	Decrease (8.05 %)	NA	24501399
DrugRepV_4371	N-(1,3-benzodioxol-5-ylmethyl)-2-(3-cyano-2-methyl-1H-indol-1-yl)acetamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (24.79 %)	NA	24501399
DrugRepV_4372	N-benzyl-6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (31.07 %)	NA	24501399
DrugRepV_4373	9H-carbazol-3-amine	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (8.2 %)	NA	24501399
DrugRepV_4374	7-(1H-benzimidazol-2-ylthio)-8-methyl[1,3]dioxolo[4,5-g]quinolin-6(5H)-one	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (37.87 %)	NA	24501399
DrugRepV_4375	N-[2-(2-methoxyethyl)-1,2,3,4-tetrahydropyrazino[1,2-a]benzimidazol-8-yl]benzamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-0.67 %)	NA	24501399
DrugRepV_4376	tris[4-(dimethylamino)phenyl]methanol	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (108.4 %)	NA	24501399
DrugRepV_4377	6-chloro-N-[3-(4-methyl-1H-pyrazol-1-yl)propyl]-2-(3-pyridinyl)-4-quinolinecarboxamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (39.17 %)	NA	24501399
DrugRepV_4378	1-(2-furoyl)-5-(2-furyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (5.24 %)	NA	24501399
DrugRepV_4379	2-[(1H-benzimidazol-2-ylmethyl)thio]-1-[2-(4-methylphenoxy)ethyl]-1H-benzimidazole	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-2.7 %)	NA	24501399
DrugRepV_4380	N-(3-chloro-4-fluorophenyl)-N-[4-(4-morpholinylsulfonyl)phenyl]urea	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (40.4 %)	NA	24501399
DrugRepV_4381	4-{[(5-methyl-2-thienyl)methyl]amino}phenol	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-14.4 %)	NA	24501399
DrugRepV_4382	N-[5-(1H-benzimidazol-2-yl)-2-methylphenyl]-1,3-benzodioxole-5-carboxamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-7.77 %)	NA	24501399
DrugRepV_4383	N-[1-benzyl-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]benzamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (0.34 %)	NA	24501399
DrugRepV_4384	2-methoxy-N-[1-methyl-2-(1-pyrrolidinylmethyl)-1H-benzimidazol-5-yl]benzamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-9.26 %)	NA	24501399
DrugRepV_4385	N-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-2-(2-naphthyloxy)acetamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (73.49 %)	NA	24501399
DrugRepV_4386	N-(2,5-dimethoxyphenyl)-N-[4-(trifluoromethyl)phenyl]urea	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-4.08 %)	NA	24501399
DrugRepV_4387	4-{[(1H-benzimidazol-2-ylthio)acetyl]amino}phenyl thiocyanate	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (7.92 %)	NA	24501399
DrugRepV_4388	N-(3,4-dichlorophenyl)-N-[3-(trifluoromethyl)phenyl]urea	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (42.12 %)	NA	24501399
DrugRepV_4389	N-1,3-benzodioxol-5-yl-6-chloro-2-(3-pyridinyl)-4-quinolinecarboxamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (32.88 %)	NA	24501399
DrugRepV_4390	N-(3-chlorophenyl)-N-(4-cyanophenyl)urea	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (24.49 %)	NA	24501399
DrugRepV_4391	N-[4-(1H-benzimidazol-2-yl)phenyl]-2-chloro-5-(4H-1,2,4-triazol-4-yl)benzamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (0.86 %)	NA	24501399
DrugRepV_4392	N-[3-(aminocarbonyl)-5-benzyl-2-thienyl]-2-methyl-3-furamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (6.5 %)	NA	24501399
DrugRepV_4393	4,5-dimethyl-2-{[(5-propyl-3-thienyl)carbonyl]amino}-N-(3-pyridinylmethyl)-3-thiophenecarboxamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-7.5 %)	NA	24501399
DrugRepV_4394	1-(isopropylamino)-3-(3-phenyl-4,5-dihydropyrazolo[4,3-a]carbazol-10(3H)-yl)-2-propanol	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (35.73 %)	NA	24501399
DrugRepV_4395	2-[(4-tert-butyl-1,3-thiazol-2-yl)amino]-8-quinolinol	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-2.85 %)	NA	24501399
DrugRepV_4396	N-(aminocarbonyl)-2-{[(5-methyl-3-thienyl)carbonyl]amino}-3-thiophenecarboxamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (37.33 %)	NA	24501399
DrugRepV_4397	2-chloro-N-(4-phenyl-1,3-thiazol-2-yl)-5-(4H-1,2,4-triazol-4-yl)benzamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (22.44 %)	NA	24501399
DrugRepV_4398	N-[3-(2-oxo-2H-chromen-3-yl)phenyl]-1,3-benzodioxole-5-carboxamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (37.22 %)	NA	24501399
DrugRepV_4399	4,5-dimethyl-2-[(phenoxyacetyl)amino]-N-(3-pyridinylmethyl)-3-thiophenecarboxamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (33.41 %)	NA	24501399
DrugRepV_4400	N-(4-{[(5-methyl-3-isoxazolyl)amino]sulfonyl}phenyl)-1-benzothiophene-3-carboxamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (7.38 %)	NA	24501399
DrugRepV_4401	3-[(1H-benzimidazol-2-ylmethyl)thio]-9-benzyl-9H-[1,2,4]triazolo[4,3-a]benzimidazole	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-0.01 %)	NA	24501399
DrugRepV_4402	methyl N-[4,6-bis(isopropylamino)-1,3,5-triazin-2-yl]-N-cyanoglycinate	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (90.92 %)	NA	24501399
DrugRepV_4403	N-(3,4-dichlorophenyl)-2-oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (12.1 %)	NA	24501399
DrugRepV_4404	N-(3-pyridinylmethyl)dibenzo[b,d]furan-3-amine	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (21.93 %)	NA	24501399
DrugRepV_4405	(1,3-benzodioxol-5-ylmethyl)[4-(1-pyrrolidinyl)phenyl]amine	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-8.72 %)	NA	24501399
DrugRepV_4406	4-methyl-5-phenyl-N-3-pyridinyl-2-thiophenecarboxamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (17.7 %)	NA	24501399
DrugRepV_4407	N-(2,5-dimethoxyphenyl)-2-(2-oxo-1,3-benzoxazol-3(2H)-yl)acetamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (23.22 %)	NA	24501399
DrugRepV_4408	3-[(2,4-dichlorophenoxy)methyl]-N-(3-pyridinylmethyl)benzamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (23.55 %)	NA	24501399
DrugRepV_4409	5-phenyl-2-(2-phenylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (3.55 %)	NA	24501399
DrugRepV_4410	6-bromo-2-oxo-N-3-pyridinyl-2H-chromene-3-carboxamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (32.65 %)	NA	24501399
DrugRepV_4411	2-[(2-methyl-8-quinolinyl)amino]-4H-pyrido[3,2-e][1,3]thiazin-4-one	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (3.23 %)	NA	24501399
DrugRepV_4412	N-(3-chloro-4-fluorophenyl)-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]urea	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (25.12 %)	NA	24501399
DrugRepV_4413	4-({[(3-chloro-4-fluorophenyl)amino]carbonyl}amino)-N-methylbenzenesulfonamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-11.51 %)	NA	24501399
DrugRepV_4414	2-(4-fluorophenyl)-N-(4-{[(4-methylphenyl)amino]sulfonyl}phenyl)acetamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (5.7 %)	NA	24501399
DrugRepV_4415	5-methyl-N-[4-(1-pyrrolidinylsulfonyl)phenyl]-3-thiophenecarboxamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-10.47 %)	NA	24501399
DrugRepV_4416	2-amino-N-(3-chlorophenyl)-3-quinolinecarboxamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-2.95 %)	NA	24501399
DrugRepV_4417	2-(1,3-benzodioxol-5-yl)-1-(1,3-benzodioxol-5-ylmethyl)-1H-benzimidazole	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-9.09 %)	NA	24501399
DrugRepV_4418	N-{3-[(benzylamino)carbonyl]phenyl}-5-methyl-3-thiophenecarboxamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-0.72 %)	NA	24501399
DrugRepV_4419	8-chloro-N-[3-(3-methyl-1H-pyrazol-1-yl)propyl]-2-(2-pyridinyl)-4-quinolinecarboxamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (-10.37 %)	NA	24501399
DrugRepV_4420	N-[4-(2,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(2-thienyl)acetamide	NA	NA	Hendra virus	F0, amino acids 105 to 114	NA	CatL-Peptide cleavage	Decrease (3.26 %)	NA	24501399
DrugRepV_4421	N-(1,3-benzodioxol-5-ylmethyl)-2-(3-cyano-2-methyl-1H-indol-1-yl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (91.98 %)	NA	24501399
DrugRepV_4422	N-benzyl-6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (98.65 %)	NA	24501399
DrugRepV_4423	9H-carbazol-3-amine	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (42.29 %)	NA	24501399
DrugRepV_4424	7-(1H-benzimidazol-2-ylthio)-8-methyl[1,3]dioxolo[4,5-g]quinolin-6(5H)-one	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (60.65 %)	NA	24501399
DrugRepV_4425	N-[2-(2-methoxyethyl)-1,2,3,4-tetrahydropyrazino[1,2-a]benzimidazol-8-yl]benzamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (-0.15 %)	NA	24501399
DrugRepV_4426	tris[4-(dimethylamino)phenyl]methanol	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (82.15 %)	NA	24501399
DrugRepV_4427	6-chloro-N-[3-(4-methyl-1H-pyrazol-1-yl)propyl]-2-(3-pyridinyl)-4-quinolinecarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (88.99 %)	NA	24501399
DrugRepV_4428	1-(2-furoyl)-5-(2-furyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (24.06 %)	NA	24501399
DrugRepV_4429	2-[(1H-benzimidazol-2-ylmethyl)thio]-1-[2-(4-methylphenoxy)ethyl]-1H-benzimidazole	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (57.39 %)	NA	24501399
DrugRepV_4430	N-(3-chloro-4-fluorophenyl)-N-[4-(4-morpholinylsulfonyl)phenyl]urea	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (77.83 %)	NA	24501399
DrugRepV_4431	4-{[(5-methyl-2-thienyl)methyl]amino}phenol	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (1.34 %)	NA	24501399
DrugRepV_4432	N-[5-(1H-benzimidazol-2-yl)-2-methylphenyl]-1,3-benzodioxole-5-carboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (76.53 %)	NA	24501399
DrugRepV_4433	N-[1-benzyl-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]benzamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (14.51 %)	NA	24501399
DrugRepV_4434	2-methoxy-N-[1-methyl-2-(1-pyrrolidinylmethyl)-1H-benzimidazol-5-yl]benzamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (8.55 %)	NA	24501399
DrugRepV_4435	N-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-2-(2-naphthyloxy)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (79.93 %)	NA	24501399
DrugRepV_4436	N-(2,5-dimethoxyphenyl)-N-[4-(trifluoromethyl)phenyl]urea	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (69.24 %)	NA	24501399
DrugRepV_4437	4-{[(1H-benzimidazol-2-ylthio)acetyl]amino}phenyl thiocyanate	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (65.51 %)	NA	24501399
DrugRepV_4438	N-(3,4-dichlorophenyl)-N-[3-(trifluoromethyl)phenyl]urea	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (80.76 %)	NA	24501399
DrugRepV_4439	N-1,3-benzodioxol-5-yl-6-chloro-2-(3-pyridinyl)-4-quinolinecarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (65.73 %)	NA	24501399
DrugRepV_4440	N-(3-chlorophenyl)-N-(4-cyanophenyl)urea	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (78.34 %)	NA	24501399
DrugRepV_4441	N-[4-(1H-benzimidazol-2-yl)phenyl]-2-chloro-5-(4H-1,2,4-triazol-4-yl)benzamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (52.46 %)	NA	24501399
DrugRepV_4442	N-[3-(aminocarbonyl)-5-benzyl-2-thienyl]-2-methyl-3-furamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (24.34 %)	NA	24501399
DrugRepV_4443	4,5-dimethyl-2-{[(5-propyl-3-thienyl)carbonyl]amino}-N-(3-pyridinylmethyl)-3-thiophenecarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (39.61 %)	NA	24501399
DrugRepV_4444	1-(isopropylamino)-3-(3-phenyl-4,5-dihydropyrazolo[4,3-a]carbazol-10(3H)-yl)-2-propanol	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (44.31 %)	NA	24501399
DrugRepV_4445	2-[(4-tert-butyl-1,3-thiazol-2-yl)amino]-8-quinolinol	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (38.88 %)	NA	24501399
DrugRepV_4446	N-(aminocarbonyl)-2-{[(5-methyl-3-thienyl)carbonyl]amino}-3-thiophenecarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (38.54 %)	NA	24501399
DrugRepV_4447	2-chloro-N-(4-phenyl-1,3-thiazol-2-yl)-5-(4H-1,2,4-triazol-4-yl)benzamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (50.22 %)	NA	24501399
DrugRepV_4448	N-[3-(2-oxo-2H-chromen-3-yl)phenyl]-1,3-benzodioxole-5-carboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (51.28 %)	NA	24501399
DrugRepV_4449	4,5-dimethyl-2-[(phenoxyacetyl)amino]-N-(3-pyridinylmethyl)-3-thiophenecarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (39.55 %)	NA	24501399
DrugRepV_4450	N-(4-{[(5-methyl-3-isoxazolyl)amino]sulfonyl}phenyl)-1-benzothiophene-3-carboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (33.84 %)	NA	24501399
DrugRepV_4451	3-[(1H-benzimidazol-2-ylmethyl)thio]-9-benzyl-9H-[1,2,4]triazolo[4,3-a]benzimidazole	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (23.55 %)	NA	24501399
DrugRepV_4452	methyl N-[4,6-bis(isopropylamino)-1,3,5-triazin-2-yl]-N-cyanoglycinate	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (77.79 %)	NA	24501399
DrugRepV_4453	N-(3,4-dichlorophenyl)-2-oxo-2,3-dihydro-1,3-benzoxazole-6-sulfonamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (56.45 %)	NA	24501399
DrugRepV_4454	N-(3-pyridinylmethyl)dibenzo[b,d]furan-3-amine	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (47.55 %)	NA	24501399
DrugRepV_4455	(1,3-benzodioxol-5-ylmethyl)[4-(1-pyrrolidinyl)phenyl]amine	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (-3.09 %)	NA	24501399
DrugRepV_4456	4-methyl-5-phenyl-N-3-pyridinyl-2-thiophenecarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (72.37 %)	NA	24501399
DrugRepV_4457	N-(2,5-dimethoxyphenyl)-2-(2-oxo-1,3-benzoxazol-3(2H)-yl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (47.94 %)	NA	24501399
DrugRepV_4458	3-[(2,4-dichlorophenoxy)methyl]-N-(3-pyridinylmethyl)benzamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (53.23 %)	NA	24501399
DrugRepV_4459	5-phenyl-2-(2-phenylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (28.07 %)	NA	24501399
DrugRepV_4460	6-bromo-2-oxo-N-3-pyridinyl-2H-chromene-3-carboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (25.6 %)	NA	24501399
DrugRepV_4461	2-[(2-methyl-8-quinolinyl)amino]-4H-pyrido[3,2-e][1,3]thiazin-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (37.16 %)	NA	24501399
DrugRepV_4462	N-(3-chloro-4-fluorophenyl)-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]urea	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (61.47 %)	NA	24501399
DrugRepV_4463	4-({[(3-chloro-4-fluorophenyl)amino]carbonyl}amino)-N-methylbenzenesulfonamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (66.62 %)	NA	24501399
DrugRepV_4464	2-(4-fluorophenyl)-N-(4-{[(4-methylphenyl)amino]sulfonyl}phenyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (32.44 %)	NA	24501399
DrugRepV_4465	5-methyl-N-[4-(1-pyrrolidinylsulfonyl)phenyl]-3-thiophenecarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (30.53 %)	NA	24501399
DrugRepV_4466	2-amino-N-(3-chlorophenyl)-3-quinolinecarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (47.39 %)	NA	24501399
DrugRepV_4467	2-(1,3-benzodioxol-5-yl)-1-(1,3-benzodioxol-5-ylmethyl)-1H-benzimidazole	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (49.81 %)	NA	24501399
DrugRepV_4468	N-{3-[(benzylamino)carbonyl]phenyl}-5-methyl-3-thiophenecarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (51.17 %)	NA	24501399
DrugRepV_4469	8-chloro-N-[3-(3-methyl-1H-pyrazol-1-yl)propyl]-2-(2-pyridinyl)-4-quinolinecarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (41.66 %)	NA	24501399
DrugRepV_4470	N-[4-(2,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(2-thienyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	S, amino acids 674 to 683	NA	CatL-Peptide cleavage	Decrease (40.85 %)	NA	24501399
DrugRepV_4486	Brincidofovir	NA	Viral infections	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	Investigational	26526586
DrugRepV_4487	CMX029	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4488	CMX021	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4489	CMX028	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4490	CMX16669	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4491	CMX16663	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4492	CMX167	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4493	CMX157	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4494	CMX101	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4495	CMX004	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4496	CMX16689	NA	NA	Ebola virus	EBOV-GFP	NA	Luciferase assay	Decrease (50 %)	NA	26526586
DrugRepV_4500	(1S,2R,5S)-5-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	Zaire	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4501	(1S,2R,5R)-5-(6-amino-9H-purin-9-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	Zaire	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4502	(1S,2R,5R)-5-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	Zaire	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4503	(1R,2S,5R)-3-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	Zaire	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4504	(1R,2S,5R)-3-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-5-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	Zaire	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4505	(1S,2R,5S)-5-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4506	(1S,2R,5R)-5-(6-amino-9H-purin-9-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4507	(1S,2R,5R)-5-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4508	(1R,2S,5R)-3-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4509	(1R,2S,5R)-3-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-5-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4510	(1S,2R,5S)-5-(6-amino-9H-purin-9-yl)-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Ebola virus	NA	NA	NA	Decrease (50 %)	NA	30385162
DrugRepV_4511	(1S,2R,5S)-5-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Influenza virus	NA		NA	Decrease (50 %)	NA	30385162
DrugRepV_4519	Alferon	NA	Condylomata acuminata	Severe acute respiratory syndrome coronavirus	NA	NA	Plaque reduction assay	Decrease (50 %)	Approved	15200845
DrugRepV_4525	IFN-alphan3	NA	Condylomata acuminata	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (100 %)	Approved, Investigational	15200845
DrugRepV_4540	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,4-triazole-3-carboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	16451078
DrugRepV_4541	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-imidazole-4-carboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	16451078
DrugRepV_4542	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,3-triazole-4-carboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	16451078
DrugRepV_4543	Alferon	NA	Condylomata acuminata	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Approved	16451078
DrugRepV_4547	Aurintricarboxylic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	15961169
DrugRepV_4548	DS5000	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	15961169
DrugRepV_4549	Novaron	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	15961169
DrugRepV_4551	S-Nitroso-N-acetylpenicillamine	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	15961169
DrugRepV_4552	7-(benzyloxy)-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4553	2-(3,4-dihydroxyphenyl)-7-[(2-fluorophenyl)methoxy]-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4554	7-[(2-chlorophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4555	7-[(2-bromophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4556	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(2-iodophenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4557	2-({[2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4-oxo-4H-chromen-7-yl]oxy}methyl)benzonitrile	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4558	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(2-nitrophenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4559	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(2-methylphenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4560	2-(3,4-dihydroxyphenyl)-7-[(3-fluorophenyl)methoxy]-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4561	7-[(3-chlorophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4562	7-[(3-bromophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4563	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(3-iodophenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4564	3-({[2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4-oxo-4H-chromen-7-yl]oxy}methyl)benzonitrile	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4565	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(3-nitrophenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4566	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(3-methylphenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4567	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(3-methoxyphenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4568	2-(3,4-dihydroxyphenyl)-7-[(4-fluorophenyl)methoxy]-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4569	7-[(4-chlorophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4570	7-[(4-bromophenyl)methoxy]-2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4571	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(4-iodophenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4572	4-({[2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4-oxo-4H-chromen-7-yl]oxy}methyl)benzonitrile	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4573	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(4-nitrophenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4574	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(4-methylphenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4575	2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-[(4-methoxyphenyl)methoxy]-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	22297745
DrugRepV_4577	Glycyrrhetinic Acid	NA	Apparent mineralocorticoid excess syndrome	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	15715493
DrugRepV_4578	(2S,4aS,6aS,6bR,10S,12aS)-10-[(6-{[2-(benzylsulfanyl)-1-carboxyethyl]carbamoyl}-3-[(6-{[2-(benzylsulfanyl)-1-carboxyethyl]carbamoyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4579	(2S,4aS,6aS,6bR,10S,12aS)-10-[(6-{[2-(benzylsulfanyl)-1-carboxyethyl]carbamoyl}-3-[(6-{[2-(benzylsulfanyl)-1-carboxyethyl]carbamoyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4580	(2S,4aS,6aS,6bR,10S,12aS)-10-({4,5-dihydroxy-6-[({[(2S)-4-methyl-1-oxopentan-2-yl]carbamoyl}methyl)carbamoyl]-3-({3,4,5-trihydroxy-6-[({[(2S)-4-methyl-1-oxopentan-2-yl]carbamoyl}methyl)carbamoyl]oxan-2-yl}oxy)oxan-2-yl}oxy)-2,4a,6a,6b,9,9,12a-heptame	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4581	6-{[(3S,6aR,6bS,8aS,11S,14bS)-4,4,6a,6b,8a,11,14b-heptamethyl-11-{[(2S)-4-methyl-1-oxopentan-2-yl]carbamoyl}-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-3,4-dihydroxy-N-[(2S)-4-methyl-1-oxopentan-2-yl]-5-[(3	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4582	butyl (2S)-2-{[(2S,4aS,6aS,6bR,10S,12aS)-10-[(6-{[(2S)-1-butoxy-3-methyl-1-oxobutan-2-yl]carbamoyl}-3-[(6-{[(2S)-1-butoxy-3-methyl-1-oxobutan-2-yl]carbamoyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4583	methyl (2S)-2-(2-{[(2S,4aS,6aS,6bR,10S,12aS)-10-({4,5-dihydroxy-6-[({[(2S)-1-methoxy-3-methyl-1-oxobutan-2-yl]carbamoyl}methyl)carbamoyl]-3-({3,4,5-trihydroxy-6-[({[(2S)-1-methoxy-3-methyl-1-oxobutan-2-yl]carbamoyl}methyl)carbamoyl]oxan-2-yl}oxy)oxan	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4584	(4S)-4-{[(2S,4aS,6aS,6bR,10S,12aS)-10-[(6-{[(2S)-4-carboxy-1-oxobutan-2-yl]carbamoyl}-3-[(6-{[(2S)-4-carboxy-1-oxobutan-2-yl]carbamoyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4585	butyl (2S)-2-{[(2S,4aS,6aS,6bR,10S,12aS)-10-[(6-{[(2S)-1-butoxy-1-oxopropan-2-yl]carbamoyl}-3-[(6-{[(2S)-1-butoxy-1-oxopropan-2-yl]carbamoyl}-3,4,5-trihydroxyoxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4586	(2S,4aS,6aS,6bR,10S,12aS)-10-{[4,5-dihydroxy-6-(2-hydroxyacetyl)-3-{[3,4,5-trihydroxy-6-(2-hydroxyacetyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carbo	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4587	(2S,4aS,6aS,6bR,10S,12aS)-10-({4,5-dihydroxy-6-[(6-oxo-2-sulfanylidene-1,2,3,6-tetrahydropyrimidin-4-yl)carbamoyl]-3-({3,4,5-trihydroxy-6-[(6-oxo-2-sulfanylidene-1,2,3,6-tetrahydropyrimidin-4-yl)carbamoyl]oxan-2-yl}oxy)oxan-2-yl}oxy)-2,4a,6a,6b,9,9,1	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4588	5-{6-[(2-{[(3S,6aR,6bS,8aS,11S,14bS)-11-(2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl)-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-6-(2,4-dioxo-1,2,3,4-tetrahydropyrimidi	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4589	methyl (2S,4aS,6aS,6bR,10S,12aS)-10-({6-[(hydrazinecarbonyl)carbonyl]-3-({6-[(hydrazinecarbonyl)carbonyl]-3,4,5-trihydroxyoxan-2-yl}oxy)-4,5-dihydroxyoxan-2-yl}oxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4590	methyl (2S,4aS,6aS,6bR,10S,12aS)-10-{[6-(2-azidoacetyl)-3-{[6-(2-azidoacetyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl]oxy}-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-ca	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4591	2-{[(6aR,6bS,8aS,11S,14bS)-11-(acetyloxy)-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4592	4-{[(6aR,6bS,8aS,11S,14bS)-11-(acetyloxy)-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-4-oxobutanoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	FFM1	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	15715493
DrugRepV_4593	3-(benzyloxy)-7-[(3-chlorophenyl)methoxy]-8-hydroxy-1,4-dihydronaphthalen-1-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4594	3-[(2-chlorophenyl)methoxy]-7-[(3-chlorophenyl)methoxy]-8-hydroxy-1,4-dihydronaphthalen-1-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4595	3,7-bis[(3-chlorophenyl)methoxy]-8-hydroxy-1,4-dihydronaphthalen-1-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4596	7-[(3-chlorophenyl)methoxy]-3-[(2,4-dichlorophenyl)methoxy]-8-hydroxy-1,4-dihydronaphthalen-1-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4597	7-[(3-chlorophenyl)methoxy]-8-hydroxy-3-[(2-iodophenyl)methoxy]-1,4-dihydronaphthalen-1-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4598	7-[(3-chlorophenyl)methoxy]-8-hydroxy-3-[(3-iodophenyl)methoxy]-1,4-dihydronaphthalen-1-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4599	2-[({6-[(3-chlorophenyl)methoxy]-5-hydroxy-4-oxo-1,4-dihydronaphthalen-2-yl}oxy)methyl]benzonitrile	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4600	(2Z)-4-(3-{[(4-chlorophenyl)methyl]amino}phenyl)-2-hydroxy-4-oxobut-2-enoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4601	5,7-dihydroxy-3-[(3-nitrophenyl)methoxy]-2-phenyl-4H-chromen-4-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4602	3-{[(3,5-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy]methyl}benzonitrile	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	NA	21925774
DrugRepV_4603	1H-1,2,3-benzotriazol-1-yl 1H-indole-5-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4604	5-chloropyridin-3-yl 1H-indole-5-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4605	5-chloropyridin-3-yl 1-acetyl-1H-indole-5-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4606	5-chloropyridin-3-yl 1-(4-methylbenzenesulfonyl)-1H-indole-5-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4607	5-chloropyridin-3-yl 1-(3-nitrobenzenesulfonyl)-1H-indole-5-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4608	5-chloropyridin-3-yl1H-indole-6-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4609	5-chloropyridin-3-yl 1H-indole-4-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4610	5-chloropyridin-3-yl 1-acetyl-1H-indole-4-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4611	5-chloropyridin-3-yl 1H-indole-7-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4612	5-chloropyridin-3-yl (6R)-6-{[(tert-butoxy)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4613	5-chloropyridin-3-yl 2-acetyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	NA	Decrease (50 %)	NA	18796354
DrugRepV_4618	Calpain VI inhibitor	NA	NA	Severe acute respiratory syndrome coronavirus	v2163	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4619	Calpain VI inhibitor	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4620	Calpain IV inhibitor	NA	NA	Severe acute respiratory syndrome coronavirus	v2163	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4621	Calpain IV inhibitor	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4624	Ampligen	NA	NA	Severe acute respiratory syndrome coronavirus	v2163	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4625	Ampligen	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4626	UDA	NA	NA	Severe acute respiratory syndrome coronavirus	v2163	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4627	UDA	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4628	EP128533	NA	NA	Severe acute respiratory syndrome coronavirus	v2163	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4629	EP128533	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19853271
DrugRepV_4631	Ampligen	NA	NA	Severe acute respiratory syndrome coronavirus	v2163	NA	Survival assay	Increase	NA	19853271
DrugRepV_4632	UDA	NA	NA	Severe acute respiratory syndrome coronavirus	v2163	NA	Survival assay	Increase	NA	19853271
DrugRepV_4633	Cremaphor	NA	NA	Severe acute respiratory syndrome coronavirus	v2163	NA	Survival assay	No significant effect	NA	19853271
DrugRepV_4634	TG-0205221	NA	SARS coronavirus	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	16884309
DrugRepV_4635	ethyl (2E,4S)-4-[(2S)-3-(4-fluorophenyl)-2-[(2S)-3-methyl-2-[(5-methyl-1,2-oxazol-3-yl)formamido]butanamido]propanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	16884309
DrugRepV_4636	ethyl (2E,4S)-4-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methylbutanamido]-3-phenylpropanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	16884309
DrugRepV_4637	ethyl (2E,4S)-4-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methylbutanamido]-4-methylpentanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	16884309
DrugRepV_4638	ethyl (2E,4S)-4-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-(tert-butoxy)butanamido]-4-methylpentanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate	NA	NA	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	16884309
DrugRepV_4639	TG-0205221	NA	SARS coronavirus	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (6.4 Log10)	NA	16884309
DrugRepV_4640	TG-0205221	NA	SARS coronavirus	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease	NA	16884309
DrugRepV_4641	5CI-IS-AC	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	20390088
DrugRepV_4642	SPIII-5H	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	20390088
DrugRepV_4643	SPIII-5Cl	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	20390088
DrugRepV_4644	SPIII-5Br	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	20390088
DrugRepV_4645	SPIII-5F	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	20390088
DrugRepV_4646	SPIII-5Me	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	20390088
DrugRepV_4647	SPIII-NA	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	20390088
DrugRepV_4654	6-Azauridine	NA	Cancer	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4657	Kitasamycin	NA	Bacterial infections	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	Experimental	27909576
DrugRepV_4658	SAM002589981	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4659	SAM002564206	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4660	SAM002564189	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4661	SAM002554886	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4662	SAM002548975	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4663	SAM002548938	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4664	SAM002264636	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4665	SAM001247107	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4666	SAM001247103	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4667	SAM001247083	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4668	SAM001247075	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4669	SAM001247056	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4670	SAM001247054	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4671	SAM001247052	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4672	SAM001247038	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4673	SAM001246989	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4674	SAM001246979	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4675	SAM001246977	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4676	SAM001246883	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4677	SAM001246690	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4678	SAM001246644	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4679	SAM001246622	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4680	SAM001246545	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4681	N-(4-hydroxyphenyl) retinamide	NA	NA	Zika virus	MR766	NA	Plaque assay	Decrease (90 %)	Investigational	29051080
DrugRepV_4682	Arbidol	NA	Viral infection	Zika virus	MR766	NA	NA	Decrease (50 %)	Investigational	29895962
DrugRepV_4684	2-C-Methylcytidine	NA	Hepatitis C virus	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Experimental	30061280
DrugRepV_4685	2-C-Methyladenosine	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4686	2-C-Methylguanosine	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4687	2-C-Methyluridine	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4689	5-Fluoro-2-deoxyuridine	NA	Cancer	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Approved	30061280
DrugRepV_4690	5-Fluorouridine	NA	Cancer	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Experimental	30061280
DrugRepV_4691	5-Fluorocytidine	NA	Breast Cancer	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Phase IV	30061280
DrugRepV_4693	2-O-Methylcytidine	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4694	3-Deoxyadenosine	NA	Leukemia	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Investigational	30061280
DrugRepV_4695	3-Deoxycytidine	NA	Cancer	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Phase I	30061280
DrugRepV_4696	3-O-Methylguanosine	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4697	3-O-Methyluridine	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4698	9-(beta-D-Arabinofuranosyl)guanine	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4699	2-C-Methylcytidine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4700	2-C-Methyluridine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4701	2-C-Methyladenosine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4702	3-Deoxyadenosine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4703	5-Fluorocytidine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4704	3-O-Methyluridine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4705	2-O-Methylcytidine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4706	3-Deoxycytidine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4707	3-Deoxy-3-fluoroguanosine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4708	2,4-dichloro-6-(3,4-dibromo-5-fluoro-1H-pyrrole-2-carbonyl)phenol	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4710	2,4-dichloro-6-(3,4-dibromo-5-fluoro-1H-pyrrole-2-carbonyl)phenol	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease	NA	30061280
DrugRepV_4711	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Zika virus	MR766	NA	Plaque assay	Decrease (50 %)	Investigational	27889529
DrugRepV_4713	GSK369796	NA	NA	Zika virus	MR766	NA	Plaque assay	Decrease (50 %)	NA	27889529
DrugRepV_4714	Nutlin-3	NA	NA	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	29795047
DrugRepV_4724	Methotrimeprazine Maleate Salt	NA	NA	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	29795047
DrugRepV_4725	N1-(4-pyridyl)-2-chloro-5-nitrobenzamide	NA	NA	Middle East respiratory syndrome coronavirus	EMC/2012 strain	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	29795047
DrugRepV_4729	L-NAME	NA	Hypotension | Spinal Cord Injury	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (15 %)	Investigational	25487801
DrugRepV_4730	AG490	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (17 %)	NA	25487801
DrugRepV_4731	PKC-412	NA	Acute myeloid leukemia	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (33 %)	Approved, Investigational	25487801
DrugRepV_4732	Ro 31-8220	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (73 %)	NA	25487801
DrugRepV_4733	GF109203X	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (53 %)	NA	25487801
DrugRepV_4734	SB203580	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (45 %)	NA	25487801
DrugRepV_4735	U0126	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (50 %)	NA	25487801
DrugRepV_4736	Wortmannin	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (40 %)	Experimental	25487801
DrugRepV_4738	Bay 11-7082	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (28 %)	NA	25487801
DrugRepV_4739	GW5074	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (50 %)	NA	25487801
DrugRepV_4740	PP2	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (23 %)	NA	25487801
DrugRepV_4747	tert-butyl 4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4748	sodium (2S)-2-[(2S)-2-{[({1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4749	1-methanesulfonylpiperidin-4-yl N-[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4750	sodium (2S)-1-hydroxy-2-[(2S)-2-({[(1-methanesulfonylpiperidin-4-yl)oxy]carbonyl}amino)-4-methylpentanamido]-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4751	tert-butyl 4-benzyl-4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4752	sodium (2S)-2-[(2S)-2-{[({4-benzyl-1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4753	4-benzyl-1-methanesulfonylpiperidin-4-yl N-[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4754	sodium (2S)-2-[(2S)-2-({[(4-benzyl-1-methanesulfonylpiperidin-4-yl)oxy]carbonyl}amino)-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4755	tert-butyl 4-ethyl-4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4756	sodium (2S)-2-[(2S)-2-{[({1-[(tert-butoxy)carbonyl]-4-ethylpiperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4757	ethyl 4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4758	sodium (2S)-2-[(2S)-2-[({[1-(ethoxycarbonyl)piperidin-4-yl]oxy}carbonyl)amino]-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4759	tert-butyl 4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4760	sodium (2S)-2-[(2S)-2-{[({1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4761	1-methanesulfonylpiperidin-4-yl N-[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4762	sodium (2S)-1-hydroxy-2-[(2S)-2-({[(1-methanesulfonylpiperidin-4-yl)oxy]carbonyl}amino)-4-methylpentanamido]-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4763	tert-butyl 4-benzyl-4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4764	sodium (2S)-2-[(2S)-2-{[({4-benzyl-1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4765	4-benzyl-1-methanesulfonylpiperidin-4-yl N-[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4766	sodium (2S)-2-[(2S)-2-({[(4-benzyl-1-methanesulfonylpiperidin-4-yl)oxy]carbonyl}amino)-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4767	tert-butyl 4-ethyl-4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4768	sodium (2S)-2-[(2S)-2-{[({1-[(tert-butoxy)carbonyl]-4-ethylpiperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4769	ethyl 4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4770	sodium (2S)-2-[(2S)-2-[({[1-(ethoxycarbonyl)piperidin-4-yl]oxy}carbonyl)amino]-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	FRET protease assay	Decrease (50 %)	NA	29544147
DrugRepV_4771	sodium (2S)-2-[(2S)-2-{[({1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (50 %)	NA	29544147
DrugRepV_4772	sodium (2S)-2-[(2S)-2-{[({4-benzyl-1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (50 %)	NA	29544147
DrugRepV_4775	N-ethylmaleimide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Experimental	25542975
DrugRepV_4782	IFN-universal	NA	NA	Middle East respiratory syndrome coronavirus	Hu/Jordan-N3/2012	NA	Virus yield reduction assay	Decrease (50 %)	NA	24323636
DrugRepV_4784	2-(5-{[(4Z)-1-(3-carboxyphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4785	2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4786	2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4787	2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4788	4-chloro-2-(5-{[(4Z)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4789	4-chloro-2-(5-{[(4Z)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4790	4-chloro-2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4791	4-chloro-2-(5-{[(4Z)-5-oxo-3-phenyl-1-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4792	2-(5-{[(4Z)-1-(4-tert-butylphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4793	(4Z)-1,3-diphenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-5-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4794	3-[(4Z)-5-oxo-3-phenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4795	3-[(4Z)-3-methyl-5-oxo-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4796	2-(5-{[(4Z)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4797	2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4798	2-(5-{[(4Z)-5-oxo-3-phenyl-1-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4799	2-(5-{[(4Z)-1-(4-tert-butylphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4800	2-(5-{[(4Z)-1-(4-cyanophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4801	2-(5-{[(4Z)-1-(4-methoxyphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoicacid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4802	3-[(4Z)-4-[(furan-2-yl)methylidene]-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4803	2-(5-{[(4Z)-1-(3-carboxyphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4804	2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4805	2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4806	2-(5-{[(4Z)-1-(3-carboxyphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4807	4-chloro-2-(5-{[(4Z)-3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4808	4-chloro-2-(5-{[(4Z)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4809	4-chloro-2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4810	4-chloro-2-(5-{[(4Z)-5-oxo-3-phenyl-1-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4811	2-(5-{[(4Z)-1-(4-tert-butylphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)-4-chlorobenzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4812	(4Z)-1,3-diphenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-5-one	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4813	3-[(4Z)-5-oxo-3-phenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4814	3-[(4Z)-3-methyl-5-oxo-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4815	2-(5-{[(4Z)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4816	2-(5-{[(4Z)-1-(4-fluorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4817	2-(5-{[(4Z)-5-oxo-3-phenyl-1-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4818	2-(5-{[(4Z)-1-(4-tert-butylphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4819	2-(5-{[(4Z)-1-(4-cyanophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4820	2-(5-{[(4Z)-1-(4-methoxyphenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl}furan-2-yl)benzoicacid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4821	3-[(4Z)-4-[(furan-2-yl)methylidene]-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	27240464
DrugRepV_4828	CTSL inhibitor	NA	NA	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	26953343
DrugRepV_4833	8-(trifluoromethyl)-9H-purin-6-amine	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	25746232
DrugRepV_4834	8-(trifluoromethyl)-9H-purin-6-amine	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	25746232
DrugRepV_4835	5-amino-2-methyl-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	25746232
DrugRepV_4836	2-methyl-5-[(methylamino)methyl]-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	25746232
DrugRepV_4837	N-[(2H-1,3-benzodioxol-5-yl)methyl]-1-[(1R)-1-(naphthalen-1-yl)ethyl]piperidine-4-carboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	25746232
DrugRepV_4838	N-[(2H-1,3-benzodioxol-5-yl)methyl]-1-[(1S)-1-(naphthalen-1-yl)ethyl]piperidine-4-carboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	25746232
DrugRepV_4839	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}thiophene-2-carboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4840	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}benzamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4841	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}cyclobutanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4842	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}cyclohexanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4843	2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(pyridin-4-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4844	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-2-methylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4845	2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(2-methoxypyridin-3-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4846	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}cyclopropanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4847	2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(2-methoxypyrimidin-5-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4848	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-2,2,2-trifluoroacetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4849	2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(pyridin-3-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4850	2-methylpropyl N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}carbamate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4851	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4852	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-2-methoxyacetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4853	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-3-methoxypropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4854	2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(methylamino)phenyl]-N-[(thiophen-3-yl)methyl]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4855	2-(1H-1,2,3-benzotriazol-1-yl)-N-[4-(benzylamino)phenyl]-N-[(thiophen-3-yl)methyl]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4856	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-2,2-dimethylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4857	2-methyl-N-(4-{N-[(thiophen-3-yl)methyl]-2-(1H-1,2,3-triazol-1-yl)acetamido}phenyl)propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4858	methyl 2-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}-1H-pyrrole-1-carboxylate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (31 %)	NA	26190463
DrugRepV_4859	2-(1H-1,2,3-benzotriazol-1-yl)-N-{[1,1-biphenyl]-4-yl}-N-[(thiophen-3-yl)methyl]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4860	N-(4-tert-butylphenyl)-N-[(pyridin-3-yl)methyl]-1H-imidazole-4-carboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (49 %)	NA	26190463
DrugRepV_4861	2-methyl-N-{4-[2-(4-phenyl-1H-1,2,3-triazol-1-yl)-N-[(thiophen-3-yl)methyl]acetamido]phenyl}propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (25 %)	NA	26190463
DrugRepV_4862	N-(4-tert-butylphenyl)-N-[(pyridin-3-yl)methyl]furan-3-carboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (24 %)	NA	26190463
DrugRepV_4863	2-methyl-N-(4-{N-[(thiophen-3-yl)methyl]-2-[4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl]acetamido}phenyl)propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_4864	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1-methyl-1H-imidazol-4-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4865	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(benzylcarbamoyl)(3-fluorophenyl)methyl]acetamido]phenyl}-2-methylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4866	2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-(4-acetamidophenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4867	N-tert-butyl-2-(N-{2-cyano-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4868	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(1H-indol-3-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4869	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}cyclopropanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4870	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(benzylcarbamoyl)(3-fluorophenyl)methyl]acetamido]phenyl}cyclobutanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4871	N-tert-butyl-2-(N-{4-[(fluoromethoxy)methyl]phenyl}-2-(1H-indol-3-yl)acetamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4872	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}benzamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4873	N-tert-butyl-2-[2-(1H-indol-3-yl)-N-[4-(propan-2-yl)phenyl]acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4874	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(benzylcarbamoyl)(3-fluorophenyl)methyl]acetamido]phenyl}cyclopropanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4875	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1,3-oxazol-5-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4876	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-imidazol-4-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4877	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4878	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-imidazol-4-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4879	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}-1,2-oxazole-5-carboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4880	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-imidazol-4-yl)formamido]-2-(pyrimidin-5-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4881	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}-2-methylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4882	N-{4-[2-(1H-1,3-benzodiazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4883	2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-(4-acetamidophenyl)acetamido]-N-tert-butyl-2-(3-fluorophenyl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4884	2-[N-(4-aminophenyl)-2-(1H-1,2,3-benzotriazol-1-yl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4885	(2S)-N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4886	N-{4-[2-(1H-1,3-benzodiazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}-2-methylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4887	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1,3-oxazol-5-yl)formamido]-2-(pyrimidin-5-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	26190463
DrugRepV_4888	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}thiophene-2-carboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (26 %)	NA	26190463
DrugRepV_4889	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}cyclobutanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4890	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}cyclohexanecarboxamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4891	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (34 %)	NA	26190463
DrugRepV_4892	N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}-2,2-dimethylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4893	N-tert-butyl-2-[1-(4-cyanophenyl)-N-(4-fluorophenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (53 %)	NA	26190463
DrugRepV_4894	N-tert-butyl-2-[N-cyclopropyl-2-(1H-indol-3-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (49 %)	NA	26190463
DrugRepV_4895	N-tert-butyl-2-[N-cyclopropyl-2-(pyridin-3-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (48 %)	NA	26190463
DrugRepV_4896	N-tert-butyl-2-[N-(4-fluorophenyl)-2-(pyridin-3-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (47 %)	NA	26190463
DrugRepV_4897	N-tert-butyl-2-[N-cyclopropyl-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (43 %)	NA	26190463
DrugRepV_4898	N-tert-butyl-2-{N-cyclopropyl-1-[5-(trifluoromethyl)pyridin-2-yl]formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (42 %)	NA	26190463
DrugRepV_4899	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(pyrazin-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (41 %)	NA	26190463
DrugRepV_4900	N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-2-(pyridin-3-yl)acetamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (41 %)	NA	26190463
DrugRepV_4901	N-tert-butyl-2-[N-(4-fluorophenyl)-2-(1H-indol-3-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (41 %)	NA	26190463
DrugRepV_4902	N-tert-butyl-2-[N-(4-fluorophenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (41 %)	NA	26190463
DrugRepV_4903	(2S)-2-{N-[4-(butan-2-yl)phenyl]-1-(furan-2-yl)formamido}-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (39 %)	NA	26190463
DrugRepV_4904	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridazin-4-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (35 %)	NA	26190463
DrugRepV_4905	N-tert-butyl-2-[1-(3-methylfuran-2-yl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (36 %)	NA	26190463
DrugRepV_4906	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (34 %)	NA	26190463
DrugRepV_4907	2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-(4-acetamidophenyl)acetamido]-2-(3-fluorophenyl)-N-phenylacetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (32 %)	NA	26190463
DrugRepV_4908	N-tert-butyl-2-{N-[4-(difluoromethoxy)phenyl]-1-(furan-2-yl)formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (31 %)	NA	26190463
DrugRepV_4909	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(1H-indol-3-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (31 %)	NA	26190463
DrugRepV_4910	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(1H-pyrrol-3-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (31 %)	NA	26190463
DrugRepV_4911	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1,3-oxazol-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (30 %)	NA	26190463
DrugRepV_4912	N-tert-butyl-2-[N-(4-fluorophenyl)-1-[5-(trifluoromethyl)pyridin-2-yl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (29 %)	NA	26190463
DrugRepV_4913	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-2-(pyridin-3-yl)acetamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (29 %)	NA	26190463
DrugRepV_4914	[(tert-butylcarbamoyl)(pyridin-3-yl)methyl](4-tert-butylphenyl)carbamic acid	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (29 %)	NA	26190463
DrugRepV_4915	2-[2-(1H-1,3-benzodiazol-1-yl)-N-(4-methanesulfonamidophenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (28 %)	NA	26190463
DrugRepV_4916	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-pyrazol-5-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (28 %)	NA	26190463
DrugRepV_4917	N-tert-butyl-2-[1-(4-cyanophenyl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (28 %)	NA	26190463
DrugRepV_4918	N-tert-butyl-2-{N-[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]-1-(furan-2-yl)formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (28 %)	NA	26190463
DrugRepV_4919	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (28 %)	NA	26190463
DrugRepV_4920	2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-(4-methanesulfonamidophenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (27 %)	NA	26190463
DrugRepV_4921	N-tert-butyl-2-[N-(4-acetamidophenyl)-2-(1H-1,2,3-triazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (27 %)	NA	26190463
DrugRepV_4922	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(4-chlorophenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (27 %)	NA	26190463
DrugRepV_4923	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(5-methylfuran-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (26 %)	NA	26190463
DrugRepV_4924	N-tert-butyl-2-[2-(naphthalen-1-yl)-N-[4-(propan-2-yl)phenyl]acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (26 %)	NA	26190463
DrugRepV_4925	N-tert-butyl-2-(4-tert-butylphenyl)-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (26 %)	NA	26190463
DrugRepV_4926	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(naphthalen-1-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (26 %)	NA	26190463
DrugRepV_4927	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-2-(1H-indol-3-yl)acetamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (25 %)	NA	26190463
DrugRepV_4928	N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (25 %)	NA	26190463
DrugRepV_4929	N-tert-butyl-2-[2-(1H-indol-3-yl)-N-[4-(propan-2-yl)phenyl]acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (25 %)	NA	26190463
DrugRepV_4930	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(2-methylpropoxy)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (25 %)	NA	26190463
DrugRepV_4931	2-{N-[4-(benzyloxy)phenyl]-1-(furan-2-yl)formamido}-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (25 %)	NA	26190463
DrugRepV_4932	N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-2-(pyridin-3-yl)acetamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (24 %)	NA	26190463
DrugRepV_4933	N-tert-butyl-2-[N-(4-fluorophenyl)-2-(pyridin-3-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (24 %)	NA	26190463
DrugRepV_4934	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(1H-imidazol-4-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (24 %)	NA	26190463
DrugRepV_4935	N-tert-butyl-2-{N-[4-(difluoromethoxy)phenyl]-1-(1H-indazol-3-yl)formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (24 %)	NA	26190463
DrugRepV_4936	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(pyridin-3-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (23 %)	NA	26190463
DrugRepV_4937	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-indazol-3-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (23 %)	NA	26190463
DrugRepV_4938	N-tert-butyl-2-(N-{2,6-difluoro-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (23 %)	NA	26190463
DrugRepV_4939	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-methoxyacetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (23 %)	NA	26190463
DrugRepV_4940	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(pyridin-3-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (23 %)	NA	26190463
DrugRepV_4941	N-tert-butyl-2-[1-(4-cyanophenyl)-N-cyclopropylformamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (23 %)	NA	26190463
DrugRepV_4942	N-tert-butyl-2-[N-(4-fluorophenyl)-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (22 %)	NA	26190463
DrugRepV_4943	N-tert-butyl-2-[N-cyclopropyl-2-(naphthalen-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (22 %)	NA	26190463
DrugRepV_4944	N-tert-butyl-2-[N-(4-fluorophenyl)-2-(naphthalen-1-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (22 %)	NA	26190463
DrugRepV_4945	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-imidazol-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (22 %)	NA	26190463
DrugRepV_4946	2-(N-{[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (22 %)	NA	26190463
DrugRepV_4947	N-tert-butyl-2-[N-(4-fluorophenyl)-2-(1H-indol-3-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (22 %)	NA	26190463
DrugRepV_4948	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4949	N-tert-butyl-2-[N-cyclopropyl-1-(1H-indazol-3-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4950	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-2-(naphthalen-1-yl)acetamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4951	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(4-fluorophenyl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4952	N-tert-butyl-2-[1-(1H-indazol-3-yl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4953	N-tert-butyl-2-[1-(4-cyanophenyl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4954	N-tert-butyl-2-[N-cyclopropyl-1-(1H-indazol-3-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4955	N-tert-butyl-2-[1-(furan-2-yl)-N-{4-[(1E)-2-phenylethenyl]phenyl}formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4956	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-1-(5,6,7,8-tetrahydronaphthalen-2-yl)formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (21 %)	NA	26190463
DrugRepV_4957	(2R)-2-{N-[4-(butan-2-yl)phenyl]-1-(furan-2-yl)formamido}-N-tert-butyl-2-(pyridin-4-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4958	N-tert-butyl-2-[N-(4-acetamidophenyl)-2-[4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl]acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4959	2-{N-[4-(butan-2-yloxy)phenyl]-1-(furan-2-yl)formamido}-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4960	N-tert-butyl-2-[1-(4-cyanophenyl)-N-cyclopropylformamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4961	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-phenylacetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4962	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4963	N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (20 %)	NA	26190463
DrugRepV_4964	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4965	2-[1-(1-benzofuran-3-yl)-N-(4-tert-butylphenyl)formamido]-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4966	N-tert-butyl-2-[N-(4-acetamidophenyl)-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4967	N-tert-butyl-2-[N-(4-fluorophenyl)-1-[5-(trifluoromethyl)pyridin-2-yl]formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4968	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(2-methyl-1H-1,3-benzodiazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4969	N-tert-butyl-2-[1-(furan-2-yl)-N-(4-phenoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4970	2-methylpropyl N-{4-[2-(1H-1,2,3-benzotriazol-1-yl)-N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]acetamido]phenyl}carbamate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4971	N-(4-{N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]-2-(2-methyl-1H-imidazol-1-yl)acetamido}phenyl)propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (19 %)	NA	26190463
DrugRepV_4972	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(oxolan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4973	N-tert-butyl-2-[N-cyclopropyl-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4974	2-[N-(4-aminophenyl)-2-(1H-1,3-benzodiazol-1-yl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4975	N-tert-butyl-2-(N-{2,3-difluoro-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4976	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-1-[5-(trifluoromethyl)pyridin-2-yl]formamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4977	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4978	N-tert-butyl-2-[N-cyclopropyl-1-(furan-2-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4979	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(3-methoxyphenoxy)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4980	N-(4-{N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]-2-(2-methyl-1H-imidazol-1-yl)acetamido}phenyl)-2-methylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4981	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-pyrrol-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4982	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(4-cyanophenyl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4983	N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-1-[6-(trifluoromethyl)pyridin-3-yl]formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4984	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-2-(pyridin-3-yl)acetamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4985	2-[N-(adamantan-1-yl)-1-(furan-2-yl)formamido]-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (18 %)	NA	26190463
DrugRepV_4986	N-tert-butyl-2-[N-(4-fluorophenyl)-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4987	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-pyrazol-3-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4988	N-tert-butyl-2-[N-(4-acetamidophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4989	tert-butyl 2-(4-{N-[(tert-butylcarbamoyl)(pyridin-3-yl)methyl]furan-2-amido}phenyl)-1H-pyrrole-1-carboxylate	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4990	N-tert-butyl-2-{N-[4-(difluoromethoxy)phenyl]-1-(1H-indazol-3-yl)formamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4991	N-tert-butyl-2-[N-cyclopropyl-2-(1H-indol-3-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4992	2-[N-(4-aminophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4993	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-2-(naphthalen-1-yl)acetamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4994	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-[6-(trifluoromethyl)pyridin-3-yl]formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4995	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(3-methoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4996	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(2-methoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (17 %)	NA	26190463
DrugRepV_4997	N-tert-butyl-2-(N-{3-cyano-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_4998	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyrimidin-5-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_4999	N-tert-butyl-2-[N-(4-fluorophenyl)-1-(furan-2-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5000	2-[N-(adamantan-1-yl)-2-(1H-1,2,3-benzotriazol-1-yl)acetamido]-N-benzyl-2-(3-fluorophenyl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5001	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(thiophen-3-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5002	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-[5-(trifluoromethyl)furan-2-yl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5003	N-tert-butyl-2-[N-cyclopropyl-2-(pyridin-3-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5004	N-tert-butyl-2-[1-(4-cyanophenyl)-N-[4-(fluoromethoxy)phenyl]formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5005	N-tert-butyl-2-(N-{2,4-difluoro-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5006	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-indazol-3-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5007	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(1H-pyrrol-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5008	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(4-methoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5009	2-[N-(4-benzenesulfonamidophenyl)-1-(furan-2-yl)formamido]-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5010	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(1H-1,2,3-triazol-4-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5011	2-(N-{bicyclo[2.2.1]heptan-2-yl}-1-(furan-2-yl)formamido)-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5012	N-tert-butyl-2-{N-[4-(2-fluoropyridin-4-yl)phenyl]-1-(furan-2-yl)formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (16 %)	NA	26190463
DrugRepV_5013	2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-{bicyclo[2.2.1]heptan-2-yl}acetamido]-N-tert-butyl-2-(3-fluorophenyl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5014	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(pyridin-3-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5015	2-[2-(1H-1,3-benzodiazol-1-yl)-N-(4-tert-butylphenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5016	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(naphthalen-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5017	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-[6-(trifluoromethyl)pyridin-3-yl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5018	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5019	N-tert-butyl-2-{N-[4-(propan-2-yl)phenyl]-1-[6-(trifluoromethyl)pyridin-3-yl]formamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5020	N-tert-butyl-2-{N-[4-(fluoromethoxy)phenyl]-1-[6-(trifluoromethyl)pyridin-3-yl]formamido}-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5021	N-tert-butyl-2-[1-(4-cyanophenyl)-N-[4-(fluoromethoxy)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5022	N-tert-butyl-2-[N-(4-fluorophenyl)-2-(naphthalen-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (15 %)	NA	26190463
DrugRepV_5023	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5024	N-tert-butyl-2-[N-(4-fluorophenyl)-1-(1H-indazol-3-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5025	N-tert-butyl-2-(N-{4-cyano-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5026	N-(4-{N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]-2-(2-methyl-1H-1,3-benzodiazol-1-yl)acetamido}phenyl)-2-methylpropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5027	2-[N-(adamantan-1-yl)-2-(1H-1,2,3-benzotriazol-1-yl)acetamido]-N-tert-butyl-2-(3-fluorophenyl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5028	2-[2-(1H-1,3-benzodiazol-1-yl)-N-(4-acetamidophenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5029	2-{N-[4-(benzyloxy)phenyl]-1-(furan-2-yl)formamido}-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5030	N-tert-butyl-2-[N-cyclopropyl-1-(5,6,7,8-tetrahydronaphthalen-1-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5031	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(pyrimidin-5-yl)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5032	2-[N-(4-aminophenyl)-2-(2-methyl-1H-1,3-benzodiazol-1-yl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (14 %)	NA	26190463
DrugRepV_5033	N-tert-butyl-2-{N-[4-(difluoromethoxy)phenyl]-1-(furan-2-yl)formamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5034	N-tert-butyl-2-[N-(4-methanesulfonamidophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5035	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(pyrimidin-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5036	N-tert-butyl-2-[2-(naphthalen-1-yl)-N-[4-(propan-2-yl)phenyl]acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5037	N-tert-butyl-2-[1-(furan-2-yl)-N-[4-(propan-2-yloxy)phenyl]formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5038	N-tert-butyl-2-[1-(4-cyanophenyl)-N-(4-fluorophenyl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5039	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(pyridin-3-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5040	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(pyridin-4-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5041	N-[(tert-butylcarbamoyl)(pyridin-3-yl)methyl]-N-(4-tert-butylphenyl)-3,3,3-trifluoropropanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (13 %)	NA	26190463
DrugRepV_5042	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(5-chlorofuran-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5043	N-tert-butyl-2-{N-cyclopropyl-1-[6-(trifluoromethyl)pyridin-3-yl]formamido}-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5044	N-tert-butyl-2-[N-(4-ethoxyphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5045	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(1H-pyrazol-4-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5046	2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-{bicyclo[2.2.1]heptan-2-yl}acetamido]-N-benzyl-2-(3-fluorophenyl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5047	N-tert-butyl-2-(N-{3,4-difluoro-[1,1-biphenyl]-4-yl}-1-(furan-2-yl)formamido)-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5048	N-tert-butyl-2-[1-(furan-2-yl)-N-(4-methanesulfonamidophenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5049	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(pyridin-3-yl)formamido]-2-(pyridin-2-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (12 %)	NA	26190463
DrugRepV_5050	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(4-hydroxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5051	N-tert-butyl-2-[N-(4-fluorophenyl)-1-(1H-indazol-3-yl)formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5052	N-tert-butyl-2-[N-(4-tert-butylphenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5053	N-tert-butyl-2-[N-cyclopropyl-2-(naphthalen-1-yl)acetamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5054	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5055	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(4-cyanophenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5056	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(2-hydroxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5057	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(1H-pyrazol-5-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5058	N-tert-butyl-2-[1-(1H-indazol-3-yl)-N-[4-(propan-2-yl)phenyl]formamido]-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (11 %)	NA	26190463
DrugRepV_5059	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(3-hydroxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (10 %)	NA	26190463
DrugRepV_5060	N-tert-butyl-2-[1-(furan-2-yl)-N-(4-propoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (10 %)	NA	26190463
DrugRepV_5061	N-tert-butyl-2-[1-(furan-2-yl)-N-(4-methoxyphenyl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (10 %)	NA	26190463
DrugRepV_5062	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(1H-imidazol-4-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (9 %)	NA	26190463
DrugRepV_5063	2-[2-(1H-1,2,3-benzotriazol-1-yl)-N-(4-tert-butylphenyl)acetamido]-N-tert-butyl-2-(thiophen-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (9 %)	NA	26190463
DrugRepV_5064	2-[N-(4-benzylphenyl)-1-(furan-2-yl)formamido]-N-tert-butyl-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (8 %)	NA	26190463
DrugRepV_5065	N-(4-{N-[(tert-butylcarbamoyl)(thiophen-3-yl)methyl]-2-(2-methyl-1H-1,3-benzodiazol-1-yl)acetamido}phenyl)propanamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (8 %)	NA	26190463
DrugRepV_5066	N-tert-butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(6-methylpyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (8 %)	NA	26190463
DrugRepV_5067	N-tert-butyl-2-[N-cyclohexyl-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (6 %)	NA	26190463
DrugRepV_5068	Alisporivir	NA	Hepatitis C virus	Middle East respiratory syndrome coronavirus	EMC/2012	NA	Virus yield reduction assay	Decrease (50 %)	Investigational	27840112
DrugRepV_5069	Alisporivir	NA	Hepatitis C virus	Middle East respiratory syndrome coronavirus	N3/Jordan	NA	CPE inhibition assay	Decrease (50 %)	Investigational	27840112
DrugRepV_5070	Alisporivir	NA	Hepatitis C virus	Severe acute respiratory syndrome coronavirus	MA-15	NA	CPE inhibition assay	Decrease (50 %)	Investigational	27840112
DrugRepV_5089	S-Nitroso-N-acetylpenicillamine	NA	NA	Crimean-Congo hemorrhagic fever virus	IbAr 10200	NA	Immunoflourescence assay	Decrease (>90 %)	NA	16632039
DrugRepV_5090	S-Nitroso-N-acetylpenicillamine	NA	NA	Crimean-Congo hemorrhagic fever virus	IbAr 10200	NA	Western blot	Decrease	NA	16632039
DrugRepV_5091	S-Nitroso-N-acetylpenicillamine	NA	NA	Crimean-Congo hemorrhagic fever virus	IbAr 10200	NA	Real-time PCR	Decrease	NA	16632039
DrugRepV_5100	2-Deoxy-2-fluorocytidine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (50 %)	NA	29024765
DrugRepV_5102	2-Chloroadenosine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Increase (-26 %)	NA	29024765
DrugRepV_5103	2-Deoxy-2-fluorocytidine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (98 %)	NA	29024765
DrugRepV_5104	2-C-Methylcytidine	NA	HCV	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (4 %)	Experimental	29024765
DrugRepV_5105	2-C-Methyluridine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Increase (-9 %)	NA	29024765
DrugRepV_5106	2-O-Methylcytidine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (7 %)	NA	29024765
DrugRepV_5107	2-O-Methyluridine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (7 %)	NA	29024765
DrugRepV_5108	3-Deazauridine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (19 %)	NA	29024765
DrugRepV_5110	5-Azidouridine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (28 %)	NA	29024765
DrugRepV_5111	5-Bromouridine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (1 %)	NA	29024765
DrugRepV_5112	5-Chlorouridine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (0 %)	NA	29024765
DrugRepV_5113	5-Fluorouridine	NA	Cancer	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (7 %)	Experimental	29024765
DrugRepV_5114	5-Methylcytidine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (6 %)	NA	29024765
DrugRepV_5115	6-Aza-2-thiouridine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (17 %)	NA	29024765
DrugRepV_5116	6-Azauridine	NA	Cancer	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (36 %)	NA	29024765
DrugRepV_5117	7-DMA	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (26 %)	NA	29024765
DrugRepV_5118	8-Azaadenosine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (92 %)	NA	29024765
DrugRepV_5119	8-Azidoadenosine	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (87 %)	NA	29024765
DrugRepV_5122	BCX4430	NA	Ebola virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (18 %)	Investigational	29024765
DrugRepV_5129	PSI-6130	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Increase (-6 %)	NA	29024765
DrugRepV_5130	PSI-6206	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Increase (-1 %)	NA	29024765
DrugRepV_5131	PSI-7976	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (9 %)	NA	29024765
DrugRepV_5133	R-1479	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (15 %)	NA	29024765
DrugRepV_5135	RO-9187	NA	NA	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (12 %)	NA	29024765
DrugRepV_5141	PF-4708671	NA	NA	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Decrease (50 %)	NA	29652799
DrugRepV_5142	Pteridinone	NA	NA	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Increase (50 %)	NA	29652799
DrugRepV_5143	PF-4708671-BI-D1870	NA	NA	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Decrease (50 %)	NA	29652799
DrugRepV_5144	SB203580	NA	NA	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Decrease (50 %)	NA	29652799
DrugRepV_5145	PD0325901	NA	Melanoma | Solid Tumour | Solid Tumors | Advanced Cancer | Breast Neoplasms	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Decrease (50 %)	Investigational	29652799
DrugRepV_5147	Rapamycin-SB203580	NA	NA	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Decrease (50 %)	NA	29652799
DrugRepV_5148	Rapamycin-PD0325901	NA	NA	Rift Valley fever virus	MP12ΔNSs-Luc	NA	Luciferase assay	Decrease (50 %)	NA	29652799
DrugRepV_5149	PF-4708671	NA	NA	Rift Valley fever virus	MP12	NA	Western blot	Decrease	NA	29652799
DrugRepV_5150	PF-4708671	NA	NA	Rift Valley fever virus	MP12	NA	Plaque assay	No significant effect (0.5 log pfu/ml)	NA	29652799
DrugRepV_5151	PF-4708671-BI-D1870	NA	NA	Rift Valley fever virus	MP12	NA	Western blot	Decrease	NA	29652799
DrugRepV_5152	PF-4708671-BI-D1870	NA	NA	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (2 log pfu/ml)	NA	29652799
DrugRepV_5153	SB203580	NA	NA	Rift Valley fever virus	MP12	NA	Western blot	No significant effect	NA	29652799
DrugRepV_5154	SB203580	NA	NA	Rift Valley fever virus	MP12	NA	Plaque assay	No significant effect (<0.5log pfu/ml)	NA	29652799
DrugRepV_5155	PD0325901	NA	Melanoma | Solid Tumour | Solid Tumors | Advanced Cancer | Breast Neoplasms	Rift Valley fever virus	MP12	NA	Western blot	Decrease	Investigational	29652799
DrugRepV_5156	PD0325901	NA	Melanoma | Solid Tumour | Solid Tumors | Advanced Cancer | Breast Neoplasms	Rift Valley fever virus	MP12	NA	Plaque assay	No significant effect (0.5log pfu/ml)	Investigational	29652799
DrugRepV_5158	Rapamycin-SB203580	NA	NA	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (>3log pfu/ml)	NA	29652799
DrugRepV_5159	Rapamycin-PD0325901	NA	NA	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (3log pfu/ml)	NA	29652799
DrugRepV_5160	Benzavir-2	NA	NA	Rift Valley fever virus	rRVFV?NSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	29386590
DrugRepV_5161	Benzavir-1	NA	NA	Rift Valley fever virus	rRVFV?NSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	29386590
DrugRepV_5162	2-[[4-chloro-2-[(2-fluorobenzoyl)amino]benzoyl]amino]benzoic acid	NA	NA	Rift Valley fever virus	rRVFV?NSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	29386590
DrugRepV_5163	2-[[2-(2,2-dimethylpropanoylamino)benzoyl]amino]benzoic acid	NA	NA	Rift Valley fever virus	rRVFV?NSs::Katushka	NA	Fluorescence-based assay	No significant effect (50 %)	NA	29386590
DrugRepV_5164	2-[[2-(cyclohexanecarbonylamino)benzoyl]amino]benzoic acid	NA	NA	Rift Valley fever virus	rRVFV?NSs::Katushka	NA	Fluorescence-based assay	No significant effect (50 %)	NA	29386590
DrugRepV_5171	3-(2,3-Diphenyl-1H-indol-1-yl)-N-(3-hydroxybenzylidene) propanohydrazide	NA	NA	Rift Valley fever virus	rRVFVΔNSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	26762502
DrugRepV_5172	1-(3,5-Di-tert-butyl-4-hydroxyphenyl)-2-(2-imino-3-(4-methylbenzyl)-2,3- dihydro-1H-benzimidazol-1-yl)ethanone hydrobromide	NA	NA	Rift Valley fever virus	rRVFVΔNSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	26762502
DrugRepV_5173	4-Hydroxy-3-methoxybenzaldehyde (4-(3,4-dimethoxyphenyl)-6-phenyl-2- pyrimidinyl)hydrazone	NA	NA	Rift Valley fever virus	rRVFVΔNSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	26762502
DrugRepV_5174	1-(3,4-Dichlorophenyl)-3-(4-(3,4-dimethoxyphenyl)-1-methylpyrrolidin-3- yl)urea	NA	NA	Rift Valley fever virus	rRVFVΔNSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	26762502
DrugRepV_5175	2-Chloro-N-(2-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-ylcarbamoyl)phenyl) benzamide	NA	NA	Rift Valley fever virus	rRVFVΔNSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	26762502
DrugRepV_5176	2-(4-Bromo-5-chlorothiophene-2-sulfonamido)-N-(4-fluorophenyl) benzamide	NA	NA	Rift Valley fever virus	rRVFVΔNSs::Katushka	NA	Fluorescence-based assay	Decrease (50 %)	NA	26762502
DrugRepV_5180	C795-0925	NA	NA	Rift Valley fever virus	ZH501	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5181	D011-2120	NA	NA	Rift Valley fever virus	ZH501	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5182	F694-1532	NA	NA	Rift Valley fever virus	ZH501	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5183	G202-0362	NA	NA	Rift Valley fever virus	ZH501	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5186	C795-0925	NA	NA	Rift Valley fever virus	ZH501	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5187	D011-2120	NA	NA	Rift Valley fever virus	ZH501	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5188	F694-1532	NA	NA	Rift Valley fever virus	ZH501	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5189	G202-0362	NA	NA	Rift Valley fever virus	ZH501	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5192	C795-0925	NA	NA	Ebola virus	Zaire	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5193	D011-2120	NA	NA	Ebola virus	Zaire	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5194	F694-1532	NA	NA	Ebola virus	Zaire	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5195	G202-0362	NA	NA	Ebola virus	Zaire	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5197	C795-0925	NA	NA	Marburg virus	Ci67	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5198	D011-2120	NA	NA	Marburg virus	Ci67	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5199	F694-1532	NA	NA	Marburg virus	Ci67	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5200	G202-0362	NA	NA	Marburg virus	Ci67	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5202	C795-0925	NA	NA	Lassa virus	Josiah	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5203	D011-2120	NA	NA	Lassa virus	Josiah	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5204	F694-1532	NA	NA	Lassa virus	Josiah	NA	Immunoflourescence assay	Decrease (50 %)	NA	25144302
DrugRepV_5208	Curcumin	NA	Depressive disorder	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (3 log pfu/ml)	Approved	22847000
DrugRepV_5209	SC-514	NA	NA	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (<1 log pfu/ml)	NA	22847000
DrugRepV_5210	Curcumin	NA	Depressive disorder	Rift Valley fever virus	ZH501	NA	Plaque assay	Decrease (4 log pfu/ml)	Approved	22847000
DrugRepV_5211	Curcumin	NA	Depressive disorder	Rift Valley fever virus	MP12	NA	Plaque assay	Decrease (5 log pfu/ml)	Approved	22847000
DrugRepV_5213	Quinacrine Dihydrochloride	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Rift Valley fever virus	NA	NA	RVFV nucleocapsid (N) protein RNA-binding activity	Decrease (50 %)	Investigational	22644268
DrugRepV_5214	N-methyl-2,3-diphenyl-1,2,4-thiadiazol-5-imine;hydrobromide	NA	NA	Rift Valley fever virus	NA	NA	RVFV nucleocapsid (N) protein RNA-binding activity	Decrease (50 %)	NA	22644268
DrugRepV_5215	4-(3,6-dioxocyclohexa-1,4-dien-1-yl)benzoic acid	NA	NA	Rift Valley fever virus	NA	NA	RVFV nucleocapsid (N) protein RNA-binding activity	Decrease (50 %)	NA	22644268
DrugRepV_5216	BTB 11461	NA	NA	Rift Valley fever virus	NA	NA	RVFV nucleocapsid (N) protein RNA-binding activity	Decrease (50 %)	NA	22644268
DrugRepV_5226	Ribamidine	NA	NA	Crimean-Congo hemorrhagic fever virus	IbAr 10200	NA	Neutral red uptake assay	Decrease (50 %)	Investigational	15026198
DrugRepV_5227	6-Azauridine	NA	Cancer	Crimean-Congo hemorrhagic fever virus	IbAr 10200	NA	Neutral red uptake assay	Decrease (50 %)	NA	15026198
DrugRepV_5228	Selenazofurin	NA	NA	Crimean-Congo hemorrhagic fever virus	IbAr 10200	NA	Neutral red uptake assay	Decrease (50 %)	NA	15026198
DrugRepV_5231	Ribamidine	NA	NA	Crimean-Congo hemorrhagic fever virus	Spu 128/81	NA	Neutral red uptake assay	Decrease (50 %)	Investigational	15026198
DrugRepV_5232	6-Azauridine	NA	Cancer	Crimean-Congo hemorrhagic fever virus	Spu 128/81	NA	Neutral red uptake assay	Decrease (50 %)	NA	15026198
DrugRepV_5233	Selenazofurin	NA	NA	Crimean-Congo hemorrhagic fever virus	Spu 128/81	NA	Neutral red uptake assay	Decrease (50 %)	NA	15026198
DrugRepV_5236	Ribamidine	NA	NA	Crimean-Congo hemorrhagic fever virus	Hy-13	NA	Neutral red uptake assay	Decrease (50 %)	Investigational	15026198
DrugRepV_5237	6-Azauridine	NA	Cancer	Crimean-Congo hemorrhagic fever virus	Hy-13	NA	Neutral red uptake assay	Decrease (50 %)	NA	15026198
DrugRepV_5238	Selenazofurin	NA	NA	Crimean-Congo hemorrhagic fever virus	Hy-13	NA	Neutral red uptake assay	Decrease (50 %)	NA	15026198
DrugRepV_5241	Ribamidine	NA	NA	Crimean-Congo hemorrhagic fever virus	UG3010	NA	Neutral red uptake assay	Decrease (50 %)	Investigational	15026198
DrugRepV_5242	6-Azauridine	NA	Cancer	Crimean-Congo hemorrhagic fever virus	UG3010	NA	Neutral red uptake assay	Decrease (50 %)	NA	15026198
DrugRepV_5243	Selenazofurin	NA	NA	Crimean-Congo hemorrhagic fever virus	UG3010	NA	Neutral red uptake assay	Decrease (50 %)	NA	15026198
DrugRepV_5245	Cytarabine	NA	Leukemia	Variola virus	Harvey	NA	Focus forming assay	Decrease (82.3 %)	Approved	198636
DrugRepV_5246	Cytarabine	NA	Leukemia	Variola virus	Harvey	NA	Focus forming assay	Decrease (30.2 %)	Approved	198636
DrugRepV_5247	6-Azauridine	NA	Cancer	Variola virus	Harvey	NA	Focus forming assay	Decrease (1.2 %)	NA	198636
DrugRepV_5248	Cytarabine	NA	Leukemia	Variola virus	Yamamoto P	NA	Focus forming assay	Decrease (66.1 %)	Approved	198636
DrugRepV_5249	6-Azauridine	NA	Cancer	Variola virus	Yamamoto P	NA	Focus forming assay	Decrease (2.9 %)	NA	198636
DrugRepV_5250	Cytarabine	NA	Leukemia	Variola virus	Butler	NA	Focus forming assay	Decrease (44.4 %)	Approved	198636
DrugRepV_5251	6-Azauridine	NA	Cancer	Variola virus	Butler	NA	Focus forming assay	No significant effect (No inhibition %)	NA	198636
DrugRepV_5253	beta-D-cyclopentenyl cytosine	NA	NA	Variola virus	Bangladesh 1975	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5254	beta-D-cyclopentenyl cytosine	NA	NA	Variola virus	7124	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5255	beta-D-cyclopentenyl-5-iodocytidine	NA	NA	Variola virus	Bangladesh 1975	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5256	beta-D-cyclopentenyl-5-iodocytidine	NA	NA	Variola virus	7124	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5257	beta-D-Cyclopentenyl-5-chlorocytidine	NA	NA	Variola virus	Bangladesh 1975	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5258	beta-D-Cyclopentenyl-5-chlorocytidine	NA	NA	Variola virus	7124	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5259	beta-D-cyclopentenyl-5-bromocytidine	NA	NA	Variola virus	Bangladesh 1975	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5260	beta-D-cyclopentenyl-5-bromocytidine	NA	NA	Variola virus	7124	NA	NA	Decrease (50 %)	NA	14604375
DrugRepV_5261	Delphinidin Chloride	NA	NA	Zika virus	MR766	NA	Plaque assay	Decrease (102 Log)	NA	28744282
DrugRepV_5263	Delphinidin Chloride	NA	NA	Zika virus	PA259459	NA	Plaque assay	Decrease	NA	28744282
DrugRepV_5265	Tetra-O-methyl nordihydroguaiaretic acid (M4N)	NA	Brain and Central Nervous System Tumors	Zika virus	PA259459	NA	Plaque assay	Decrease (50 %)	Investigational	28507114
DrugRepV_5266	Tetra-O-methyl nordihydroguaiaretic acid (M4N)	NA	Brain and Central Nervous System Tumors	Zika virus	PA259459	NA	Plaque assay	Decrease (50 %)	Investigational	28507114
DrugRepV_5267	25-Hydroxycholesterol	NA	NA	Lassa virus	Josiah	NA	TCID50 assay	Decrease (>1.1 Log)	Experimental	27999160
DrugRepV_5268	25-Hydroxycholesterol	NA	NA	Lassa virus	Josiah	NA	TCID50 assay	Decrease (1.4 Log)	Experimental	27999160
DrugRepV_5273	1-{[2-(benzyloxy)ethoxy]methyl}-1H-imidazole-4,5-dicarbonitrile	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5274	diethyl {[2-(4,5-dicyano-1H-imidazol-1-yl)ethoxy]methyl}phosphonate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5275	diethyl {2-[(4,5-dicyano-1H-imidazol-1-yl)methoxy]ethyl}phosphonate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5276	1-[(2-bromoethoxy)methyl]-1H-imidazole-4,5-dicarbonitrile	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5277	2-[(4,5-dicyano-1H-imidazol-1-yl)methoxy]ethyl acetate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5278	1-[(2-hydroxyethoxy)methyl]-1H-imidazole-4,5-dicarbonitrile	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5279	1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarbonitrile	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5280	{2-[4,5-bis(methoxycarbonyl)-1H-imidazol-1-yl]ethoxy}phosphonic acid	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5281	4,5-dimethyl 1-[(2R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5282	4,5-dimethyl 1-(2-hydroxyethyl)-1H-imidazole-4,5-dicarboxylate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5283	4,5-dimethyl 1-[2-(acetyloxy)ethyl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5284	4,5-dimethyl 1-[(2R,5S)-3,4-bis(acetyloxy)-5-[(acetyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5285	4,5-dimethyl 1-[(2R,5S)-3,4-bis(benzoyloxy)-5-[(benzoyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5286	4,5-dimethyl 1-[(2R,5S)-4-(4-methylbenzoyloxy)-5-[(4-methylbenzoyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5287	1-(2-hydroxyethyl)-1H-imidazole-4,5-dicarboxylic acid	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5288	1-{[2-(benzyloxy)ethoxy]methyl}-1H-imidazole-4,5-dicarboxylic acid	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5289	1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarbohydrazide	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5290	1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarboxamide	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5291	1-{[2-(benzyloxy)ethoxy]methyl}-1H-imidazole-4,5-dicarbonitrile	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5292	diethyl {[2-(4,5-dicyano-1H-imidazol-1-yl)ethoxy]methyl}phosphonate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5293	diethyl {2-[(4,5-dicyano-1H-imidazol-1-yl)methoxy]ethyl}phosphonate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5294	1-[(2-bromoethoxy)methyl]-1H-imidazole-4,5-dicarbonitrile	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5295	2-[(4,5-dicyano-1H-imidazol-1-yl)methoxy]ethyl acetate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5296	1-[(2-hydroxyethoxy)methyl]-1H-imidazole-4,5-dicarbonitrile	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5297	1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarbonitrile	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5298	{2-[4,5-bis(methoxycarbonyl)-1H-imidazol-1-yl]ethoxy}phosphonic acid	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5299	4,5-dimethyl 1-[(2R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5300	4,5-dimethyl 1-(2-hydroxyethyl)-1H-imidazole-4,5-dicarboxylate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5301	4,5-dimethyl 1-[2-(acetyloxy)ethyl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5302	4,5-dimethyl 1-[(2R,5S)-3,4-bis(acetyloxy)-5-[(acetyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5303	4,5-dimethyl 1-[(2R,5S)-3,4-bis(benzoyloxy)-5-[(benzoyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5304	4,5-dimethyl 1-[(2R,5S)-4-(4-methylbenzoyloxy)-5-[(4-methylbenzoyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5305	1-(2-hydroxyethyl)-1H-imidazole-4,5-dicarboxylic acid	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5306	1-{[2-(benzyloxy)ethoxy]methyl}-1H-imidazole-4,5-dicarboxylic acid	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5307	1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarbohydrazide	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5308	1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarboxamide	NA	NA	Lassa virus	AV	NA	Real-time PCR	Decrease (90 %)	NA	15451189
DrugRepV_5309	1-{[2-(benzyloxy)ethoxy]methyl}-1H-imidazole-4,5-dicarbonitrile	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5310	diethyl {[2-(4,5-dicyano-1H-imidazol-1-yl)ethoxy]methyl}phosphonate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5311	diethyl {2-[(4,5-dicyano-1H-imidazol-1-yl)methoxy]ethyl}phosphonate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5312	1-[(2-bromoethoxy)methyl]-1H-imidazole-4,5-dicarbonitrile	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5313	2-[(4,5-dicyano-1H-imidazol-1-yl)methoxy]ethyl acetate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5314	1-[(2-hydroxyethoxy)methyl]-1H-imidazole-4,5-dicarbonitrile	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5315	1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarbonitrile	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5316	{2-[4,5-bis(methoxycarbonyl)-1H-imidazol-1-yl]ethoxy}phosphonic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5317	4,5-dimethyl 1-[(2R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5318	4,5-dimethyl 1-(2-hydroxyethyl)-1H-imidazole-4,5-dicarboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5319	4,5-dimethyl 1-[2-(acetyloxy)ethyl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5320	4,5-dimethyl 1-[(2R,5S)-3,4-bis(acetyloxy)-5-[(acetyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5321	4,5-dimethyl 1-[(2R,5S)-3,4-bis(benzoyloxy)-5-[(benzoyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5322	4,5-dimethyl 1-[(2R,5S)-4-(4-methylbenzoyloxy)-5-[(4-methylbenzoyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5323	1-(2-hydroxyethyl)-1H-imidazole-4,5-dicarboxylic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5324	1-{[2-(benzyloxy)ethoxy]methyl}-1H-imidazole-4,5-dicarboxylic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5325	1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarbohydrazide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5326	1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5327	1-{[2-(benzyloxy)ethoxy]methyl}-1H-imidazole-4,5-dicarbonitrile	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5328	diethyl {[2-(4,5-dicyano-1H-imidazol-1-yl)ethoxy]methyl}phosphonate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5329	diethyl {2-[(4,5-dicyano-1H-imidazol-1-yl)methoxy]ethyl}phosphonate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5330	1-[(2-bromoethoxy)methyl]-1H-imidazole-4,5-dicarbonitrile	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5331	2-[(4,5-dicyano-1H-imidazol-1-yl)methoxy]ethyl acetate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5332	1-[(2-hydroxyethoxy)methyl]-1H-imidazole-4,5-dicarbonitrile	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5333	1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarbonitrile	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5334	{2-[4,5-bis(methoxycarbonyl)-1H-imidazol-1-yl]ethoxy}phosphonic acid	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5335	4,5-dimethyl 1-[(2R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5336	4,5-dimethyl 1-(2-hydroxyethyl)-1H-imidazole-4,5-dicarboxylate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5337	4,5-dimethyl 1-[2-(acetyloxy)ethyl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5338	4,5-dimethyl 1-[(2R,5S)-3,4-bis(acetyloxy)-5-[(acetyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5339	4,5-dimethyl 1-[(2R,5S)-3,4-bis(benzoyloxy)-5-[(benzoyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5340	4,5-dimethyl 1-[(2R,5S)-4-(4-methylbenzoyloxy)-5-[(4-methylbenzoyloxy)methyl]oxolan-2-yl]-1H-imidazole-4,5-dicarboxylate	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5341	1-(2-hydroxyethyl)-1H-imidazole-4,5-dicarboxylic acid	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5342	1-{[2-(benzyloxy)ethoxy]methyl}-1H-imidazole-4,5-dicarboxylic acid	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5343	1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarbohydrazide	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5344	1-[(2R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazole-4,5-dicarboxamide	NA	NA	Ebola virus	NA	NA	Real-time PCR	Decrease (50 %)	NA	15451189
DrugRepV_5345	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Lassa virus	AV	NA	RT-PCR	Decrease (50 %)	NA	21616094
DrugRepV_5346	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Lassa virus	AV	NA	RT-PCR	Decrease (50 %)	NA	21616094
DrugRepV_5347	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Lassa virus	AV	NA	RT-PCR	Decrease (50 %)	NA	21616094
DrugRepV_5348	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Lassa virus	AV	NA	RT-PCR	Decrease (50 %)	NA	21616094
DrugRepV_5349	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	NA	21616094
DrugRepV_5350	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	NA	21616094
DrugRepV_5351	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	NA	21616094
DrugRepV_5352	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (50 %)	NA	21616094
DrugRepV_5353	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Lassa virus	AV	NA	RT-PCR	Decrease (90 %)	NA	21616094
DrugRepV_5354	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Lassa virus	AV	NA	RT-PCR	Decrease (90 %)	NA	21616094
DrugRepV_5355	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Lassa virus	AV	NA	RT-PCR	Decrease (90 %)	NA	21616094
DrugRepV_5356	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Lassa virus	AV	NA	RT-PCR	Decrease (90 %)	NA	21616094
DrugRepV_5357	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (90 %)	NA	21616094
DrugRepV_5358	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (90 %)	NA	21616094
DrugRepV_5359	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (90 %)	NA	21616094
DrugRepV_5360	5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide	NA	NA	Ebola virus	NA	NA	RT-PCR	Decrease (90 %)	NA	21616094
DrugRepV_5377	2-deoxy-2-fluorocytidine	NA	NA	Lassa virus	Josiah	NA	Minigenome assays	Decrease (50 %)	NA	27771389
DrugRepV_5378	5-fluorouridine	NA	Cancer	Lassa virus	Josiah	NA	Minigenome assays	Decrease (50 %)	Experimental	27771389
DrugRepV_5379	8-Azaadenosine	NA	NA	Lassa virus	Josiah	NA	Minigenome assays	Decrease (50 %)	NA	27771389
DrugRepV_5380	8-Azidoadenosine	NA	NA	Lassa virus	Josiah	NA	Minigenome assays	Decrease (50 %)	NA	27771389
DrugRepV_5381	Toyocamycin	NA	NA	Lassa virus	Josiah	NA	Minigenome assays	Decrease (50 %)	Experimental	27771389
DrugRepV_5382	6-Azauridine	NA	Cancer	Lassa virus	Josiah	NA	Minigenome assays	Decrease (50 %)	NA	27771389
DrugRepV_5383	8-Azaadenosine	NA	NA	Ebola virus	Ebola virus/H.sapiens-rec/LBR/2014/ Makona-L2014	NA	Minigenome assays	Decrease (50 %)	NA	27771389
DrugRepV_5384	Toyocamycin	NA	NA	Ebola virus	Ebola virus/H.sapiens-rec/LBR/2014/ Makona-L2015	NA	Minigenome assays	Decrease (50 %)	Experimental	27771389
DrugRepV_5385	6-Azauridine	NA	Cancer	Ebola virus	Ebola virus/H.sapiens-rec/LBR/2014/ Makona-L2016	NA	Minigenome assays	Decrease (50 %)	NA	27771389
DrugRepV_5386	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	NA	NA	qRT-PCR	Decrease	Investigational	31307979
DrugRepV_5387	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Chikungunya virus	NA	NA	NA	Decrease (50 %)	Investigational	31307979
DrugRepV_5388	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Ebola virus	NA	NA	NA	Decrease (50 %)	Investigational	31307979
DrugRepV_5389	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Influenza virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_5390	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Middle East respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Investigational	31307979
DrugRepV_5391	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Rift Valley fever virus	NA	NA	NA	Decrease (50 %)	Investigational	31307979
DrugRepV_5392	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Zika virus	NA	NA	NA	Decrease (50 %)	Investigational	31307979
DrugRepV_5393	Zoniporide	NA	NA	Lassa virus	Josiah	NA	Luciferase assay	Decrease (50 %)	NA	30700611
DrugRepV_5394	Zoniporide	NA	NA	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	NA	30700611
DrugRepV_5399	Apilimod	NA	Crohn's disease | Psoriasis | Psoriatic disorders	Lassa virus	Josiah	NA	Luciferase assay	Decrease (50 %)	Investigational	30700611
DrugRepV_5400	Apilimod	NA	Crohn's disease | Psoriasis | Psoriatic disorders	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Investigational	30700611
DrugRepV_5401	Arbidol	NA	Viral infection	Lassa virus	Josiah	NA	Luciferase assay	Decrease (50 %)	Investigational	30700611
DrugRepV_5402	Arbidol	NA	Viral infection	Ebola virus	Mayinga	NA	Luciferase assay	Decrease (50 %)	Investigational	30700611
DrugRepV_5410	Desethylamodiaquine	NA	NA	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5411	Desethylchloroquine	NA	NA	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5413	Desethylamodiaquine	NA	NA	Zika virus	MR 766	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5414	Desethylchloroquine	NA	NA	Zika virus	MR 766	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5416	Desethylamodiaquine	NA	NA	Zika virus	PRVABC59	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5417	Desethylchloroquine	NA	NA	Zika virus	PRVABC59	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5420	Losmapimod	NA	Chronic Obstructive Pulmonary Disease	Lassa virus	Josiah	NA	TCID50 assay	Decrease (50 %)	Investigational	30953674
DrugRepV_5421	Losmapimod	NA	Chronic Obstructive Pulmonary Disease	Lassa virus	Josiah	NA	RT-qPCR	Decrease (50 %)	Investigational	30953674
DrugRepV_5422	Losmapimod	NA	Chronic Obstructive Pulmonary Disease	Lassa virus	LP	NA	NA	Decrease (50 %)	Investigational	30953674
DrugRepV_5423	Losmapimod	NA	Chronic Obstructive Pulmonary Disease	Lassa virus	803213	NA	NA	Decrease (50 %)	Investigational	30953674
DrugRepV_5424	Losmapimod	NA	Chronic Obstructive Pulmonary Disease	Lassa virus	GA391	NA	NA	Decrease (50 %)	Investigational	30953674
DrugRepV_5425	Losmapimod	NA	Chronic Obstructive Pulmonary Disease	Lassa virus	Josiah	NA	NA	Decrease (50 %)	Investigational	30953674
DrugRepV_5426	ST-193	NA	NA	Lassa virus	LP	NA	NA	Decrease (50 %)	NA	30953674
DrugRepV_5427	ST-193	NA	NA	Lassa virus	803213	NA	NA	Decrease (50 %)	NA	30953674
DrugRepV_5428	ST-193	NA	NA	Lassa virus	GA391	NA	NA	Decrease (50 %)	NA	30953674
DrugRepV_5429	ST-193	NA	NA	Lassa virus	Josiah	NA	NA	Decrease (50 %)	NA	30953674
DrugRepV_5431	Gallium nitrate	NA	NA	Influenza virus	A/Puerto Rico/8/34 (PR8)		Plaque reduction assay	Decrease (50 %)	Approved, Investigational	31244822
DrugRepV_5435	Gallium nitrate	NA	NA	Influenza virus	pdm09A/Mexico/InDRE4487/2009		Plaque reduction assay	Decrease (50 %)	Approved, Investigational	31244822
DrugRepV_5439	Gallium nitrate	NA	NA	Influenza virus	A/Victoria/36/2011		Plaque reduction assay	Decrease (50 %)	Approved, Investigational	31244822
DrugRepV_5443	Gallium nitrate	NA	NA	Influenza virus	A/Puerto Rico/8/34 (PR8)		Virus inhibition assay	Decrease (5.3 log)	Approved, Investigational	31244822
DrugRepV_5447	Gallium nitrate	NA	NA	Influenza virus	pdm09A/Mexico/InDRE4487/2009		Virus inhibition assay	Decrease (5.2 log)	Approved, Investigational	31244822
DrugRepV_5451	Gallium nitrate	NA	NA	Influenza virus	A/Victoria/36/2011		Virus inhibition assay	Decrease (5.5 log)	Approved, Investigational	31244822
DrugRepV_5477	Nafamostat	NA	Blood vessel coagulation | Hemorrhagic lesions	SARS Coronavirus-2	nCoV- 2019BetaCoV/Wuhan/WIV04/2019	NA	qRT-PCR	Decrease (50 %)	Investigational	32020029
DrugRepV_5479	Beta-D-N4-hydroxycytidine	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (50 %)	NA	31578288
DrugRepV_5482	RK-33	NA	NA	Zika virus	Asian/Cook Islands/2014	NA	Plaque assay	Decrease (50 %)	NA	31936642
DrugRepV_5483	RK-33	NA	NA	Zika virus	Asian/Cook Islands/2014	NA	qRT-PCR	Decrease (50 %)	NA	31936642
DrugRepV_5487	Novobiocin	NA	Staphylococci infections	Zika virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved, Investigational, Vet approved	31786251
DrugRepV_5495	Winthrop	NA	NA	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	NA	31882748
DrugRepV_5496	Winthrop	NA	NA	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	NA	31882748
DrugRepV_5497	Winthrop	NA	NA	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	NA	31882748
DrugRepV_5498	N-Desethylamodiaquine hydrochloride	NA	NA	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	NA	31882748
DrugRepV_5499	N-Desethylamodiaquine hydrochloride	NA	NA	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	NA	31882748
DrugRepV_5500	N-Desethylamodiaquine hydrochloride	NA	NA	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	NA	31882748
DrugRepV_5501	Dihydroartimesinin	NA	Malaria	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	Experimental, Investigational	31882748
DrugRepV_5502	Dihydroartimesinin	NA	Malaria	Ebola virus	NA	NA	Cell based assay	Decrease (50 %)	Experimental, Investigational	31882748
DrugRepV_5506	Anthralin	NA	Psoriasis	Influenza virus	H1N1		TCID50 assay	Decrease (99 %)	Approved	32132985
DrugRepV_5507	Anthralin	NA	Psoriasis	Influenza virus	H1N1		TCID50 assay	Decrease (99 %)	Approved	32132985
DrugRepV_5508	Amuvatinib	NA	Cancer	Lassa virus	NA	NA	Gaussia luciferase (Gluc) Glow assay	Decrease (50 %)	Investigational	31786250
DrugRepV_5510	Azoxystrobin	NA	Fungal infections	Lassa virus	NA	NA	Gaussia luciferase (Gluc) Glow assay	Decrease (50 %)	Experimental	31786250
DrugRepV_5511	Buparvaquone	NA	NA	Lassa virus	NA	NA	Gaussia luciferase (Gluc) Glow assay	Decrease (50 %)	NA	31786250
DrugRepV_5512	Dequalinium chloride hydrate	NA	NA	Lassa virus	NA	NA	Gaussia luciferase (Gluc) Glow assay	Decrease (50 %)	NA	31786250
DrugRepV_5513	Manassantin A	NA	NA	Lassa virus	NA	NA	Gaussia luciferase (Gluc) Glow assay	Decrease (50 %)	NA	31786250
DrugRepV_5514	Monensin sodium salt	NA	NA	Lassa virus	NA	NA	Gaussia luciferase (Gluc) Glow assay	Decrease (50 %)	Experimental, Vet approved	31786250
DrugRepV_5515	Mubritinib	NA	Lung Neoplasm, Renal Neoplasm, Breast Neoplasm, Ovarian Neoplasm, and Pancreatic Neoplasm	Lassa virus	NA	NA	Gaussia luciferase (Gluc) Glow assay	Decrease (50 %)	Investigational	31786250
DrugRepV_5519	Rotenone	NA	NA	Lassa virus	NA	NA	Gaussia luciferase (Gluc) Glow assay	Decrease (50 %)	Vet approved	31786250
DrugRepV_5520	Spautin-1	NA	NA	Lassa virus	NA	NA	Gaussia luciferase (Gluc) Glow assay	Decrease (50 %)	NA	31786250
DrugRepV_5521	Valinomycin	NA	NA	Lassa virus	NA	NA	Gaussia luciferase (Gluc) Glow assay	Decrease (50 %)	Experimental	31786250
DrugRepV_5523	Tryptanthrin	NA	NA	Lassa virus	NA	NA	Gaussia luciferase (Gluc) Glow assay	Decrease (50 %)	NA	31786250
DrugRepV_5531	JQ1	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5532	RVX-208	NA	Diabetes, Atherosclerosis, and Coronary Artery Disease	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5533	Silmitasertib	NA	Medulloblastoma	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Investigational	32353859
DrugRepV_5534	TMCB	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5535	Apicidin	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5538	E-52862	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5539	PD-144418	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5540	RS-PPCC	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5541	PB28	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5547	H-89	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5548	Merimepodib	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Investigational	32353859
DrugRepV_5552	XL413	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5553	CCT 365623	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5556	ZINC1775962367	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5557	ZINC4326719	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5558	ZINC4511851	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5559	ZINC95559591	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5560	AC-55541	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5561	AZ8838	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5563	GB110	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5564	S-verapamil	NA	Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders).	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5565	AZ3451	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5566	ABBV-744	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5567	dBET6	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5568	MZ1	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5569	CPI-0610	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5570	Sapanisertib	NA	Tumor	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Investigational	32353859
DrugRepV_5572	Zotatifin	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5573	Verdinexor	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Investigational	32353859
DrugRepV_5576	WDB002	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5577	Sanglifehrin A	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Experimental	32353859
DrugRepV_5579	Pevonedistat	NA	Lymphoma	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Investigational	32353859
DrugRepV_5580	Ternatin 4	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5581	4E2RCat	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5582	Tomivosertib	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Investigational	32353859
DrugRepV_5583	(2R,5S,11S,14S,17R,18R,21E)-2-(2-aminoethyl)-18-methoxy-11,17-dimethyl-14-(propan-2-yl)-3-oxa-9,12,15,28-tetraazatricyclo[21.3.1.1?,?]octacosa-1(26),21,23(27),24-tetraene-4,10,13,16-tetrone	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5584	N-(5-{3-[(4-Hydroxyphenyl)sulfamoyl]-4-methoxyphenyl}-4-methyl-1,3-thiazol-2-yl)-2,2-dimethylpropanamide	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5585	PS3061	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5586	IHVR-19029	NA	NA	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	NA	32353859
DrugRepV_5590	Nafamostat	NA	Blood vessel coagulation | Hemorrhagic lesions	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Investigational	32353859
DrugRepV_5604	Sunitinib-Erlotinib	NA	NA	Dengue virus	N124D/K128E		NA	Increase	NA	28240606
DrugRepV_5605	Sunitinib-Erlotinib	NA	NA	Dengue virus	N124D/K128E		Real-time PCR	Decrease (11 Fold)	NA	28240606
DrugRepV_5615	AMG-458	NA	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (60 %)	NA	28099856
DrugRepV_5616	AMG-458	NA	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	No significant effect (40 %)	NA	28099856
DrugRepV_5617	AMG-458	NA	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	No significant effect (5 %)	NA	28099856
DrugRepV_5708	R1479	NA	NA	Dengue virus	MY-10340		Plaque assay	Decrease (50 %)	NA	24257621
DrugRepV_5709	Sunitinib-Erlotinib	NA	NA	Dengue virus	NA		Survival assay	Increase	NA	29753658
DrugRepV_5710	Sunitinib-Erlotinib	NA	NA	Dengue virus	NA		Plaque assay	Decrease (>5 Log (pfu/g))	NA	29753658
DrugRepV_5714	Carrageenan	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5715	Tannic Acid	NA	Cold sores | Diaper rash | Fever blisters | Poison ivy	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Approved	20973722
DrugRepV_5716	Tannic Acid	NA	Cold sores | Diaper rash | Fever blisters | Poison ivy	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Approved	20973722
DrugRepV_5717	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Investigational	20973722
DrugRepV_5718	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Investigational	20973722
DrugRepV_5721	BIBU 1361	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5722	BIBU 1361	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5724	3-[(4-chloro-phenyl)-phenyl-methoxy]-tropane	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5725	3-[(4-chloro-phenyl)-phenyl-methoxy]-tropane	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5727	H-89	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5728	H-89	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5729	MPP	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5730	MPP	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5734	W-9	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5735	W-9	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5736	AZ 10417808	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5737	AZ 10417808	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5738	Niguldipine	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Experimental	20973722
DrugRepV_5739	Niguldipine	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Experimental	20973722
DrugRepV_5740	3a-bis-(4-fluorophenyl) Methoxytropane	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5741	LE 135	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5742	LE 135	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5761	Myriocin	NA	Bacterial infections	Dengue virus	NGC		Plaque assay	No significant effect	NA	25313218
DrugRepV_5762	Fenretinide-Myriocin	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (4 Logs)	NA	25313218
DrugRepV_5763	Butylated Hydroxyanisole	NA	Antioxidant	Dengue virus	NGC		Plaque assay	No significant effect	NA	25313218
DrugRepV_5764	Fenretinide-Butylated Hydroxyanisole	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (1.5 Logs)	NA	25313218
DrugRepV_5766	Fenretinide-Vitamin C	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (3 Logs)	NA	25313218
DrugRepV_5775	Allantoin	NA	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (78 %)	Approved	25251726
DrugRepV_5777	Brucine	NA	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (75 %)	NA	25251726
DrugRepV_5778	Dicloxacillium Sodium	NA	Bacterial infections	Dengue virus	Singapore isolates		Plaque assay	Decrease (72 %)	Approved	25251726
DrugRepV_5780	Acrisorcin	NA	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (72 %)	NA	25251726
DrugRepV_5782	Oxantel Pamoate	NA	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (68 %)	NA	25251726
DrugRepV_5787	Lasalocid Sodium	NA	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (62 %)	NA	25251726
DrugRepV_5803	Lapachaone Alpha	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (98.84 %)	NA	22155902
DrugRepV_5809	Shikonin	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (78.94 %)	NA	22155902
DrugRepV_5811	Chelerythrine Chloride	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (73.36 %)	NA	22155902
DrugRepV_5812	Skimmianine	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (61.96 %)	NA	22155902
DrugRepV_5816	Tunicamycin B	NA	Bacterial infections	Dengue virus	NA		Immunoflourescence assay	Decrease (55.01 %)	Experimental	22155902
DrugRepV_5817	Acivicin	NA	Cancer	Dengue virus	NA		Immunoflourescence assay	Decrease (54.32 %)	Phase I	22155902
DrugRepV_5821	Gitoxigenin	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (49.01 %)	NA	22155902
DrugRepV_5822	Kainic Acid	NA	Neuroexcitatory	Dengue virus	NA		Immunoflourescence assay	Decrease (48.87 %)	NA	22155902
DrugRepV_5825	Diacetoxyscirpenol	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (45.55 %)	NA	22155902
DrugRepV_5826	Austricin	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (45.01 %)	NA	22155902
DrugRepV_5827	Valinomycin	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (43.34 %)	Experimental	22155902
DrugRepV_5828	Thapsigargin	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (42.9 %)	NA	22155902
DrugRepV_5829	Strophanthidin Acetate	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (41.96 %)	NA	22155902
DrugRepV_5831	Echinomycin	NA	Bacterial infections	Dengue virus	NA		Immunoflourescence assay	Decrease (41.52 %)	NA	22155902
DrugRepV_5832	Chromomycin A3	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (40.87 %)	NA	22155902
DrugRepV_5835	Strophanthidin Acetate	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (50 %)	NA	22155902
DrugRepV_5839	Strophanthidin Acetate	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (98 %)	NA	22155902
DrugRepV_5843	Strophanthidin Acetate	NA	NA	Dengue virus	NA		Plaque assay	Decrease (5 Logs reduction)	NA	22155902
DrugRepV_5890	Quinacrine Mustard	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Dengue virus	NA		Plaque assay	Decrease (> 99 %)	Experimental	24680954
DrugRepV_5908	Quinacrine Mustard	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Dengue virus	NA		Plaque assay	Decrease (50 %)	Experimental	24680954
DrugRepV_5969	ZX-2401	NA	Rhinovirus 1A | Rhinovirus 30 | Rhinovirus 13 | Rhinovirus 8 | Rhinovirus 2	Dengue virus	New Guinea		Cytopathic effect (CPE) assay	Decrease (50 %)	NA	16199098
DrugRepV_5975	Deoxynojirimycin	NA	NA	Dengue virus	FGA/89		Focus immunoassay	Decrease (80 %)	NA	10590151
DrugRepV_6001	U18666A	NA	NA	Dengue virus	New Guinea		Plaque assay	Decrease (3 Log (pfu/ml))	NA	22146564
DrugRepV_6002	U18666A	NA	NA	Dengue virus	Replicon systen		Luciferase reporter assay	Decrease (50 %)	NA	22146564
DrugRepV_6003	U18666A	NA	NA	Dengue virus	Replicon systen		Luciferase reporter assay	Decrease (50 %)	NA	22146564
DrugRepV_6006	Chebulagic Acid	NA	Immunosuppressive and hepatoprotective	Dengue virus	16681		Plaque assay	Decrease (50 %)	NA	23924316
DrugRepV_6008	Chebulagic Acid	NA	Immunosuppressive and hepatoprotective	Dengue virus	16681		Plaque assay	Decrease (100 %)	NA	23924316
DrugRepV_6013	N-nonyl-deoxynojirimycin	NA	NA	Dengue virus	PL046		FITC- assay	Decrease (98 %)	NA	11907199
DrugRepV_6014	N-nonyl-deoxynojirimycin	NA	NA	Dengue virus	PL046		Plaque assay	Decrease (4 Log)	NA	11907199
DrugRepV_6015	N-nonyl-deoxynojirimycin	NA	NA	Dengue virus	PL046		Western blot	Decrease (Decrease Band Intensity)	NA	11907199
DrugRepV_6016	N-nonyl-deoxynojirimycin	NA	NA	Dengue virus	PL046		Western blot	Decrease (Decrease Band Intensity)	NA	11907199
DrugRepV_6017	N-nonyl-deoxynojirimycin	NA	NA	Dengue virus	PL046		Real-time PCR	Decrease (Decrease Ct Value)	NA	11907199
DrugRepV_6018	N-nonyl-deoxynojirimycin	NA	NA	Dengue virus	PL046		Real-time PCR	Decrease (Decrease Ct Value)	NA	11907199
DrugRepV_6038	4-(5-(4-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6039	4-(5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6040	4-(5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6041	4-(3-Phenyl-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6042	4-(3-Phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6043	4-(3-(4-phenoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6044	4-(5-(2-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6045	4-(5-(3-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6046	4-(5-(4-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6047	4-(5-(2-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6048	4-(5-(3-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6049	4-(5-(4-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6050	4-(3-(4-phenoxyphenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6051	4-(3-(4-phenoxyphenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6052	4-(3-(4-phenoxyphenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6053	4-(3-(4-(benzyloxy)phenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6054	4-(3-(4-(benzyloxy)phenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6055	4-(3-(4-(benzyloxy)phenyl)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6056	4-(3-(4-(benzyloxy)phenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6057	4-(3-(4-(benzyloxy)phenyl)-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6058	4-(3-(4-(benzyloxy)phenyl)-5-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6059	4-(3-(4-(benzyloxy)phenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6060	4-(3-(4-(benzyloxy)phenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6061	4-(3-(4-(benzyloxy)phenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6062	4-(3-(4-(benzyloxy)phenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6064	N2-(4-fluorophenyl)-N3-(4-methyl-2-(3-methyl-1H-pyrazol- 5-yl)phenyl) pyrazine-2,3 dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6065	N2-(4-methyl-2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N3-(p- tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6066	N2-(4-fluorophenyl)-N3-(4-methyl-2-(thiophen-2-yl)phenyl) pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6067	N2-(4-methyl-2-(thiophen-2-yl)phenyl)-N3-(p-tolyl) pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6068	N2-(4-fluorophenyl)-N3-(4-methyl-2-(5-methylthiophen-2-yl)phenyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6069	N2-(4-methyl-2-(5-methylthiophen-2-yl)phenyl)-N3-(p- tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6070	N2-(4-fluorophenyl)-N3-(4-methyl-2-(thiophen-3-yl) phenyl)pyrazine-2,3- dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6071	N2-(4-methyl-2-(thiophen-3-yl)phenyl)-N3-(p-tolyl) pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6072	N2-(4-fluorophenyl)-N3-(2-(thiophen-3-yl)benzyl)pyrazine- 2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6073	N2-(2-(thiophen-3-yl)benzyl)-N3-(p-tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6074	N2-(4-fluorophenyl)-N3-(4-(thiophen-3-yl)benzyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6075	N2-(4-(thiophen-3-yl)benzyl)-N3-(p-tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6076	N2-(4-fluorophenyl)-N3-(2-(3-methyl-1H-pyrazol-5-yl) phenyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6077	N2-(2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N3-(p-tolyl) pyrazine-2,3-di-carboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6078	N1-(4-fluorophenyl)-N2-(4-methyl-2-(3-methyl-1H-pyrazol-5-yl)phenyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6079	N1-(4-fluorophenyl)-N2-(4-methyl-2-(thiophen-2-yl) phenyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6080	N1-(4-methyl-2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N2-(p- tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6081	N1-(4-methyl-2-(thiophen-2-yl)phenyl)-N2-(p-tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6082	N1-(4-methyl-2-(5-methylthiophen-2-yl)phenyl)-N2-(p- tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6083	N1-(4-fluorophenyl)-N2-(4-methyl-2-(5-methylthiophen-2- yl)phenyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6084	N1-(4-methyl-2-(thiophen-3-yl)phenyl)-N2-(p-tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6085	N1-(4-fluorophenyl)-N2-(4-methyl-2-(thiophen-3-yl) phenyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6086	N1-(4-fluorophenyl)-N2-(2-(thiophen-3-yl)benzyl) phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6087	N1-(2-(thiophen-3-yl)benzyl)-N2-(p-tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6088	N1-(4-fluorophenyl)-N2-(4-(thiophen-3-yl)benzyl) phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6089	N1-(4-(thiophen-3-yl)benzyl)-N2-(p-tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6090	N1-(4-fluorophenyl)-N2-(2-(3-methyl-1H-pyrazol-5-yl) phenyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6091	N1-(2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N2-(p-tolyl) phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6092	2-(4-fluorobenzamido)-N-(4-methyl-2-(thiophen-3-yl) phenyl)benzamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6093	2-(4-fluorobenzamido)-N-(4-methyl-2-(5-methylthiophen- 2-yl)phenyl)benzamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6094	2-(4-fluorobenzamido)-N-(4-methyl-2-(pyridin-4-yl)phenyl) benzamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6095	2-(4-fluorobenzamido)-N-(4-methyl-2-(pyridin-3-yl)phenyl) benzamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6097	SA-3	NA	NA	Dengue virus	New Guinea C (NGC)		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_6098	SA-11	NA	NA	Dengue virus	New Guinea C (NGC)		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_6099	SA-17	NA	NA	Dengue virus	New Guinea C (NGC)		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_6100	SA-17	NA	NA	Dengue virus	New Guinea C		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_6101	CM-10-18	NA	NA	Dengue virus	New Guinea C		MTT assay	Decrease (50 %)	NA	23578725
DrugRepV_6102	IHVR11029	NA	NA	Dengue virus	New Guinea C		MTT assay	Decrease (50 %)	NA	23578725
DrugRepV_6103	IHVR17028	NA	NA	Dengue virus	New Guinea C		MTT assay	Decrease (50 %)	NA	23578725
DrugRepV_6104	IHVR19029	NA	NA	Dengue virus	New Guinea C		MTT assay	Decrease (50 %)	NA	23578725
DrugRepV_6105	BCX4430	NA	Ebola virus	Dengue virus	New Guinea C		RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_6106	IHVR-19029	NA	NA	Dengue virus	NA		qRT-PCR	Decrease (50 %)	NA	29253498
DrugRepV_6107	Coumarin A	NA	NA	Dengue virus	NG		RT-PCR	Decrease (50 %)	NA	28100218
DrugRepV_6108	Coumarin B	NA	NA	Dengue virus	NG		RT-PCR	Decrease (50 %)	NA	28100218
DrugRepV_6109	Lupeol Acetate 26SK001	NA	NA	Dengue virus	NG		RT-PCR	Decrease (50 %)	NA	28100218
DrugRepV_6110	Voacangine 26SK002	NA	NA	Dengue virus	NG		RT-PCR	Decrease (50 %)	NA	28100218
DrugRepV_6111	Coumarin A	NA	NA	Dengue virus	NG		RT-PCR	Decrease (37.1 %)	NA	28100218
DrugRepV_6112	Coumarin B	NA	NA	Dengue virus	NG		RT-PCR	Decrease (99.25 %)	NA	28100218
DrugRepV_6113	Lupeol Acetate 26SK001	NA	NA	Dengue virus	NG		RT-PCR	Decrease (23 %)	NA	28100218
DrugRepV_6114	Voacangine 26SK002	NA	NA	Dengue virus	NG		RT-PCR	Decrease (23 %)	NA	28100218
DrugRepV_6117	FGI-106	NA	NA	Dengue virus	NA		Flow cytometry	Decrease (50 %)	NA	19523489
DrugRepV_6118	FGI-106	NA	NA	Dengue virus	NA		Flow cytometry	Decrease (50 %)	NA	19523489
DrugRepV_6119	FGI-106	NA	NA	Dengue virus	NA		Flow cytometry	Decrease (50 %)	NA	19523489
DrugRepV_6120	FGI-106	NA	NA	Dengue virus	NA		Flow cytometry	Decrease (50 %)	NA	19523489
DrugRepV_6121	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Dengue virus	NA		Plaque assay	Decrease (50 %)	Investigational	27889529
DrugRepV_6123	GSK369796	NA	NA	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	27889529
DrugRepV_6124	Tomatidine	NA	NA	Dengue virus	16681		MTT assay	Decrease (50 %)	NA	30468746
DrugRepV_6125	Tomatidine	NA	NA	Dengue virus	16007		MTT assay	Decrease (50 %)	NA	30468746
DrugRepV_6126	Tomatidine	NA	NA	Dengue virus	H87		MTT assay	Decrease (50 %)	NA	30468746
DrugRepV_6127	Tomatidine	NA	NA	Dengue virus	1036		MTT assay	Decrease (50 %)	NA	30468746
DrugRepV_6130	VGTI-A3	NA	NA	Dengue virus	New Guinea C		Focus forming assay	Decrease (90 %)	NA	29709563
DrugRepV_6131	VGTI-A3-03	NA	NA	Dengue virus	New Guinea C		Focus forming assay	Decrease (90 %)	NA	29709563
DrugRepV_6132	Ribavirin Nucleobase	NA	NA	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	NA	29672522
DrugRepV_6133	Mizoribine Nucleobase	NA	NA	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	NA	29672522
DrugRepV_6134	T-1105	NA	Zika virus	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	NA	29672522
DrugRepV_6135	Diaminopurine	NA	NA	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	NA	29672522
DrugRepV_6140	T-1106	NA	Yellow Fever virus	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	NA	29672522
DrugRepV_6141	Diaminopurine Riboside	NA	NA	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	NA	29672522
DrugRepV_6142	T-1105	NA	Zika virus	Dengue virus	New Guinea C		Titer reduction assay	Decrease (50 %)	NA	29672522
DrugRepV_6143	T-1106	NA	Yellow Fever virus	Dengue virus	New Guinea C		Titer reduction assay	Decrease (50 %)	NA	29672522
DrugRepV_6144	5,7-dichloro-2-(propan-2-yl)quinolin-8-ol	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	29547522
DrugRepV_6145	5,7-dichloro-2-(2-methylpropyl)quinolin-8-ol	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	29547522
DrugRepV_6150	AR-12	NA	Solid Tumors and Lymphoma	Dengue virus	NA		qRT-PCR	Decrease	Phase I	28666323
DrugRepV_6151	AR-12	NA	Solid Tumors and Lymphoma	Dengue virus	NA		qRT-PCR	Decrease	Phase I	28666323
DrugRepV_6152	AR-12	NA	Solid Tumors and Lymphoma	Dengue virus	NA		qRT-PCR	Decrease	Phase I	28666323
DrugRepV_6153	AR-12	NA	Solid Tumors and Lymphoma	Dengue virus	NA		qRT-PCR	Decrease	Phase I	28666323
DrugRepV_6154	Schisandrin A	NA	NA	Dengue virus	NA		qRT-PCR	Decrease (50 %)	NA	28338050
DrugRepV_6155	Schisandrin B	NA	NA	Dengue virus	NA		qRT-PCR	Decrease (50 %)	NA	28338050
DrugRepV_6156	Schisandrin C	NA	NA	Dengue virus	NA		qRT-PCR	Decrease (50 %)	NA	28338050
DrugRepV_6157	Schisandrin A	NA	NA	Dengue virus	NA		Survival assay	Decrease	NA	28338050
DrugRepV_6160	5hydroxyl-6,7,3,4,5-pentamethoxyflavone	NA	NA	Dengue virus	16681		MTT assay	Decrease (50 %)	NA	22068705
DrugRepV_6161	5,3-dihydroxy-6,7,4,5-tetramethoxyflavone	NA	NA	Dengue virus	16681		MTT assay	Decrease (50 %)	NA	22068705
DrugRepV_6162	BZ-TRP-TSC	NA	NA	Dengue virus	NA		MTT assay	Decrease (85 %)	NA	27490721
DrugRepV_6163	BZ-TRP-TSC	NA	NA	Dengue virus	NA		MTT assay	Decrease (76 %)	NA	27490721
DrugRepV_6164	BZ-TRP-TSC	NA	NA	Dengue virus	NA		MTT assay	Decrease (65 %)	NA	27490721
DrugRepV_6165	BZ-TRP-TSC	NA	NA	Dengue virus	NA		MTT assay	Decrease (76 %)	NA	27490721
DrugRepV_6166	Thiosemicarbazide	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease	NA	27490721
DrugRepV_6169	4-{1-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl}-2-methoxyphenol	NA	NA	Dengue virus	NA		CPE reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6170	4-[1-(4-{[1,1-biphenyl]-4-yl}-1,3-thiazol-2-yl)-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl]phenol	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6171	4-[1-(4-{[1,1-biphenyl]-4-yl}-1,3-thiazol-2-yl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-2-methoxyphenol	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6172	4-[1-(4-{[1,1-biphenyl]-4-yl}-1,3-thiazol-2-yl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenol	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6173	4-[(1E)-1-{2-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]hydrazin-1-ylidene}ethyl]phenol	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6174	4-{[1,1-biphenyl]-4-yl}-2-[(2E)-2-[1-(4-methoxyphenyl)ethylidene]hydrazin-1-yl]-1,3-thiazole	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6175	4-{[1,1-biphenyl]-4-yl}-2-[(2E)-2-[1-(4-nitrophenyl)ethylidene]hydrazin-1-yl]-1,3-thiazole	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6176	4-{[1,1-biphenyl]-4-yl}-2-[(2E)-2-(phenylmethylidene)hydrazin-1-yl]-1,3-thiazole	NA	NA	Dengue virus	NA		CPE reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6177	4-[(E)-[2-(4-{[1,1-biphenyl]-4-yl}-1,3-thiazol-2-yl)hydrazin-1-ylidene]methyl]phenol	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6179	(1S,2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)-1-[(2S,3S,4R,5R,6S)-2,4,5,6,7-pentahydroxy-3-(sulfonatooxy)heptyl]thiolan-1-ium	NA	NA	Dengue virus	ThNH-7/93		Fluorescent focus-forming assay	Decrease (50 %)	NA	22784856
DrugRepV_6180	(1R,2R,3S,4S)-1-[(2S,3S,4R,5R,6S)-2,3,4,5,6,7-hexahydroxyheptyl]-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium chloride	NA	NA	Dengue virus	ThNH-7/93		Fluorescent focus-forming assay	Decrease (50 %)	NA	22784856
DrugRepV_6181	2 -C-methyladenosine	NA	NA	Dengue virus	New Guinea C (NGC)		Cell proliferation assay	Decrease (50 %)	NA	17662475
DrugRepV_6184	UV-4B	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	26946111
DrugRepV_6185	UV-4B	NA	NA	Dengue virus	16681		Virus yield reduction assay	Decrease (50 %)	NA	26946111
DrugRepV_6186	UV-4B	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	26946111
DrugRepV_6187	UV-4B	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	26946111
DrugRepV_6193	STK332077	NA	NA	Dengue virus	New Guinea C (NGC)		Virus yield reduction assay	Decrease (50 %)	NA	26807547
DrugRepV_6194	STK529754	NA	NA	Dengue virus	New Guinea C (NGC)		Virus yield reduction assay	Decrease (50 %)	NA	26807547
DrugRepV_6195	STK530661	NA	NA	Dengue virus	New Guinea C (NGC)		Virus yield reduction assay	Decrease (50 %)	NA	26807547
DrugRepV_6196	(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-acetamido-5-[(prop-1-en-2-yl)amino]pentanamido]-3-hydroxybutanamido]-3-hydroxypropanamido]hexanamido]-N-[(1S)-4-carbamimidamido-1-carbamoylbutyl]hexanamide	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.31 ± 0.06 Log PFU/ml)	NA	25823617
DrugRepV_6197	(E)-N-[(E)-({4-[(E)-{[(diaminomethylidene)amino]imino}methyl]phenyl}methylidene)amino]ethanimidamide	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.37 ± 0.15 Log PFU/ml)	NA	25823617
DrugRepV_6198	(2S)-6-amino-N-[(1S)-4-carbamimidamido-1-[(5-carbamimidamido-1-oxopentan-2-yl)carbamoyl]butyl]-2-[(2S)-2-(phenylformamido)propanamido]hexanamide	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.38 ± 0.10 Log PFU/ml)	NA	25823617
DrugRepV_6199	7-[(phenylamino)(pyridin-2-yl)methyl]quinolin-8-ol	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.34 ± 0.15 Log PFU/ml)	NA	25823617
DrugRepV_6200	1,8-dihydroxy-4,5-dinitro-9,10-dihydroanthracene-9,10-dione	NA	NA	Dengue virus	NA		Cell based assay	Decrease (50 %)	NA	25823617
DrugRepV_6201	4-carbamimidamidophenyl 4-carbamimidamidobenzoate	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.30 ± 0.10 Log PFU/ml)	NA	25823617
DrugRepV_6202	4-nitrophenyl 4-carbamimidamidobenzoate	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.41 ± 0.17 Log PFU/ml)	NA	25823617
DrugRepV_6203	(2E)-2-cyano-3-(4-hydroxyphenyl)prop-2-enamide	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.46 ± 0.15 Log PFU/ml)	NA	25823617
DrugRepV_6204	4-[2-(2,4-dinitrophenyl)diazen-1-yl]naphthalen-1-ol	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.49 ± 0.26 Log PFU/ml)	NA	25823617
DrugRepV_6205	1-ethyl-2-[(1E)-3-[(2Z)-1-ethyl-1H,2H-naphtho[1,2-d][1,3]oxazol-2-ylidene]prop-1-en-1-yl]naphtho[1,2-d][1,3]oxazol-1-ium	NA	NA	Dengue virus	NA		Cell based assay	Decrease (50 %)	NA	25823617
DrugRepV_6206	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-(phenylformamido)pentanamido]-N-[(1R)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.35 ± 0.21 Log PFU/ml)	NA	25823617
DrugRepV_6207	(4R,7S,10S,13S,16S,22R)-22-amino-10,16-bis(4-aminobutyl)-13-(3-carbamimidamidopropyl)-7-(hydroxymethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosane-4-carboxylic acid	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.46 ± 0.35 Log PFU/ml)	NA	25823617
DrugRepV_6208	1-[N-(2-ethylhexyl)carbamimidamido]-N-(6-{N-[N-(2-ethylhexyl)carbamimidoyl]carbamimidamido}hexyl)methanimidamide	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.62 ± 0.20 Log PFU/ml)	NA	25823617
DrugRepV_6209	(1R,2R,4S,5S,8R,10E,12S,13S,14E,16E,20R,21R,24S)-6-[(2S)-butan-2-yl]-21,24-dihydroxy-12-{[(2R,4S,6S)-5-{[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,11,13,22-tetramethyl-3,7,19-trioxaspiro[oxane-2,6-tet	NA	NA	Dengue virus	NA		Cell based assay	Decrease	NA	25823617
DrugRepV_6210	(1R,2R,4S,5S,6S,8R,10E,13S,14E,16E,20R,21E,24S)-6-cyclohexyl-24-hydroxy-12-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-21-(hydroxyimino)-5,11,13,22-tetramethyl-3,7,19-trioxaspiro[oxane-2,6-tetracyclo[15.6.1.14,8.0	NA	NA	Dengue virus	NA		Cell based assay	Decrease	NA	25823617
DrugRepV_6221	2-chloro-10-(prop-2-en-1-yl)-9,10-dihydroacridin-9-one	NA	NA	Dengue virus	Hawaii		Virus yield inhibition assay	Decrease (50 %)	NA	25908170
DrugRepV_6222	2-chloro-10-(prop-2-en-1-yl)-9,10-dihydroacridin-9-one	NA	NA	Dengue virus	New Guinea C		Virus yield inhibition assay	Decrease (50 %)	NA	25908170
DrugRepV_6223	2-chloro-10-(prop-2-en-1-yl)-9,10-dihydroacridin-9-one	NA	NA	Dengue virus	H87		Virus yield inhibition assay	Decrease (50 %)	NA	25908170
DrugRepV_6224	2-chloro-10-(prop-2-en-1-yl)-9,10-dihydroacridin-9-one	NA	NA	Dengue virus	8124		Virus yield inhibition assay	Decrease (50 %)	NA	25908170
DrugRepV_6227	6-MPTF	NA	NA	Dengue virus	16681		Plaque assay	Decrease (2.05 * 106 pfu/ml)	NA	7201778
DrugRepV_6228	Sinefungin	NA	NA	Dengue virus	NA		2-O-MTase assays	Decrease (50 %)	Experimental	23769894
DrugRepV_6229	AdoHcy	NA	NA	Dengue virus	NA		2-O-MTase assays	Decrease (50 %)	Experimental	23769894
DrugRepV_6230	Aurintricarboxylic acid	NA	NA	Dengue virus	NA		2-O-MTase assays	Decrease (50 %)	NA	23769894
DrugRepV_6231	5,50 -Methylene-disalicylic acid	NA	NA	Dengue virus	NA		2-O-MTase assays	Decrease (50 %)	NA	23769894
DrugRepV_6232	YK 51	NA	NA	Dengue virus	New Guinea C		CPE inhibition assay	Decrease (92 %)	NA	20567498
DrugRepV_6233	YK 73	NA	NA	Dengue virus	New Guinea C		CPE inhibition assay	Decrease (90 %)	NA	20567498
DrugRepV_6234	YK 73x	NA	NA	Dengue virus	New Guinea C		CPE inhibition assay	Decrease (91 %)	NA	20567498
DrugRepV_6235	YK 101	NA	NA	Dengue virus	New Guinea C		CPE inhibition assay	Decrease (94 %)	NA	20567498
DrugRepV_6236	YK 38	NA	NA	Dengue virus	New Guinea C		CPE inhibition assay	Decrease (83 %)	NA	20567498
DrugRepV_6237	YK 38	NA	NA	Dengue virus	New Guinea C		Virus plaque assay	Decrease (3.2 * 103 pfu/ml)	NA	20567498
DrugRepV_6238	YK 51	NA	NA	Dengue virus	New Guinea C		Virus plaque assay	Decrease (3.4 * 103 pfu/ml)	NA	20567498
DrugRepV_6239	YK 73	NA	NA	Dengue virus	New Guinea C		Virus plaque assay	Decrease (3.5 * 103 pfu/ml)	NA	20567498
DrugRepV_6240	YK 73x	NA	NA	Dengue virus	New Guinea C		Virus plaque assay	Decrease (2.8 * 103 pfu/ml)	NA	20567498
DrugRepV_6241	YK 101	NA	NA	Dengue virus	New Guinea C		Virus plaque assay	Decrease (2.6 * 103 pfu/ml)	NA	20567498
DrugRepV_6242	9-benzyl-6-[(1-methyl-4-nitro-4,5-dihydro-1H-imidazol-5-yl)methyl]-9H-purin-2-amine	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6243	2-{[(3-nitrophenyl)methyl]sulfanyl}-9H-purin-6-ol	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6244	2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)aniline	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6245	1-(4-Bromophenyl)-2-(ethylamino)-2-methylpropyl hydrodisulfide	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6246	N-[4-(4-aminobenzenesulfonyl)phenyl]pyridine-3-carboxamide	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6247	2-(2-{2-[(2E,5E)-3-ethyl-4-oxo-5-[(phenylamino)methylidene]-1,3-thiazolidin-2-ylidene]hydrazin-1-yl}-1,3-thiazol-5-yl)-N-(2-methylphenyl)acetamide	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6248	(2E)-3-(3,4-dichlorophenyl)-1-[2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]prop-2-en-1-one	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6249	2-{[5-(4-{[(4-chlorophenyl)methylidene]amino}phenyl)-1,3,4-oxadiazol-2-yl]sulfanyl}-N-(2-nitrophenyl)acetamide	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6250	1,3-bis({4-[(1E)-1-(carbamimidamidoimino)ethyl]phenyl})urea	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6251	3-{[(4-chlorophenyl)methyl]sulfanyl}-5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-4-methyl-4H-1,2,4-triazole	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_6252	2-({[5-(5-methyl-3-phenyl-1,2-oxazol-4-yl)-1,2,4-oxadiazol-3-yl]methyl}sulfanyl)pyridin-1-ium-1-olate	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_6253	1-(4-chlorophenyl)-2-({5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3,4-oxadiazol-2-yl}sulfanyl)ethan-1-one	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_6254	1-(2-chlorophenyl)-3-{2-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3-thiazol-4-yl}urea	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_6255	2-chloro-6-(4-chlorophenoxy)-4-{4-methyl-5-[(1E)-1-(2-phenylhydrazin-1-ylidene)ethyl]-1,3-thiazol-2-yl}pyridine	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_6260	HHA	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6261	GNA	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6262	UDA	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6264	Mannan	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6265	HHA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6266	GNA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6267	UDA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6269	Mannan	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6270	HHA	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6271	GNA	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6272	UDA	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6274	Mannan	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6275	HHA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6276	GNA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6277	UDA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6279	Mannan	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6280	G3d	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6281	C2S-3	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6283	DS8000	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6284	G3d	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6285	C2S-3	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6287	DS8000	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6288	G3d	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6289	C2S-3	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6291	DS8000	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6292	G3d	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6293	C2S-3	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6295	DS8000	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6296	G3d	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6297	C2S-3	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6299	DS8000	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6300	G3d	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6301	C2S-3	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6303	DS8000	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6304	G3d	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6305	C2S-3	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6307	DS8000	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6308	G3d	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6309	C2S-3	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6311	DS8000	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6313	PI-88	NA	Hepatocellular carcinoma | Liver cancer | Melanoma | Multiple myeloma	Dengue virus	NGC		Flow cytometry	Decrease (53 %)	Investigational	16309754
DrugRepV_6315	PPS	NA	NA	Dengue virus	NGC		Flow cytometry	Decrease (76 %)	NA	16309754
DrugRepV_6316	Lapachaone Alpha	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (98.84 %)	NA	22155902
DrugRepV_6322	Shikonin	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (78.94 %)	NA	22155902
DrugRepV_6324	Chelerythrine Chloride	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (73.36 %)	NA	22155902
DrugRepV_6325	Skimmianine	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (61.96 %)	NA	22155902
DrugRepV_6329	Tunicamycin B	NA	Bacterial infections	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (55.01 %)	Experimental	22155902
DrugRepV_6330	Acivicin	NA	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (54.32 %)	Phase I	22155902
DrugRepV_6334	Gitoxigenin	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (49.01 %)	NA	22155902
DrugRepV_6335	Kainic acid	NA	Neuroexcitatory	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (48.87 %)	NA	22155902
DrugRepV_6338	Diacetoxyscirpenol	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (45.55 %)	NA	22155902
DrugRepV_6339	Austricin	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (45.01 %)	NA	22155902
DrugRepV_6340	Valinomycin	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (43.34 %)	Experimental	22155902
DrugRepV_6341	Thapsigargin	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (42.9 %)	NA	22155902
DrugRepV_6344	Echinomycin	NA	Bacterial infections	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (41.52 %)	NA	22155902
DrugRepV_6345	Chromomycin A3	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (40.87 %)	NA	22155902
DrugRepV_6346	AM404	NA	Pain and Fever	Dengue virus	New Guinea C (NGC)		NA	Decrease (50 %)	Phase IV	26856827
DrugRepV_6349	(2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-butyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6350	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-cyclopentyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6351	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-cyclohexyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6352	methyl 2-[(5Z)-5-[(4-{[(1S)-1-{[(1S)-5-amino-1-{[(1S)-1-carbamoylpentyl]carbamoyl}pentyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}phenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]hexanoate	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6353	(2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6354	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-methylphenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6355	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-methoxyphenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6356	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-fluorophenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6357	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-chlorophenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6358	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-4-oxo-3-(2-phenylethyl)-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6359	(2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-butyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6360	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-cyclopentyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6361	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-cyclohexyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6362	2-[(5Z)-5-[(4-{[(1S)-1-{[(1S)-5-amino-1-{[(1S)-1-carbamoylpentyl]carbamoyl}pentyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}phenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]ethyl acetate	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6363	(2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-benzyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6364	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-methylphenyl)methyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6365	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-methoxyphenyl)methyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6366	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-fluorophenyl)methyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6367	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-chlorophenyl)methyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6368	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-2,4-dioxo-3-(2-phenylethyl)-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6369	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-6,7-dioxo-8-(phenylformamido)undecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6370	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-6,7-dioxo-8-[(thiophen-2-yl)formamido]undecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6371	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-8-({4-[(1E)-2-cyano-2-(cyclopropylcarbamoyl)eth-1-en-1-yl]phenyl}formamido)-6,7-dioxoundecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6372	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-8-({4-[(1E)-2-carbamoyleth-1-en-1-yl]phenyl}formamido)-6,7-dioxoundecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6373	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-6,7-dioxo-8-[(2E)-3-phenylprop-2-enamido]undecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6374	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6375	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-methyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6376	(2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-butyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6377	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-cyclopentyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6378	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-cyclohexyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6379	methyl 2-[(5Z)-5-[(4-{[(1S)-1-{[(1S)-5-amino-1-{[(1S)-1-carbamoylpentyl]carbamoyl}pentyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}phenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]hexanoate	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6380	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-4-oxo-3-(prop-2-en-1-yl)-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6381	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-(2-hydroxyethyl)-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6382	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-(4-methoxyphenyl)-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6383	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-(4-chlorophenyl)-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6384	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-methoxyphenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6385	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-chlorophenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6386	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-4-oxo-3-(2-phenylethyl)-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6387	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6388	(2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-butyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6389	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-cyclopentyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6390	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-(2-hydroxyethyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6391	(2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-benzyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6392	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-chlorophenyl)methyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6393	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-2,4-dioxo-3-(2-phenylethyl)-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6394	(2S)-N-[(4S,7S)-1-amino-7-{[1-(4-{[(5Z)-3-benzyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)ethenyl]amino}-10-carbamimidamido-5,6-dioxodecan-4-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6395	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-6,7-dioxo-8-[(3-{[(5Z)-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]undecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6396	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-8-[(3-{[(5Z)-3-cyclopentyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-6,7-dioxoundecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6397	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-8-[(2S)-2-[(5Z)-5-[(3,4-dimethoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]-3-phenylpropanamido]-6,7-dioxoundecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6398	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-8-(2-{3-[(4-methoxyphenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-yl}acetamido)-6,7-dioxoundecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6399	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-8-{2-[(5Z)-3-[(4-methoxyphenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]acetamido}-6,7-dioxoundecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6400	HHA	NA	NA	Dengue virus	D1/H/IMTSSA/98/606		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6401	HHA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6402	HHA	NA	NA	Dengue virus	H87		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6403	HHA	NA	NA	Dengue virus	Dak HD 34 460		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6404	HHA	NA	NA	Dengue virus	D1/H/IMTSSA/98/606		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6405	HHA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6406	HHA	NA	NA	Dengue virus	H87		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6407	HHA	NA	NA	Dengue virus	Dak HD 34 460		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6408	GNA	NA	NA	Dengue virus	D1/H/IMTSSA/98/606		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6409	GNA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6410	GNA	NA	NA	Dengue virus	H87		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6411	GNA	NA	NA	Dengue virus	Dak HD 34 460		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6412	GNA	NA	NA	Dengue virus	D1/H/IMTSSA/98/606		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6413	GNA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6414	GNA	NA	NA	Dengue virus	H87		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6415	GNA	NA	NA	Dengue virus	Dak HD 34 460		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6416	UDA	NA	NA	Dengue virus	D1/H/IMTSSA/98/606		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6417	UDA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6418	UDA	NA	NA	Dengue virus	H87		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6419	UDA	NA	NA	Dengue virus	Dak HD 34 460		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6420	UDA	NA	NA	Dengue virus	D1/H/IMTSSA/98/606		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6421	UDA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6422	UDA	NA	NA	Dengue virus	H87		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6423	UDA	NA	NA	Dengue virus	Dak HD 34 460		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6424	Carbenoxolone disodium	NA	Digestive tract ulcers	Dengue virus	Hawaii		TCID50 assay	Decrease (500 Fold)	Experimental	27155198
DrugRepV_6425	Carbenoxolone disodium	NA	Digestive tract ulcers	Dengue virus	New Guinea C		TCID50 assay	Decrease (2000 Fold)	Experimental	27155198
DrugRepV_6426	Cdt yellow	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6427	Cdt white	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6428	Crotoxin	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6429	Crotapotin	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6430	Crotamin	NA	NA	Dengue virus	NGC		NA	Decrease (11 %)	NA	21723310
DrugRepV_6431	Convulxin	NA	NA	Dengue virus	NGC		NA	Decrease (5 %)	NA	21723310
DrugRepV_6432	PLA2-IC	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6433	PLA2-IC	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6434	Cdt yellow	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_6435	Cdt white	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_6436	Crotoxin	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_6437	Crotapotin	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_6438	Crotamin	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (33 %)	NA	21723310
DrugRepV_6439	Convulxin	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (32 %)	NA	21723310
DrugRepV_6440	PLA2-IC	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_6441	PLA2-IC	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_6442	Cdt yellow	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_6443	Cdt white	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_6444	Crotoxin	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_6445	Crotapotin	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_6446	Crotamin	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (100 %)	NA	21723310
DrugRepV_6447	Convulxin	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (100 %)	NA	21723310
DrugRepV_6448	PLA2-IC	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_6449	PLA2-IC	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_6450	Cdt yellow	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_6451	Cdt white	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_6452	Crotoxin	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_6453	Crotapotin	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (41 %)	NA	21723310
DrugRepV_6454	Crotamin	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (46 %)	NA	21723310
DrugRepV_6455	Convulxin	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (2.3 %)	NA	21723310
DrugRepV_6456	PLA2-IC	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_6457	PLA2-IC	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_6458	(3E)-N-tert-butyl-2-oxo-4-phenylbut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (26.3 %)	NA	21641807
DrugRepV_6459	(3E)-N-tert-butyl-3-methyl-2-oxo-4-phenylbut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (25.6 %)	NA	21641807
DrugRepV_6460	(3E)-N-tert-butyl-2-oxo-4-(thiophen-2-yl)but-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (27.6 %)	NA	21641807
DrugRepV_6461	(3E)-N-tert-butyl-4-(4-methoxyphenyl)-2-oxobut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (16.7 %)	NA	21641807
DrugRepV_6462	(3E)-N-tert-butyl-4-(3,4-dimethoxyphenyl)-2-oxobut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (36.1 %)	NA	21641807
DrugRepV_6463	(3E)-N-tert-butyl-4-(4-hydroxyphenyl)-2-oxobut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (37.6 %)	NA	21641807
DrugRepV_6464	(3E)-4-(4-aminophenyl)-N-tert-butyl-2-oxobut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (40.6 %)	NA	21641807
DrugRepV_6465	(3E)-N-tert-butyl-4-(4-chlorophenyl)-2-oxobut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (15.9 %)	NA	21641807
DrugRepV_6466	(3E)-N-tert-butyl-4-(1H-indol-3-yl)-2-oxobut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (39.1 %)	NA	21641807
DrugRepV_6467	(3E)-N-tert-butyl-4-[4-(dimethylamino)phenyl]-2-oxobut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (13.8 %)	NA	21641807
DrugRepV_6468	(3E)-N-cyclopropyl-2-oxo-4-phenylbut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (31.2 %)	NA	21641807
DrugRepV_6469	2-[(3E)-2-oxo-4-phenylbut-3-enamido]ethyl acetate	NA	NA	Dengue virus	NA		Protease assay	Decrease (35.8 %)	NA	21641807
DrugRepV_6470	(3E)-2-oxo-4-phenyl-N-(1-phenylethyl)but-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (0 %)	NA	21641807
DrugRepV_6471	methyl 3-hydroxy-2-[(3E)-2-oxo-4-phenylbut-3-enamido]propanoate	NA	NA	Dengue virus	NA		Protease assay	Decrease (35.1 %)	NA	21641807
DrugRepV_6472	Delphinidin Chloride	NA	NA	Dengue virus	NA		Plaque assay	Decrease	NA	28744282
DrugRepV_6474	N-nonyl-deoxynojirimycin	NA	NA	Dengue virus	New Guinea C		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_6475	N-pentyl-(1-hydroxycyclohexyl)-DNJ	NA	NA	Dengue virus	New Guinea C		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_6476	N-Propylcyclohexyl-DNJ	NA	NA	Dengue virus	New Guinea C		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_6477	N-Butylcyclohexyl-DNJ	NA	NA	Dengue virus	New Guinea C		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_6479	N-acetyl cysteine	NA	Acetaminophen poisoning	Dengue virus	NA		Cell viability assay	Decrease (50 %)	Approved	30928439
DrugRepV_6480	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Dengue virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_6487	KX2-391	NA	Colon cancer | Pancreatic cancer | Prostate cancer | Breast cancer	Human immunodeficiency virus	HXB2 luciferase reporter virus		Luciferase reporter assay	Decrease (80 %)	Investigational	26807966
DrugRepV_6488	KX2-391	NA	Colon cancer | Pancreatic cancer | Prostate cancer | Breast cancer	Human immunodeficiency virus	JR-FL luciferase reporter virus		Luciferase reporter assay	Decrease (90 %)	Investigational	26807966
DrugRepV_6496	Decitabine	NA	Myelodysplastic syndromes +Different types of Cancer	Human immunodeficiency virus	NA		Plaque assay	Decrease (73 %)	NA	20610712
DrugRepV_6498	Decitabine	NA	NA	Human immunodeficiency virus	NA		Plaque assay	Decrease (75 %)	NA	20610712
DrugRepV_6500	Decitabine	NA	Myelodysplastic syndromes +Different types of Cancer	Human immunodeficiency virus	NA		Real-time PCR	Decrease	NA	20610712
DrugRepV_6867	4-(3,5-Diphenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6868	4-(5-(2-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6869	4-(5-(3-fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6870	4-(5-(4-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6871	4-(5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6872	4-(5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6873	4-(5-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6874	4-(3-Phenyl-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6875	4-(3-Phenyl-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6876	4-(3-Phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6877	4-(3-(4-phenoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6878	4-(5-(2-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6879	4-(5-(3-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6880	4-(5-(4-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6881	4-(5-(2-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6882	4-(5-(3-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6883	4-(5-(4-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6884	4-(3-(4-phenoxyphenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6885	4-(3-(4-phenoxyphenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6886	4-(3-(4-phenoxyphenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6887	4-(3-(4-(benzyloxy)phenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6888	4-(3-(4-(benzyloxy)phenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6889	4-(3-(4-(benzyloxy)phenyl)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6890	4-(3-(4-(benzyloxy)phenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6891	4-(3-(4-(benzyloxy)phenyl)-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6892	4-(3-(4-(benzyloxy)phenyl)-5-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6893	4-(3-(4-(benzyloxy)phenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6894	4-(3-(4-(benzyloxy)phenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6895	4-(3-(4-(benzyloxy)phenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6896	4-(3-(4-(benzyloxy)phenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6897	Phorbol	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6898	Phorbol-12-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6899	Phorbol-12-decanoate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6900	Phorbol-13-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6901	Phorbol-13-butyrate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6902	Phorbol-13-decanoate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6903	Phorbol-13-tetradecanoate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6904	Phorbol-12,13-diacetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6905	Phorbol-12,13-dibutyrate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6906	Phorbol-12,13- dihexanoate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6907	Phorbol-12,13-didecanoate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6908	4α-phorbol-12,13-didecanoate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6909	12-O-tetradecanoylphorbol-13-acetate	NA	Cancer	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	Phase II	25970561
DrugRepV_6910	12-O-tetradecanoyl-4γ-phorbol-13-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6911	12-O- tiglylphorbol-13-decanoate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6912	12-O-(N-methylanthranilate) phorbol-13-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6913	Phorbol-13,20-diacetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6914	12,13-O,O-dinonanoylphorbol-20-homovanillate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6915	12-O-phenylacetyl-13-O-acetylphorbol-20-homovanillate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6916	Phorbol-12,13,20-triacetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6917	20-oxo-20-deoxyphorbol-12,13-dibutyrate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6918	12-O-tetradecanoyl-20-oxo-20-deoxyphorbol-13-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6919	12-deoxyphorbol-13-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6920	13-O-isobutyryl-12-deoxyphorbol-20-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6921	13-O-phenylacetyl-12-deoxyphorbol-20-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6925	Resiniferatoxin	NA	Interstitial cystitis and urinary incontinence	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	Investigational	25970561
DrugRepV_6927	Phorbol	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6928	Phorbol-12-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6929	Phorbol-12-decanoate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6930	Phorbol-13-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6931	Phorbol-13-butyrate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6932	Pphorbol-13-decanoate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6933	Phorbol-13-tetradecanoate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6934	Phorbol-12,13-diacetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6935	Phorbol-12,13-dibutyrate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6936	Phorbol-12,13- dihexanoate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6937	Phorbol-12,13-didecanoate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6938	4α-phorbol-12,13-didecanoate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6939	12-O-tetradecanoylphorbol-13-acetate	NA	Cancer	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	Phase II	25970561
DrugRepV_6940	12-O-tetradecanoyl-4?-phorbol-13-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6941	12-O- tiglylphorbol-13-decanoate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6942	12-O-(N-methylanthranilate) phorbol-13-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6943	Phorbol-13,20-diacetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6944	12,13-O,O-dinonanoylphorbol-20-homovanillate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6945	12-O-phenylacetyl-13-O-acetylphorbol-20-homovanillate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6946	Phorbol-12,13,20-triacetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6947	20-oxo-20-deoxyphorbol-12,13-dibutyrate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6948	12-O-tetradecanoyl-20-oxo-20-deoxyphorbol-13-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6949	12-deoxyphorbol-13-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6950	13-O-isobutyryl-12-deoxyphorbol-20-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6951	13-O-phenylacetyl-12-deoxyphorbol-20-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6955	Resiniferatoxin	NA	Interstitial cystitis and urinary incontinence	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	Investigational	25970561
DrugRepV_6957	FGI-106	NA	NA	Human immunodeficiency virus	NA		Luciferase assay	Decrease (50 %)	NA	19523489
DrugRepV_6964	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]uracil	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6965	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]thymine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6966	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorouracil	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6967	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]cytosine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6968	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorocytosine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6969	L-Neplanocin A	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6970	(1S,2R,3S)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl] hypoxanthine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6971	(1S,2R,3S)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]guanine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6972	Cyclopentenyl nucleosides	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6973	(1R,2S,3R)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl] hypoxanthine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6974	(1R,2S,3R)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]guanine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6975	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]uracil	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6976	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]thymine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6977	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorouracil	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6978	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]cytosine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6979	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorocytosine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	11689085
DrugRepV_6980	Octadecyloxyethyl benzyl 9-[(2-phosphonomethoxy)ethyl]guanine	NA	NA	Human immunodeficiency virus	NA		RT-PCR	Decrease (50 %)	NA	27933957
DrugRepV_6981	3-azido-2,3-dideoxyuridine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6982	1-(4-azido-5-hydroxyoxolan-2-yl)-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6983	1-(4-azido-5-hydroxyoxolan-2-yl)-5-(trifluoromethyl)-1,2,3,4-tetrahydropyrimidine-2,4-dione	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6984	2- deoxy-5-fluorouridine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6985	2- deoxy-5-bromouridine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6986	2-deoxy-5-iodouridine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6987	3-Azido-2,3-dideoxy-5-aminouridine Hydrochloride	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6988	3-Azido-2,3-dideoxy-5-(methylamino)uridine hydrochloride	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6989	3-Azido-2,3-dideoxy-5-(dimethylamino)uridine hydrochloride	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6990	3-Azido-2,3-dideoxy-5-hydroxyuridine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6991	3-Azido-2,3-dideoxy-5-methoxyuridine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6992	3-Azido-2,3-dideoxy-5-ethoxyuridine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6993	3-Azido-2,3-dideoxy-5-(2-propynyloxy)uridine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6994	3-Azido-2,3-dideoxy-5-(propenyloxy)uridine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6995	3-Azido-2,3-dideoxy-5-[(cyanomethyl)oxy]uridine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6996	3-Azido-2,3-dideoxy-5-thiocyanatouridine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6997	3-Azido-2,3-dideoxy-5-(methylthio)uridine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6998	2-deoxycytidine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_6999	2-deoxy-5-fluorocytidine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_7000	2,-deoxy-5-methylcytidine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_7001	3-(3-Oxo-l-propenyI)-3-azido-3-deoxyThymidine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_7002	3-Azido-3-deoxy-6-azaThymidine	NA	NA	Human immunodeficiency virus	LAV		RT assay	Decrease (50 %)	NA	3339606
DrugRepV_7047	2-Aminobiphenyl borate	NA	NA	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (18 %)	NA	28814523
DrugRepV_7049	1,2-bis-(o-aminophenoxy)-ethane-N,N,N,N-tetraacetic Acid	NA	NA	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (60 %)	NA	28814523
DrugRepV_7051	2-Aminobiphenyl borate	NA	NA	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (20 %)	NA	28814523
DrugRepV_7053	1,2-bis-(o-aminophenoxy)-ethane-N,N,N,N-tetraacetic Acid	NA	NA	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (45 %)	NA	28814523
DrugRepV_7068	Quinacrine Mustard	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	West Nile virus	NA		Plaque assay	Decrease (> 99 %)	Experimental	24680954
DrugRepV_7086	Quinacrine Mustard	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	West Nile virus	NA		Plaque assay	Decrease (50 %)	Experimental	24680954
DrugRepV_7097	Abamectin	NA	Helmintic infection	Yellow fever virus	17D		Plaque assay	Decrease (5.3 Log)	Terminated	26752081
DrugRepV_7098	Berberine	NA	Parasitic and fungal infection	Yellow fever virus	17D		Plaque assay	No significant effect (No significant effect Log)	Approved	26752081
DrugRepV_7103	Chebulagic Acid	NA	Immunosuppressive and hepatoprotective	Measles virus	IC323		EGFP assay	Decrease (50 %)	NA	23924316
DrugRepV_7105	Chebulagic Acid	NA	Immunosuppressive and hepatoprotective	Measles virus	IC323		EGFP assay	Decrease (80 %)	NA	23924316
DrugRepV_7107	Arbidol	NA	Viral infection	Polio virus	NA		Plaque assay	Decrease (50 %)	Phase IV	22028179
DrugRepV_7108	N-nonyl-deoxynojirimycin	NA	NA	Japanese encephalitis virus	RP-9		Immunoflourescence assay	Decrease (90 %)	NA	11907199
DrugRepV_7109	N-nonyl-deoxynojirimycin	NA	NA	Japanese encephalitis virus	RP-9		Plaque assay	Decrease (3 Logs)	NA	11907199
DrugRepV_7110	N-nonyl-deoxynojirimycin	NA	NA	Japanese encephalitis virus	RP-9		LDH assay	No significant effect	NA	11907199
DrugRepV_7111	N-nonyl-deoxynojirimycin	NA	NA	Japanese encephalitis virus	RP-9		Western blot	No significant effect (No significant effect Band Intensity)	NA	11907199
DrugRepV_7112	N-nonyl-deoxynojirimycin	NA	NA	Japanese encephalitis virus	RP-9		Western blot	No significant effect (No significant effect Band Intensity)	NA	11907199
DrugRepV_7113	N-nonyl-deoxynojirimycin	NA	NA	Japanese encephalitis virus	RP-9		Survival assay	Increase	NA	11907199
DrugRepV_7115	4-(3,5-Diphenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7116	4-(5-(2-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7117	4-(5-(3-fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7118	4-(5-(4-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7119	4-(5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7120	4-(5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7121	4-(5-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7122	4-(3-Phenyl-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7123	4-(3-Phenyl-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7124	4-(3-Phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7125	4-(3-(4-phenoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7126	4-(5-(2-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7127	4-(5-(3-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7128	4-(5-(4-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7129	4-(5-(2-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7130	4-(5-(3-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7131	4-(5-(4-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7132	4-(3-(4-phenoxyphenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7133	4-(3-(4-phenoxyphenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7134	4-(3-(4-phenoxyphenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7135	4-(3-(4-(benzyloxy)phenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7136	4-(3-(4-(benzyloxy)phenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7137	4-(3-(4-(benzyloxy)phenyl)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7138	4-(3-(4-(benzyloxy)phenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7139	4-(3-(4-(benzyloxy)phenyl)-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7140	4-(3-(4-(benzyloxy)phenyl)-5-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7141	4-(3-(4-(benzyloxy)phenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7142	4-(3-(4-(benzyloxy)phenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7143	4-(3-(4-(benzyloxy)phenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7144	4-(3-(4-(benzyloxy)phenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7145	4-(5-(4-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7146	4-(5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7147	4-(5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7148	4-(3-Phenyl-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7149	4-(3-Phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7150	4-(3-(4-phenoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7151	4-(5-(2-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7152	4-(5-(3-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7153	4-(5-(4-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7154	4-(5-(2-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7155	4-(5-(3-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7156	4-(5-(4-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7157	4-(3-(4-phenoxyphenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7158	4-(3-(4-phenoxyphenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7159	4-(3-(4-phenoxyphenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7160	4-(3-(4-(benzyloxy)phenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7161	4-(3-(4-(benzyloxy)phenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7162	4-(3-(4-(benzyloxy)phenyl)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7163	4-(3-(4-(benzyloxy)phenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7164	4-(3-(4-(benzyloxy)phenyl)-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7165	4-(3-(4-(benzyloxy)phenyl)-5-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7166	4-(3-(4-(benzyloxy)phenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7167	4-(3-(4-(benzyloxy)phenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7168	4-(3-(4-(benzyloxy)phenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7169	4-(3-(4-(benzyloxy)phenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7173	N2-(4-fluorophenyl)-N3-(4-methyl-2-(thiophen-2-yl)phenyl) pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7174	N2-(4-fluorophenyl)-N3-(4-methyl-2-(thiophen-3-yl) phenyl)pyrazine-2,3- dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7175	N2-(4-methyl-2-(thiophen-3-yl)phenyl)-N3-(p-tolyl) pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7176	N2-(4-fluorophenyl)-N3-(2-(thiophen-3-yl)benzyl)pyrazine- 2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7177	N2-(2-(thiophen-3-yl)benzyl)-N3-(p-tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7178	N2-(4-fluorophenyl)-N3-(4-(thiophen-3-yl)benzyl)pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7179	N2-(4-(thiophen-3-yl)benzyl)-N3-(p-tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7180	N2-(4-fluorophenyl)-N3-(2-(3-methyl-1H-pyrazol-5-yl) phenyl)pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7181	N2-(2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N3-(p-tolyl) pyrazine-2,3-di-carboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7182	N1-(4-fluorophenyl)-N2-(4-methyl-2-(3-methyl-1H-pyrazol-5-yl)phenyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7183	N1-(4-fluorophenyl)-N2-(4-methyl-2-(thiophen-2-yl) phenyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7184	N1-(4-methyl-2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N2-(p- tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7185	N1-(4-methyl-2-(thiophen-2-yl)phenyl)-N2-(p-tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7186	N1-(4-methyl-2-(5-methylthiophen-2-yl)phenyl)-N2-(p- tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7187	N1-(4-fluorophenyl)-N2-(4-methyl-2-(5-methylthiophen-2- yl)phenyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7188	N1-(4-methyl-2-(thiophen-3-yl)phenyl)-N2-(p-tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7189	N1-(4-fluorophenyl)-N2-(4-methyl-2-(thiophen-3-yl) phenyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7190	N1-(4-fluorophenyl)-N2-(2-(thiophen-3-yl)benzyl) phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7191	N1-(2-(thiophen-3-yl)benzyl)-N2-(p-tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7192	N1-(4-fluorophenyl)-N2-(4-(thiophen-3-yl)benzyl) phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7193	N1-(4-(thiophen-3-yl)benzyl)-N2-(p-tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7194	N1-(4-fluorophenyl)-N2-(2-(3-methyl-1H-pyrazol-5-yl) phenyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7195	N1-(2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N2-(p-tolyl) phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7196	2-(4-fluorobenzamido)-N-(4-methyl-2-(thiophen-3-yl) phenyl)benzamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7197	2-(4-fluorobenzamido)-N-(4-methyl-2-(5-methylthiophen- 2-yl)phenyl)benzamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7198	2-(4-fluorobenzamido)-N-(4-methyl-2-(pyridin-4-yl)phenyl) benzamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7199	2-(4-fluorobenzamido)-N-(4-methyl-2-(pyridin-3-yl)phenyl) benzamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7200	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		HTS assay	Decrease (50 %)	NA	19651907
DrugRepV_7201	CCG-3394	NA	NA	Yellow fever virus	YFV 17D		HTS assay	Decrease (50 %)	NA	19651907
DrugRepV_7202	CCG-3925	NA	NA	Yellow fever virus	YFV 17D		HTS assay	Decrease (50 %)	NA	19651907
DrugRepV_7203	CCG-7648	NA	NA	Yellow fever virus	YFV 17D		HTS assay	Decrease (50 %)	NA	19651907
DrugRepV_7204	CCG-6269	NA	NA	Yellow fever virus	YFV 17D		HTS assay	Decrease (50 %)	NA	19651907
DrugRepV_7205	CCG-3374	NA	NA	Yellow fever virus	YFV 17D		HTS assay	Decrease (50 %)	NA	19651907
DrugRepV_7206	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		qRT-PCR	Decrease (20 Fold)	NA	19651907
DrugRepV_7207	CCG-3394	NA	NA	Yellow fever virus	YFV 17D		qRT-PCR	Decrease (15 Fold)	NA	19651907
DrugRepV_7208	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		Immunoflourescence assay	Decrease	NA	19651907
DrugRepV_7209	CCG-3394	NA	NA	Yellow fever virus	YFV 17D		Immunoflourescence assay	Decrease	NA	19651907
DrugRepV_7210	CCG-6269	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (87 %)	NA	19651907
DrugRepV_7211	CCG-3394	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (92 %)	NA	19651907
DrugRepV_7212	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (90 %)	NA	19651907
DrugRepV_7213	CCG-3394	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (38 %)	NA	19651907
DrugRepV_7214	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (48 %)	NA	19651907
DrugRepV_7215	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (42 %)	NA	19651907
DrugRepV_7217	SA-3	NA	NA	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_7218	SA-11	NA	NA	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_7219	SA-17	NA	NA	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_7220	SA-17	NA	NA	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_7221	2-(3-chlorophenoxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Plaque reduction assay	Decrease (60 %)	NA	28068627
DrugRepV_7222	2-(3,4-dichlorophen oxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Plaque reduction assay	Decrease (78 %)	NA	28068627
DrugRepV_7223	2-(2,3-dichlorophenoxy) acetaldehyde thiosemicarbazone	NA	NA	Yellow fever virus	NA		Plaque reduction assay	Decrease (70 %)	NA	28068627
DrugRepV_7224	2-(4-(4-fluorophenyl)thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione	NA	NA	Yellow fever virus	NA		Plaque reduction assay	Decrease (40 %)	NA	28068627
DrugRepV_7225	2-(4-(4-chlorophenyl) thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione	NA	NA	Yellow fever virus	NA		Plaque reduction assay	Decrease (55 %)	NA	28068627
DrugRepV_7226	2-(3-chlorophenoxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Flow cytometry	Decrease (17 %)	NA	28068627
DrugRepV_7227	2-(3,4-dichlorophen oxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Flow cytometry	Decrease (22 %)	NA	28068627
DrugRepV_7228	2-(2,3-dichlorophenoxy) acetaldehyde thiosemicarbazone	NA	NA	Yellow fever virus	NA		Flow cytometry	Decrease (14 %)	NA	28068627
DrugRepV_7229	2-(4-(4-fluorophenyl)thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione	NA	NA	Yellow fever virus	NA		Flow cytometry	Decrease (10 %)	NA	28068627
DrugRepV_7230	2-(4-(4-chlorophenyl) thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione	NA	NA	Yellow fever virus	NA		Flow cytometry	Decrease (3 %)	NA	28068627
DrugRepV_7231	2-(3-chlorophenoxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Flow cytometry	Increase	NA	28068627
DrugRepV_7232	2-(3,4-dichlorophen oxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Flow cytometry	Increase	NA	28068627
DrugRepV_7233	2-(2,3-dichlorophenoxy) acetaldehyde thiosemicarbazone	NA	NA	Yellow fever virus	NA		Flow cytometry	Increase	NA	28068627
DrugRepV_7234	2-(4-(4-fluorophenyl)thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione	NA	NA	Yellow fever virus	NA		Flow cytometry	Increase	NA	28068627
DrugRepV_7235	2-(4-(4-chlorophenyl) thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione	NA	NA	Yellow fever virus	NA		Flow cytometry	Increase	NA	28068627
DrugRepV_7236	2-(3-chlorophenoxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Immunoflourescence assay	Decrease	NA	28068627
DrugRepV_7237	2-(3,4-dichlorophen oxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Immunoflourescence assay	Decrease	NA	28068627
DrugRepV_7238	BCX4430	NA	Ebola virus	Measles virus	Chicago		RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_7239	BCX4430	NA	Ebola virus	Yellow fever virus	17D		RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_7240	BCX4430	NA	Ebola virus	Japanese encephalitis virus	SA14		RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_7242	IHVR-19029	NA	NA	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	NA	29253498
DrugRepV_7243	BCX4430	NA	Ebola virus	Yellow fever virus	17D		NA	Decrease (50 %)	Investigational	27095300
DrugRepV_7244	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,4-triazole-3-carboxamide	NA	NA	West Nile virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7245	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,4-triazole-3-carboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7246	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-imidazole-4-carboxamide	NA	NA	West Nile virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7247	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-imidazole-4-carboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7248	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,3-triazole-4-carboxamide	NA	NA	West Nile virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7249	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,3-triazole-4-carboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7251	3-{[(4-chlorophenyl)methyl]sulfanyl}-5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-4-methyl-4H-1,2,4-triazole	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7252	2-({[5-(5-methyl-3-phenyl-1,2-oxazol-4-yl)-1,2,4-oxadiazol-3-yl]methyl}sulfanyl)pyridin-1-ium-1-olate	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7253	1-(4-chlorophenyl)-2-({5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3,4-oxadiazol-2-yl}sulfanyl)ethan-1-one	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7254	1-(2-chlorophenyl)-3-{2-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3-thiazol-4-yl}urea	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7255	2-chloro-6-(4-chlorophenoxy)-4-{4-methyl-5-[(1E)-1-(2-phenylhydrazin-1-ylidene)ethyl]-1,3-thiazol-2-yl}pyridine	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7256	3-{[(4-chlorophenyl)methyl]sulfanyl}-5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-4-methyl-4H-1,2,4-triazole	NA	NA	Yellow fever virus	17D		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7257	2-({[5-(5-methyl-3-phenyl-1,2-oxazol-4-yl)-1,2,4-oxadiazol-3-yl]methyl}sulfanyl)pyridin-1-ium-1-olate	NA	NA	Yellow fever virus	17D		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7258	1-(4-chlorophenyl)-2-({5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3,4-oxadiazol-2-yl}sulfanyl)ethan-1-one	NA	NA	Yellow fever virus	17D		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7259	1-(2-chlorophenyl)-3-{2-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3-thiazol-4-yl}urea	NA	NA	Yellow fever virus	17D		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7260	2-chloro-6-(4-chlorophenoxy)-4-{4-methyl-5-[(1E)-1-(2-phenylhydrazin-1-ylidene)ethyl]-1,3-thiazol-2-yl}pyridine	NA	NA	Yellow fever virus	17D		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7263	PI-88	NA	Hepatocellular carcinoma | Liver cancer | Melanoma | Multiple myeloma	Japanese encephalitis virus	Nakayama		Flow cytometry	Decrease (66 %)	Investigational	16309754
DrugRepV_7265	PPS	NA	NA	Japanese encephalitis virus	Nakayama		Flow cytometry	Decrease (70 %)	NA	16309754
DrugRepV_7266	PI-88	NA	Hepatocellular carcinoma | Liver cancer | Melanoma | Multiple myeloma	West Nile virus	NY-99		Flow cytometry	Decrease (66 %)	Investigational	16309754
DrugRepV_7267	Cdt yellow	NA	NA	Yellow fever virus	17D		NA	Decrease (50 %)	NA	21723310
DrugRepV_7268	Cdt white	NA	NA	Yellow fever virus	17D		NA	Decrease (50 %)	NA	21723310
DrugRepV_7269	Crotoxin	NA	NA	Yellow fever virus	17D		NA	Decrease (50 %)	NA	21723310
DrugRepV_7270	Crotapotin	NA	NA	Yellow fever virus	17D		NA	Decrease (43 %)	NA	21723310
DrugRepV_7271	Crotamin	NA	NA	Yellow fever virus	17D		NA	Decrease (20 %)	NA	21723310
DrugRepV_7272	Convulxin	NA	NA	Yellow fever virus	17D		NA	Decrease (22 %)	NA	21723310
DrugRepV_7273	PLA2-IC	NA	NA	Yellow fever virus	17D		NA	Decrease (50 %)	NA	21723310
DrugRepV_7274	PLA2-IC	NA	NA	Yellow fever virus	17D		NA	Decrease (50 %)	NA	21723310
DrugRepV_7275	Cdt yellow	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_7276	Cdt white	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_7277	Crotoxin	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_7278	Crotapotin	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_7279	Crotamin	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (14.34 %)	NA	21723310
DrugRepV_7280	Convulxin	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (25.5 %)	NA	21723310
DrugRepV_7281	PLA2-IC	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_7282	PLA2-IC	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_7283	Cdt yellow	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7284	Cdt white	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7285	Crotoxin	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7286	Crotapotin	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7287	Crotamin	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7288	Convulxin	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7289	PLA2-IC	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7290	PLA2-IC	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7291	Cdt yellow	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_7292	Cdt white	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_7293	Crotoxin	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_7294	Crotapotin	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_7295	Crotamin	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (32 %)	NA	21723310
DrugRepV_7296	Convulxin	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (-70 %)	NA	21723310
DrugRepV_7297	PLA2-IC	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_7298	PLA2-IC	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (46 %)	NA	21723310
DrugRepV_7299	(3E)-N-tert-butyl-2-oxo-4-phenylbut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (20 %)	NA	21641807
DrugRepV_7300	(3E)-N-tert-butyl-3-methyl-2-oxo-4-phenylbut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (0 %)	NA	21641807
DrugRepV_7301	(3E)-N-tert-butyl-2-oxo-4-(thiophen-2-yl)but-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (20.3 %)	NA	21641807
DrugRepV_7302	(3E)-N-tert-butyl-4-(4-methoxyphenyl)-2-oxobut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (27.3 %)	NA	21641807
DrugRepV_7303	(3E)-N-tert-butyl-4-(3,4-dimethoxyphenyl)-2-oxobut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (31 %)	NA	21641807
DrugRepV_7304	(3E)-N-tert-butyl-4-(4-hydroxyphenyl)-2-oxobut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (31.4 %)	NA	21641807
DrugRepV_7305	(3E)-4-(4-aminophenyl)-N-tert-butyl-2-oxobut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (39.5 %)	NA	21641807
DrugRepV_7306	(3E)-N-tert-butyl-4-(4-chlorophenyl)-2-oxobut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (6.3 %)	NA	21641807
DrugRepV_7307	(3E)-N-tert-butyl-4-(1H-indol-3-yl)-2-oxobut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (40.6 %)	NA	21641807
DrugRepV_7308	(3E)-N-tert-butyl-4-[4-(dimethylamino)phenyl]-2-oxobut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (33.9 %)	NA	21641807
DrugRepV_7309	(3E)-N-cyclopropyl-2-oxo-4-phenylbut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (20 %)	NA	21641807
DrugRepV_7310	2-[(3E)-2-oxo-4-phenylbut-3-enamido]ethyl acetate	NA	NA	West Nile virus	NA		Protease assay	Decrease (29.8 %)	NA	21641807
DrugRepV_7311	(3E)-2-oxo-4-phenyl-N-(1-phenylethyl)but-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (12.2 %)	NA	21641807
DrugRepV_7312	methyl 3-hydroxy-2-[(3E)-2-oxo-4-phenylbut-3-enamido]propanoate	NA	NA	West Nile virus	NA		Protease assay	Decrease (27.5 %)	NA	21641807
DrugRepV_7313	CW-33A	NA	NA	Japanese encephalitis virus	T1P1		Virus yield reduction assay	Decrease (50 %)	NA	30413749
DrugRepV_7314	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Virus yield reduction assay	Decrease (50 %)	NA	30413749
DrugRepV_7315	CW-33A	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	30413749
DrugRepV_7316	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	30413749
DrugRepV_7319	MJ-47	NA	NA	Japanese encephalitis virus	JEVSRIP		Flow cytometry	Decrease (50 %)	NA	28394283
DrugRepV_7320	N-(6-methanesulfonyl-1,3-benzothiazol-2-yl)-4-[(4-nitro-1H-pyrazol-1-yl)methyl]benzamide	NA	NA	Japanese encephalitis virus	NS3 helicase		Flow cytometry	Decrease (79 %)	NA	27679979
DrugRepV_7321	N-[6-({[(thiophen-2-yl)formamido]methanethioyl}amino)-1,3-benzothiazol-2-yl]butanamide	NA	NA	Japanese encephalitis virus	NS3 helicase		Flow cytometry	Decrease (73 %)	NA	27679979
DrugRepV_7322	N-(6-methanesulfonyl-1,3-benzothiazol-2-yl)-4-[(4-nitro-1H-pyrazol-1-yl)methyl]benzamide	NA	NA	Japanese encephalitis virus	P3		Western blot	Decrease (70.1 %)	NA	27679979
DrugRepV_7323	N-[6-({[(thiophen-2-yl)formamido]methanethioyl}amino)-1,3-benzothiazol-2-yl]butanamide	NA	NA	Japanese encephalitis virus	P3		Western blot	Decrease (94.8 %)	NA	27679979
DrugRepV_7324	N-(6-methanesulfonyl-1,3-benzothiazol-2-yl)-4-[(4-nitro-1H-pyrazol-1-yl)methyl]benzamide	NA	NA	Japanese encephalitis virus	P3		Immunoflourescence assay	Decrease (86.71 %)	NA	27679979
DrugRepV_7325	N-[6-({[(thiophen-2-yl)formamido]methanethioyl}amino)-1,3-benzothiazol-2-yl]butanamide	NA	NA	Japanese encephalitis virus	P3		Immunoflourescence assay	Decrease (89.3 %)	NA	27679979
DrugRepV_7326	N-(6-methanesulfonyl-1,3-benzothiazol-2-yl)-4-[(4-nitro-1H-pyrazol-1-yl)methyl]benzamide	NA	NA	Japanese encephalitis virus	P3		Plaque assay	Decrease (2 log pfu/ml)	NA	27679979
DrugRepV_7327	N-[6-({[(thiophen-2-yl)formamido]methanethioyl}amino)-1,3-benzothiazol-2-yl]butanamide	NA	NA	Japanese encephalitis virus	P3		Plaque assay	Decrease (2 log pfu/ml)	NA	27679979
DrugRepV_7328	N-(6-methanesulfonyl-1,3-benzothiazol-2-yl)-4-[(4-nitro-1H-pyrazol-1-yl)methyl]benzamide	NA	NA	Japanese encephalitis virus	P3		Cell viability assay	Decrease (50 %)	NA	27679979
DrugRepV_7329	N-[6-({[(thiophen-2-yl)formamido]methanethioyl}amino)-1,3-benzothiazol-2-yl]butanamide	NA	NA	Japanese encephalitis virus	P3		Cell viability assay	Decrease (50 %)	NA	27679979
DrugRepV_7330	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Cytopathic effect (CPE) assay	Decrease	NA	27563890
DrugRepV_7331	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Cytopathic effect (CPE) assay	Decrease	NA	27563890
DrugRepV_7332	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (5 times pfu/ml)	NA	27563890
DrugRepV_7333	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (3 times pfu/ml)	NA	27563890
DrugRepV_7334	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	27563890
DrugRepV_7335	FGIN-1-27	NA	NA	Japanese encephalitis virus	P3		Plaque assay	Decrease (2 log %)	NA	24348901
DrugRepV_7338	FGIN-1-27	NA	NA	Japanese encephalitis virus	P3		Immunoflourescence assay	Decrease (80 %)	NA	24348901
DrugRepV_7341	FGIN-1-27	NA	NA	Japanese encephalitis virus	P3		Luminescence assay	Decrease (50 %)	NA	24348901
DrugRepV_7348	Indigo	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	22911608
DrugRepV_7349	Indirubin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	Investigational	22911608
DrugRepV_7350	Indirubin	NA	NA	Japanese encephalitis virus	Beijing-1		Survival assay	Increase	Investigational	22911608
DrugRepV_7351	NG-monomethyl-L-arginine	NA	Obesity | Type 2 Diabetes | Ocular Physiology | Regional Blood Flow	Japanese encephalitis virus	78668A		Survival assay	Decrease	Approved, Investigational	10762444
DrugRepV_7352	N-nitro-L-arginine methyl ester	NA	NA	Japanese encephalitis virus	RP-9		Survival assay	Decrease	NA	9188590
DrugRepV_7353	S-nitroso-N-acetylpenicillamine	NA	NA	Japanese encephalitis virus	NT109		Plaque assay	Decrease (3 log pfu/ml)	NA	9188590
DrugRepV_7354	Glycine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (16.37 %)	NA	14011545
DrugRepV_7355	DL-Phenylalanine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	No significant effect (3.63 %)	NA	14011545
DrugRepV_7356	L-Leucine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	No significant effect (3.63 %)	NA	14011545
DrugRepV_7357	DL-Aspartic acid -Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Decrease (23.63 %)	NA	14011545
DrugRepV_7358	DL-Asparagine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Decrease (36.36 %)	NA	14011545
DrugRepV_7359	DL-Alanine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (9 %)	NA	14011545
DrugRepV_7360	L-Cysteine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Decrease (18.18 %)	NA	14011545
DrugRepV_7361	DL-Lysine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (9 %)	NA	14011545
DrugRepV_7362	L-Tyrosine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	No significant effect (10 %)	NA	14011545
DrugRepV_7363	DL-Methionine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (20 %)	NA	14011545
DrugRepV_7364	2-Picolinic acid-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (0.45 %)	NA	14011545
DrugRepV_7365	Guanidine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (9.5 %)	NA	14011545
DrugRepV_7366	Diethyl Dithiocarbamic Acid-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (27.72 %)	NA	14011545
DrugRepV_7367	Diphenylthiocarbazone-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (12.14 %)	NA	14011545
DrugRepV_7368	8-Hydroxyquinoline-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	No significant effect (8.6 %)	NA	14011545
DrugRepV_7369	3,4-Dimercaptotoluene-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (10 %)	NA	14011545
DrugRepV_7370	1,10-Phenanthroline-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	No significant effect (5 %)	NA	14011545
DrugRepV_7371	1,10-Phenanthroline-3,4-dimercaptotoluene-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Decrease (35 %)	NA	14011545
DrugRepV_7372	Luteolin	NA	NA	Japanese encephalitis virus	SX09S01		Plaque assay	Decrease (50 %)	NA	27126774
DrugRepV_7373	Luteolin	NA	NA	Japanese encephalitis virus	SX09S01		Plaque assay	Decrease (2 log Log PFU/ml)	NA	27126774
DrugRepV_7374	Luteolin	NA	NA	Japanese encephalitis virus	SX09S01		Western blot	Decrease	NA	27126774
DrugRepV_7375	Chrysophanol	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	24395532
DrugRepV_7376	Aloe-emodin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	24395532
DrugRepV_7377	Aloe-emodin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7378	Aloe-emodin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7379	Shikonin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7380	Shikonin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7381	Arecoline	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	Experimental	18701259
DrugRepV_7382	Arecoline	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	Experimental	18701259
DrugRepV_7383	Hesperetin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	Experimental	18701259
DrugRepV_7384	Dehydroepiandrosterone	NA	Schizophrenia	Japanese encephalitis virus	NT113		Plaque assay	Decrease	Approved	16099910
DrugRepV_7385	Dehydroepiandrosterone	NA	Schizophrenia	Japanese encephalitis virus	NT113		Slot Blot analysis	Decrease	Approved	16099910
DrugRepV_7386	Dehydroepiandrosterone	NA	Schizophrenia	Japanese encephalitis virus	NT113		Western blot	Decrease	Approved	16099910
DrugRepV_7387	SCH16-Ribavirin	NA	NA	Japanese encephalitis virus	P20778		Cytopathic effect (CPE) assay	Decrease	NA	22738253
DrugRepV_7388	SCH16-Mycophenolic acid	NA	NA	Japanese encephalitis virus	P20778		Cytopathic effect (CPE) assay	Decrease	NA	22738253
DrugRepV_7389	Delphinidin Chloride	NA	NA	West Nile virus	NY-99		Plaque assay	Decrease (O.6 Log)	NA	28744282
DrugRepV_7390	Cyanidin Chloride	NA	NA	West Nile virus	NY-99		Plaque assay	No significant effect (No significant effect Log)	NA	28744282
DrugRepV_7392	Epicatechin	NA	Pre-diabetes	West Nile virus	NY-99		Plaque assay	No significant effect (No significant effect Log)	Investigational	28744282
DrugRepV_7393	Epigallocatechin	NA	NA	West Nile virus	NY-99		Plaque assay	Decrease (0.5 Log)	Experimental	28744282
DrugRepV_7395	Delphinidin Chloride	NA	NA	West Nile virus	NY-99		RT-PCR	Decrease (0.7 Copies/cell)	NA	28744282
DrugRepV_7397	Nordihydroguaiaretic Acid	NA	Actinic keratoses	West Nile virus	NY-99		Plaque assay	Decrease (50 %)	Approved, Investigational	28507114
DrugRepV_7398	Nordihydroguaiaretic Acid	NA	Actinic keratoses	West Nile virus	NY-99		Plaque assay	Decrease (50 %)	Approved, Investigational	28507114
DrugRepV_7400	PF-429242	NA	NA	West Nile virus	NY-99		Plaque assay	Decrease (0.4 Log)	NA	28507114
DrugRepV_7401	Fatostatin	NA	NA	West Nile virus	NY-99		Plaque assay	Decrease (0.7 Log)	NA	28507114
DrugRepV_7402	Zileuton	NA	Asthma	West Nile virus	NY-99		Plaque assay	No significant change (No significant change Log)	Approved / Withdrawn	28507114
DrugRepV_7403	BCX4430	NA	Ebola virus	West Nile virus	Eg101		Plaque assay	Decrease (50 %)	Investigational	28336346
DrugRepV_7404	BCX4430 Hydrochloride	NA	Ebola virus	West Nile virus	Eg101		Plaque assay	Decrease (50 %)	Investigational	28336346
DrugRepV_7405	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]uracil	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7406	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]thymine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7407	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorouracil	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7408	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]cytosine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7409	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorocytosine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7410	L-Neplanocin A	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7411	(1S,2R,3S)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl] hypoxanthine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7412	(1S,2R,3S)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]guanine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7413	Cyclopentenyl nucleosides	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7414	(1R,2S,3R)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl] hypoxanthine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7415	(1R,2S,3R)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]guanine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7416	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]uracil	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7417	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]thymine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7418	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorouracil	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7419	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]cytosine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7420	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorocytosine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7421	N-nonyl-deoxynojirimycin	NA	NA	West Nile virus	NA		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_7422	N-pentyl-(1-hydroxycyclohexyl)-DNJ	NA	NA	West Nile virus	NA		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_7423	N-Propylcyclohexyl-DNJ	NA	NA	West Nile virus	NA		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_7424	N-Butylcyclohexyl-DNJ	NA	NA	West Nile virus	NA		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_7426	6-Azauridine	NA	Cancer	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7427	6-Azauridine	NA	Cancer	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7428	6-Azauridine triacetate	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7429	6-Azauridine triacetate	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7430	Pyrazofurin	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7431	Pyrazofurin	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7432	2-Thio-6-azauridine	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7433	2-Thio-6-azauridine	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7434	6-Azauridine	NA	Cancer	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7435	6-Azauridine	NA	Cancer	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7436	6-Azauridine triacetate	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7437	6-Azauridine triacetate	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7438	Pyrazofurin	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7439	Pyrazofurin	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7440	2-Thio-6-azauridine	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7441	2-Thio-6-azauridine	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7442	3-Deazaguanosine	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7445	Ribamidine	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7446	Ribamidine	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7449	Selenazofurin	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7450	Selenazofurin	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7452	beta-Methylene TAD	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7453	beta-Methylene TAD	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7454	3-Deazaguanosine	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7457	Ribamidine	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7458	Ribamidine	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7461	Selenazofurin	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7462	Selenazofurin	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7464	beta-Methylene TAD	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7465	beta-Methylene TAD	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7466	3-Deazauridine	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7467	3-Deazauridine	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7468	Cyclopentenylcytosine	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7469	Cyclopentenylcytosine	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7470	3-Deazauridine	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7471	3-Deazauridine	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7472	Cyclopentenylcytosine	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7473	Cyclopentenylcytosine	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7480	5-fluorouridine	NA	Cancer	West Nile virus	New York		Visual assay	Decrease (50 %)	Experimental	12076755
DrugRepV_7481	5-fluorouridine	NA	Cancer	West Nile virus	New York		NR assay	Decrease (50 %)	Experimental	12076755
DrugRepV_7482	(S )-DHPA	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7483	(S )-DHPA	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7484	3-Deazaneplanocin A	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7485	(S )-DHPA	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7486	(S )-DHPA	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7487	3-Deazaneplanocin A	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7488	6-Bromotoyocamycin	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7489	Formycin B	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	Experimental	12076755
DrugRepV_7490	6-Bromotoyocamycin	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7491	Formycin B	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	Experimental	12076755
DrugRepV_7492	2-Thiouracil	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7494	Cyclopentyluracil	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7495	Dihydro-5-azacytidine	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7496	Uridine 2,3-dialdehyde	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7497	2-Thiouracil	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7499	Cyclopentyluracil	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7500	Dihydro-5-azacytidine	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7501	Uridine 2,3-dialdehyde	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7502	6-Azauridine	NA	Cancer	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7503	6-Azauridine triacetate	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7504	Pyrazofurin	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7505	Selenazofurin	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7508	Cyclopentenylcytosine	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7509	6-Azauridine	NA	Cancer	West Nile virus	New York		Virus yield reduction assay	Decrease (90 %)	NA	12076755
DrugRepV_7510	Pyrazofurin	NA	NA	West Nile virus	New York		Virus yield reduction assay	Decrease (90 %)	NA	12076755
DrugRepV_7513	Cyclopentenylcytosine	NA	NA	West Nile virus	New York		Virus yield reduction assay	Decrease (90 %)	NA	12076755
DrugRepV_7514	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Polio virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_7515	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	West Nile virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_7516	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Yellow fever virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_7517	Aloe-emodin	NA	NA	Enterovirus	EV71		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7518	Aloe-emodin	NA	NA	Enterovirus	EV71		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7520	beta-D-cyclopentenyl cytosine	NA	NA	Vaccinia virus	Copenhagen		NA	Decrease (50 %)	NA	14604375
DrugRepV_7521	beta-D-cyclopentenyl-5-iodocytidine	NA	NA	Vaccinia virus	Copenhagen		NA	Decrease (50 %)	NA	14604375
DrugRepV_7522	beta-D-Cyclopentenyl-5-chlorocytidine	NA	NA	Vaccinia virus	Copenhagen		NA	Decrease (50 %)	NA	14604375
DrugRepV_7523	beta-D-cyclopentenyl-5-bromocytidine	NA	NA	Vaccinia virus	Copenhagen		NA	Decrease (50 %)	NA	14604375
DrugRepV_7524	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Vaccinia virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_7575	Merimepodib	NA	NA	SARS Coronavirus-2	SARS-CoV-2 USA-WA1/2020	NA	RT-PCR	Decrease (50 %)	Investigational	32438446
DrugRepV_7576	Merimepodib	NA	NA	SARS Coronavirus-2	SARS-CoV-2 USA-WA1/2020	NA	RT-PCR	Decrease (90 %)	Investigational	32438446
DrugRepV_7664	Cetilistat	NA	Obesity	SARS Coronavirus-2		NA	Plaque reduction assay	Decrease (50 %)	Investigational	32473310
DrugRepV_7668	Cetilistat	NA	Obesity	SARS Coronavirus-2		NA	Viral load reduction assay	Decrease (90 %)	Investigational	32473310
DrugRepV_7673	ROC-325	NA	NA	SARS Coronavirus-2		NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	32511355
DrugRepV_7690	S1RA	NA	NA	SARS Coronavirus-2		NA	NA	Decrease (50 %)	NA	32577649
DrugRepV_7693	Z-FA-FMK	NA	NA	SARS Coronavirus-2		NA	NA	Decrease (50 %)	NA	32577649
DrugRepV_7694	Lactoferrin	NA	NA	SARS Coronavirus-2		NA	NA	Decrease (50 %)	NA	32577649
DrugRepV_7695	Nafamostat	NA	Blood vessel coagulation | Hemorrhagic lesions	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Investigational	32532094
DrugRepV_7696	Immunoglobulin F(ab’)2	NA	NA	SARS Coronavirus-2		NA	NA	Decrease (50 %)	NA	32659292
DrugRepV_7697	Unfractionated Heparin	NA	Prophylaxis and Venous thrombosis	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Approved, Investigational	32577638
DrugRepV_7698	UFH-de6S	NA	NA	SARS Coronavirus-2		NA	NA	Decrease (50 %)	NA	32577638
DrugRepV_7700	Enoxaparin-de6S	NA	NA	SARS Coronavirus-2		NA	NA	Decrease (50 %)	NA	32577638
DrugRepV_7701	Pegasys	NA	Hepatitis C Virus	SARS Coronavirus-2		NA	Plaque reduction assay	Decrease (50 %)	Approved, Investigational	32532085
DrugRepV_7705	Immukin	NA	Chronic granulomatous disease and Osteopetrosis	SARS Coronavirus-2		NA	Plaque reduction assay	Decrease (50 %)	Approved, Investigational	32532085
DrugRepV_7706	25-Hydroxycholesterol	NA	NA	SARS Coronavirus-2	NA	NA	Plaque reduction assay	Decrease (50 %)	Experimental	32532085
DrugRepV_7707	AM580	NA	NA	SARS Coronavirus-2		NA	Plaque reduction assay	Decrease (50 %)	NA	32532085
DrugRepV_7710	AMG-2674	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7713	DS-6930	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7714	Elopiprazole	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7715	Hanfangchin A	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7716	KW 8232	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7717	N-tert-Butylisoquine	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7718	R 82913	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	Experimental	32707573
DrugRepV_7719	SB-616234A	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7720	SDZ-62-434	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7721	SL-11128	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7722	YH-1238	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7724	AMG-2674	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7727	Elopiprazole	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7728	Hanfangchin A	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7729	MLN-3897	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7730	KW 8232	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7731	N-tert-Butylisoquine	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7732	SB-616234A	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7733	SDZ-62-434	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7734	SL-11128	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7736	8-(2-Chlorostyryl)caffeine	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7737	AMG-2674	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7739	Elopiprazole	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7740	Hanfangchin A	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7741	KW 8232	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7742	MLN-3897	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7743	N-tert-Butylisoquine	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7744	SB-616234A	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7745	SDZ-62-434	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7746	YH-1238	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7748	Apilimod	NA	Crohn's disease | Psoriasis | Psoriatic disorders	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	Investigational	32707573
DrugRepV_7749	VBY-825	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7750	ONO 5334	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7751	Z LVG CHN2	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7752	MDL 28170	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7753	SL-11128	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7755	DS-6930	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7756	R 82913	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	Experimental	32707573
DrugRepV_7757	Hanfangchin A	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7758	SB-616234A	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7759	MLN-3897	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7760	VBY-825	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7761	Apilimod	NA	Crohn's disease | Psoriasis | Psoriatic disorders	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	Investigational	32707573
DrugRepV_7762	VBY-825	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7763	ONO 5334	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7764	Z LVG CHN2	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7765	MDL 28170	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7766	Apilimod	NA	Crohn's disease | Psoriasis | Psoriatic disorders	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	Investigational	32707573
DrugRepV_7767	VBY-825	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7768	ONO 5334	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7769	Z LVG CHN2	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7770	MDL 28170	NA	NA	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	NA	32707573
DrugRepV_7773	Galidesivir	NA	Ebolavirus	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Investigational	32687696
DrugRepV_7775	Camostat mesylate	NA	Pancreatitis	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Experimental	32687696
DrugRepV_7776	Nafamostat Mesylate	NA	Blood vessel coagulation | Hemorrhagic lesions	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Investigational	32687696
DrugRepV_7778	Apilimod	NA	Crohn's disease | Psoriasis | Psoriatic disorders	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Investigational	32687696
DrugRepV_7788	SSAA09E3	NA	NA	Severe acute respiratory syndrome coronavirus	Toronto-2	NA	Dose-dependence fluorescence inhibition assay	Decrease (50 %)	NA	23678171
DrugRepV_7789	SSAA09E1	NA	NA	Severe acute respiratory syndrome coronavirus	Toronto-2	NA	Dose-dependence fluorescence inhibition assay	Decrease (50 %)	NA	23678171
DrugRepV_7790	SSAA09E2	NA	NA	Severe acute respiratory syndrome coronavirus	Toronto-2	NA	Dose-dependence fluorescence inhibition assay	Decrease (50 %)	NA	23678171
DrugRepV_7791	Ferruginol	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Cell based assay	Decrease (50 %)	NA	17663539
DrugRepV_7792	Dehydroabieta-7-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7793	Cryptojaponol	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7794	8beta-hydroxyabieta-9(11),13- dien-12-one	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7795	7beta-hydroxydeoxycryptojaponol	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7796	6,7-dehydroroyleanone	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7797	3beta,12-diacetoxyabieta-6,8,11,13- tetraene	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7798	Pinusolidic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7799	Forskolin	NA	Smooth muscle relaxant	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Experimental, Investigational	17663539
DrugRepV_7800	Cedrane-3beta,12-diol	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7801	alpha-cadinol	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7802	Betulinic acid	NA	Dysplastic Nevus Syndrome	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Investigational	17663539
DrugRepV_7803	Betulonic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7804	Hinokinin	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7805	Savinin	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7806	Honokiol	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7807	Magnolol	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17663539
DrugRepV_7808	Curcumin	NA	Depressive disorder	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Approved	17663539
DrugRepV_7810	Valinomycin	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Experimental	17663539
DrugRepV_7813	2-aminobenzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric assay	Decrease (50 %)	Experimental	16638531
DrugRepV_7814	2-(5-bromopyridin-3-yl)-1-[5-(4-chlorophenyl)furan-2-yl]-2-fluoroethanone	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	18295820
DrugRepV_7815	ML188	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Luminescent Cell Viability Assay	Decrease (50 %)	NA	23231439
DrugRepV_7816	ML300	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7817	2-(benzotriazol-1-yl)-N-(4-phenylphenyl)-N-(thiophen-3-ylmethyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7818	5-Chloro-pyridin-3-yl Furan-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric assay	Decrease (50 %)	NA	17381079
DrugRepV_7819	5-Chloropyridin-3-yl Benzofuran-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric assay	Decrease (50 %)	NA	17381079
DrugRepV_7820	5-Bromo-pyridin-3-yl Furan-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric assay	Decrease (50 %)	NA	17381079
DrugRepV_7821	5-Chloro-pyridin-3-yl-1H-indole-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric assay	Decrease (50 %)	NA	17381079
DrugRepV_7822	5-Chloropyridin-3-yl-benzo-(b)-thiophene-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric assay	Decrease (50 %)	NA	17381079
DrugRepV_7823	5-Chloropyridin-3-yl-thiazole-4-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric assay	Decrease (50 %)	NA	17381079
DrugRepV_7824	5-Chloropyridin-3-yl-3-methoxybenzoate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric assay	Decrease (50 %)	NA	17381079
DrugRepV_7825	5-Chloropyridin-3-yl-5-(4-chlorophenyl)furan-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric assay	Decrease (50 %)	NA	17381079
DrugRepV_7826	N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]propanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7827	N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]-2-methylpropanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7828	N-{4-[(1H-Benzotriazol-1-ylacetyl)(3-thienylmethyl)amino]phenyl}-2,2-dimethylpropanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7829	N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]-3-methoxypropanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7830	N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]cyclobutanecarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7831	N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]cyclohexanecarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7832	N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]benzamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7833	2-methylpropyl N-[4-[[2-(benzotriazol-1-yl)acetyl]-(thiophen-3-ylmethyl)amino]phenyl]carbamate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7834	2-(benzotriazol-1-yl)-N-[4-(methylamino)phenyl]-N-(thiophen-3-ylmethyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7835	2-(benzotriazol-1-yl)-N-[4-(benzylamino)phenyl]-N-(thiophen-3-ylmethyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7836	2-(benzotriazol-1-yl)-N-(4-pyridin-3-ylphenyl)-N-(thiophen-3-ylmethyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7837	2-(benzotriazol-1-yl)-N-[4-(2-methoxypyridin-3-yl)phenyl]-N-(thiophen-3-ylmethyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7838	2-(benzotriazol-1-yl)-N-(4-pyridin-4-ylphenyl)-N-(thiophen-3-ylmethyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7839	2-(benzotriazol-1-yl)-N-[4-(2-methoxypyrimidin-5-yl)phenyl]-N-(thiophen-3-ylmethyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	24080461
DrugRepV_7840	benzyl N-[(2S)-1-[[(2S)-3-methyl-1-[[(2S)-4-methyl-1-oxo-1-[(4,4,4-trifluoro-3-oxo-1-phenylbutan-2-yl)amino]pentan-2-yl]amino]-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7841	(4S)-4-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-3-phenylmethoxybutanoyl]amino]-4-methylpentanoyl]amino]-N,N-dimethyl-6-(5-nitro-1,4-dioxo-3H-phthalazin-2-yl)-5-oxohexanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7842	methyl (E,4S)-4-[[(2S)-4-methyl-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]pentanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7843	ethyl 3-[(3-amino-3-oxopropyl)-[[(2R,5S)-2-benzyl-7-methyl-4-oxo-5-(phenylmethoxycarbonylamino)octanoyl]amino]carbamoyl]oxirane-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7844	(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]propanoyl]amino]-N-[(2S)-3-cyclohexyl-1-[[(2S)-1-(1H-imidazol-5-yl)-3-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-3-methylbutanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7845	N-[(Benzyloxy)carbonyl]valyl-N-[1-oxo-3-(2-oxo-3-pyrrolidinyl)-1-(1,3-thiazol-2-yl)-2-propanyl]leucinamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7846	N-[(Benzyloxy)carbonyl]-L-valyl-N-{(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-D-leucinamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7847	N-{[3-(Dimethylamino)phenoxy]acetyl}-L-valyl-N-{(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-L-leucinamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7848	2-[2,3-Dichloro-4-(2-methylenebutanoyl)phenoxy]-N-(2-methyl-2-propanyl)acetamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7849	Cinanserin	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7850	5-Chloro-3-pyridinyl 1H-indole-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7851	1-(2-Naphthylmethyl)-2,3-dioxo-5-indolinecarboxamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7852	1-[(1H-Indol-5-ylcarbonyl)oxy]-1H-benzotriazole	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7853	4-(4-Chlorophenyl)-2-[(4-nitrobenzyl)sulfanyl]-6-oxo-1,6-dihydro-5-pyrimidinecarbonitrile	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7854	4-{(Z)-[1-(4-Fluorophenyl)-5-oxo-3-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene]methyl}benzoic acid	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7855	3-Benzyl-1-[(6,7-dimethyl-2-oxo-1,2-dihydro-3-quinolinyl)methyl]-1-[2-(2-methylphenyl)ethyl]urea	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7856	N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N2-(3-methylbutanoyl)-L-leucinamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7857	tert-butyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7858	benzyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7859	benzyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-1-oxohexan-2-yl]carbamate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7860	benzyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7861	Benzyl [(2S,3R)-1-({(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}amino)-3-methyl-1-oxo-2-pentanyl]carbamate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7862	benzyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]carbamate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7863	benzyl N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7864	(2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-4-methyl-2-[(2-phenylacetyl)amino]pentanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7865	(2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[[2-(4-methoxyphenyl)acetyl]amino]-4-methylpentanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7866	(2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[3-(4-methoxyphenyl)propanoylamino]-4-methylpentanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7867	N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N2-[3-(3-pyridinyl)propanoyl]-L-leucinamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7868	N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N~2~-[(2E)-3-phenyl-2-propenoyl]-L-leucinamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7869	N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N~2~-[(2E)-3-(4-methoxyphenyl)-2-propenoyl]-L-leucinamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7870	N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N~2~-[(2E)-3-(3,4-dimethoxyphenyl)-2-propenoyl]-L-leucinamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7871	(2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-4-methyl-2-[(2-phenoxyacetyl)amino]pentanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7872	N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N~2~-[(4-methoxyphenoxy)acetyl]-L-leucinamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7873	(2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[[2-(4-hydroxyphenoxy)acetyl]amino]-4-methylpentanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7874	N-{(2S)-1-(1,3-Benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-N~2~-{[3-(dimethylamino)phenoxy]acetyl}-L-leucinamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7875	(2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[[2-(4-methoxyanilino)acetyl]amino]-4-methylpentanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7876	(2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[[2-(3-methoxyanilino)acetyl]amino]-4-methylpentanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7877	(2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-2-[[2-(2-methoxyanilino)acetyl]amino]-4-methylpentanamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease (50 %)	NA	23747811
DrugRepV_7878	benzyl N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]-1-(5-phenyl-1,3-thiazol-2-yl)propan-2-yl]amino]pentan-2-yl]carbamate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7879	N~2~-[(Benzyloxy)carbonyl]-N-{(2S)-1-[5-(4-methylphenyl)-1,3-thiazol-2-yl]-1-oxo-3-[(3S)-2-oxo-3-pyrrolidinyl]-2-propanyl}-L-leucinamide	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7880	benzyl N-[(2S)-1-[[(2S)-1-[5-(4-methoxyphenyl)-1,3-thiazol-2-yl]-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7881	benzyl N-[(2S)-1-[[(2S)-1-[5-(2-methoxyphenyl)-1,3-thiazol-2-yl]-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	Fluorometric protease inhibitory assay	Decrease	NA	23747811
DrugRepV_7882	5-chloropyridin-3-yl 5-(4-chlorophenyl)oxolane-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7883	5-chloropyridin-3-yl 5-(4-nitrophenyl)oxolane-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7884	5-chloropyridin-3-yl 5-(4-chloro-2-nitrophenyl)oxolane-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7885	5-chloropyridin-3-yl 5-(2-nitrophenyl)oxolane-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7886	5-chloropyridin-3-yl 5-(3-nitrophenyl)oxolane-2-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7887	(5-chloropyridin-3-yl) pyridine-4-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7888	(5-chloropyridin-3-yl) pyridine-3-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7889	(5-chloropyridin-3-yl) 4-chlorobenzoate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7890	(5-chloropyridin-3-yl) 2-nitrobenzoate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7891	(5-chloropyridin-3-yl) 3-nitrobenzoate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7892	5-Chloro-3-pyridinyl 1-naphthoate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7893	(5-chloropyridin-3-yl) 2-oxochromene-3-carboxylate	NA	NA	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	NA	17931870
DrugRepV_7895	Rotenone	NA	NA	Lassa virus	NA	NA	GLuc assay	Decrease (50 %)	Vet approved	31786250
DrugRepV_7899	Lycorine	NA	NA	Japanese encephalitis virus	NA		NA	Decrease (50 %)	NA	31871089
DrugRepV_7900	Cephalotaxlen	NA	NA	Japanese encephalitis virus	NA		NA	Decrease (50 %)	NA	31871089
DrugRepV_7901	Schisandrin B	NA	NA	Japanese encephalitis virus	NA		NA	Decrease (50 %)	NA	31871089
DrugRepV_7902	Procyanidin	NA	NA	Japanese encephalitis virus	NA		NA	Decrease (50 %)	NA	31871089
DrugRepV_7903	Emodin	NA	Polycystic Kidney	Japanese encephalitis virus	NA		NA	Decrease (50 %)	Investigational	31871089
DrugRepV_7904	Schisandrin B	NA	NA	Japanese encephalitis virus	NA		NA	Decrease (50 %)	NA	31871089
DrugRepV_7905	RK-33	NA	NA	Dengue virus	New Guinea C		Plaque assay	Decrease (50 %)	NA	31936642
DrugRepV_7906	RK-33	NA	NA	Zika virus	Asian/Cook Islands/2014	NA	Plaque assay	Decrease (50 %)	NA	31936642
DrugRepV_7907	RK-33	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	31936642
DrugRepV_7908	Antimycin A	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7909	Brequinar	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Experimental	31941776
DrugRepV_7910	6-Azauridine	NA	Cancer	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7911	Azaribine	NA	Psoriasis	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7912	Pyrazofurin	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7913	AVN-944	NA	Cancer	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Investigational	31941776
DrugRepV_7914	Mycophenolate mofetil	NA	Organ rejection (immunosuppressants)	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Approved, Investigational	31941776
DrugRepV_7918	Antimycin A	NA	NA	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7919	Brequinar	NA	NA	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	Experimental	31941776
DrugRepV_7920	6-Azauridine	NA	Cancer	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7921	Azaribine	NA	Psoriasis	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7922	Pyrazofurin	NA	NA	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7923	AVN-944	NA	Cancer	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	Investigational	31941776
DrugRepV_7924	Mycophenolate mofetil	NA	Organ rejection (immunosuppressants)	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	Approved, Investigational	31941776
DrugRepV_7926	Antimycin A	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7927	Brequinar	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Experimental	31941776
DrugRepV_7928	6-Azauridine	NA	Cancer	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7929	Azaribine	NA	Psoriasis	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7930	Pyrazofurin	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7931	AVN-944	NA	Cancer	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Investigational	31941776
DrugRepV_7932	Mycophenolate mofetil	NA	Organ rejection (immunosuppressants)	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Approved, Investigational	31941776
DrugRepV_7934	Antimycin A	NA	NA	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7935	Brequinar	NA	NA	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	Experimental	31941776
DrugRepV_7936	6-Azauridine	NA	Cancer	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7937	Azaribine	NA	Psoriasis	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7938	Pyrazofurin	NA	NA	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7939	AVN-944	NA	Cancer	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	Investigational	31941776
DrugRepV_7940	Mycophenolate mofetil	NA	Organ rejection (immunosuppressants)	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	Approved, Investigational	31941776
DrugRepV_7942	DHBNH	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7943	3-[(E)-{[(3,4-dihydroxyphenyl)formamido]imino}methyl]-[1,1'-biphenyl]-4-carboxylic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7944	(3E)-3-{2-[4-(3,4-dihydroxyphenyl)-1,3-thiazol-2-yl]hydrazin-1-ylidene}-2,3-dihydro-1H-indol-2-one	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7945	4-[2-[(2-hydroxy-1H-indol-3-yl)diazenyl]-1,3-thiazol-4-yl]benzonitrile	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7946	NSC727447	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7947	NSC732665	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7948	2-(3,4-Dihydroxyphenyl)-1,5,6,7,8,9-hexahydro-4H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7949	2-(3,4-dihydroxybenzamido)-N-(pyridin-2-yl)-4H,5H,6H,7H,8H-cyclohepta[b]thiophene-3-carboxamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7950	5-(3,4-dihydroxyphenyl)-4-oxa-8-thia-6-azatricyclo[7.4.0.0²,?]trideca-1(9),2(7),5,10,12-pentaen-3-one	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7951	(E)-3-(3,4-dihydroxyphenyl)-N-[(Z)-octadec-9-enyl]prop-2-enamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7952	4-Butoxy-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7953	4-Butyl-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7954	4-butyl-N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7955	2-fluoro-N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7956	N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-4-nitrobenzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7957	4-amino-N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7958	3,4-dimethoxy-N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7959	3,4-dihydroxy-N-{5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7960	2-fluoro-N-{7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7961	N-{7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-4-nitrobenzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7962	4-amino-N-{7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7963	3,4-dimethoxy-N-{7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7964	3,4-dihydroxy-N-{7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7965	4-butyl-N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7966	N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-2-fluorobenzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7967	N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-4-nitrobenzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7968	4-amino-N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7969	N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-3,4-dimethoxybenzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7970	N-{5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-3,4-dihydroxybenzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7971	N-{5,7-diphenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-3,4-dihydroxybenzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7972	N-[7-(3,4-dihydroxyphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7973	N-benzoyl-N-[7-(3,4-dimethoxyphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]benzamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7974	N-(3,4-dihydroxyphenyl)-5-methyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7975	N-(3,4-dihydroxyphenyl)-7-methyl-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	32151066
DrugRepV_7988	2-(6-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}-4-(2-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}ethyl)-4-nitrohexanamido)-3-(2-phenyl-1H-indol-3-yl)propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7989	2-[6-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(2-fluorophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7990	2-[6-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-nitrophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7991	3-[2-(4-bromophenyl)-1H-indol-3-yl]-2-[6-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)-4-[2-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)ethyl]-4-nitrohexanamido]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7992	2-{6-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}-3-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7993	2-[6-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-methoxyphenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7994	3-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7995	4-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7996	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7997	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7998	4-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_7999	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8000	3-(1-benzyl-1H-indol-3-yl)-2-(6-{[2-(1-benzyl-1H-indol-3-yl)-1-carboxyethyl]carbamoyl}-4-(2-{[2-(1-benzyl-1H-indol-3-yl)-1-carboxyethyl]carbamoyl}ethyl)-4-nitrohexanamido)propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8001	2-{6-[(1-carboxy-2-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}-3-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8002	4-{[3-(2-carboxy-2-{6-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}ethyl)-1H-indol-1-yl]methyl}benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8003	4-[(3-{2-carboxy-2-[3-(3-{2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}-2,2-bis({2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}methyl)propoxy)propanamido]ethyl}-1H-indol-1-yl)me	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8004	2-(6-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}-4-(2-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}ethyl)-4-nitrohexanamido)-3-(2-phenyl-1H-indol-3-yl)propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8005	2-[6-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(2-fluorophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8006	2-[6-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-nitrophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8007	3-[2-(4-bromophenyl)-1H-indol-3-yl]-2-[6-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)-4-[2-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)ethyl]-4-nitrohexanamido]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8008	2-{6-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}-3-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8009	2-[6-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-methoxyphenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8010	3-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8011	4-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8012	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8013	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8014	4-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8015	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8016	3-(1-benzyl-1H-indol-3-yl)-2-(6-{[2-(1-benzyl-1H-indol-3-yl)-1-carboxyethyl]carbamoyl}-4-(2-{[2-(1-benzyl-1H-indol-3-yl)-1-carboxyethyl]carbamoyl}ethyl)-4-nitrohexanamido)propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8017	2-{6-[(1-carboxy-2-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}-3-{1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}propanoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8018	4-{[3-(2-carboxy-2-{6-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}ethyl)-1H-indol-1-yl]methyl}benzoic acid	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8019	4-[(3-{2-carboxy-2-[3-(3-{2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}-2,2-bis({2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}methyl)propoxy)propanamido]ethyl}-1H-indol-1-yl)me	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31809045
DrugRepV_8020	2-(6-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}-4-(2-{[1-carboxy-2-(2-phenyl-1H-indol-3-yl)ethyl]carbamoyl}ethyl)-4-nitrohexanamido)-3-(2-phenyl-1H-indol-3-yl)propanoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8021	2-[6-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(2-fluorophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(2-fluorophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8022	2-[6-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-nitrophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8023	3-[2-(4-bromophenyl)-1H-indol-3-yl]-2-[6-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)-4-[2-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)ethyl]-4-nitrohexanamido]propanoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8024	2-{6-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]-4-{2-[(1-carboxy-2-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}ethyl)carbamoyl]ethyl}-4-nitrohexanamido}-3-{2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl}propanoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8025	2-[6-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-methoxyphenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8026	3-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8027	4-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8028	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8029	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8030	4-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8031	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8032	4-[(3-{2-carboxy-2-[3-(3-{2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}-2,2-bis({2-[(1-carboxy-2-{1-[(4-carboxyphenyl)methyl]-1H-indol-3-yl}ethyl)carbamoyl]ethoxy}methyl)propoxy)propanamido]ethyl}-1H-indol-1-yl)me	NA	NA	Enterovirus	BrCr		NA	Decrease (50 %)	NA	31809045
DrugRepV_8033	2-[6-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(4-nitrophenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]-3-[2-(4-nitrophenyl)-1H-indol-3-yl]propanoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (90 %)	NA	31809045
DrugRepV_8034	3-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (90 %)	NA	31809045
DrugRepV_8035	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (90 %)	NA	31809045
DrugRepV_8036	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (90 %)	NA	31809045
DrugRepV_8037	4-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(4-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	BrCr		NA	Decrease (90 %)	NA	31809045
DrugRepV_8038	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Enterovirus	BrCr		NA	Decrease (90 %)	NA	31809045
DrugRepV_8039	MADAL-385	NA	NA	Enterovirus	11316		NA	Decrease (50 %)	NA	31809045
DrugRepV_8040	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Enterovirus	11316		NA	Decrease (50 %)	NA	31809045
DrugRepV_8041	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	11316		NA	Decrease (50 %)	NA	31809045
DrugRepV_8042	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Enterovirus	11316		NA	Decrease (50 %)	NA	31809045
DrugRepV_8043	MADAL-385	NA	NA	Enterovirus	TW/70902/08		NA	Decrease (50 %)	NA	31809045
DrugRepV_8044	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Enterovirus	TW/70902/08		NA	Decrease (50 %)	NA	31809045
DrugRepV_8045	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	TW/70902/08		NA	Decrease (50 %)	NA	31809045
DrugRepV_8046	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Enterovirus	TW/70902/08		NA	Decrease (50 %)	NA	31809045
DrugRepV_8047	MADAL-385	NA	NA	Enterovirus	H08300 461; 812		NA	Decrease (50 %)	NA	31809045
DrugRepV_8048	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Enterovirus	H08300 461; 812		NA	Decrease (50 %)	NA	31809045
DrugRepV_8049	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	H08300 461; 812		NA	Decrease (50 %)	NA	31809045
DrugRepV_8050	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Enterovirus	H08300 461; 812		NA	Decrease (50 %)	NA	31809045
DrugRepV_8051	MADAL-385	NA	NA	Enterovirus	TW/1956/05		NA	Decrease (50 %)	NA	31809045
DrugRepV_8052	5-(3-{2-carboxy-2-[6-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)-4-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethyl]-4-nitrohexanamido]ethyl}-1H-indol-2-yl)benzene-1,3-dicarboxylic acid	NA	NA	Enterovirus	TW/1956/05		NA	Decrease (50 %)	NA	31809045
DrugRepV_8053	3-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3-carboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzoic acid	NA	NA	Enterovirus	TW/1956/05		NA	Decrease (50 %)	NA	31809045
DrugRepV_8054	5-{3-[2-carboxy-2-(3-{3-[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]-2,2-bis({[2-({1-carboxy-2-[2-(3,5-dicarboxyphenyl)-1H-indol-3-yl]ethyl}carbamoyl)ethoxy]methyl})propoxy}propanamido)ethyl]-1H-indol-2-yl}benzene-1	NA	NA	Enterovirus	TW/1956/05		NA	Decrease (50 %)	NA	31809045
DrugRepV_8055	4-{[6-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8056	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8057	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8058	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8059	4-{[6-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8060	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8061	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8062	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8063	4-{[6-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8064	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8065	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8066	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8067	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8068	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8069	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8070	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8071	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8072	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8073	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8074	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8075	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-hydroxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8076	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-nitroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8077	4-{[7-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8078	4-{[7-chloro-4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8079	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8080	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8081	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8082	4-{[4-({2-amino-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-methylphenyl}amino)-7-chloroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8083	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8084	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8085	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8086	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8087	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8088	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		NA	Decrease (50 %)	NA	31599568
DrugRepV_8089	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8090	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8091	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8092	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8093	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8094	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8095	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8096	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8097	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-hydroxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8098	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-nitroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8099	4-{[7-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8100	4-{[7-chloro-4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8101	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8102	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8103	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8104	4-{[4-({2-amino-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-methylphenyl}amino)-7-chloroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8105	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8106	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8107	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8108	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8109	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8110	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	E138K		NA	Decrease (50 %)	NA	31599568
DrugRepV_8111	4-{[6-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8112	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8113	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8114	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8115	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)-6-fluoroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8116	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8117	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8118	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-methoxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8119	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-hydroxyquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8120	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)-6-nitroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8121	4-{[7-chloro-4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8122	4-{[7-chloro-4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8123	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8124	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8125	4-{[7-chloro-4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8126	4-{[4-({2-amino-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-methylphenyl}amino)-7-chloroquinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8127	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-dimethylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8128	4-{[4-({2,6-dichloro-4-[(1E)-2-cyanoeth-1-en-1-yl]phenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8129	4-{[4-({2-chloro-4-[(1E)-2-cyanoeth-1-en-1-yl]-6-fluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8130	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2,6-difluorophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8131	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-fluoro-6-methylphenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8132	4-{[4-({4-[(1E)-2-cyanoeth-1-en-1-yl]-2-methyl-6-nitrophenyl}amino)quinazolin-2-yl]amino}benzonitrile	NA	NA	Human immunodeficiency virus	K103N		NA	Decrease (50 %)	NA	31599568
DrugRepV_8133	StemRegenin 1	NA	NA	Vaccinia virus	NA		NA	Decrease (68.1 %)	NA	32708182
DrugRepV_8135	ICG-001	NA	NA	Vaccinia virus	NA		NA	Decrease (80.9 %)	NA	32708182
DrugRepV_8137	NSC 319726	NA	NA	Vaccinia virus	NA		NA	Decrease (99.8 %)	NA	32708182
DrugRepV_8139	RITA	NA	Cancer	Vaccinia virus	NA		NA	Decrease (50.2 %)	NA	32708182
DrugRepV_8143	Monensin sodium salt	NA	NA	Vaccinia virus	NA		NA	Decrease (96.7 %)	Experimental, Vet approved	32708182
DrugRepV_8145	3-Deazaneplanocin A	NA	NA	Vaccinia virus	NA		NA	Decrease (76.8 %)	NA	32708182
DrugRepV_8148	Azaguanine-8	NA	NA	Vaccinia virus	NA		NA	Decrease (12.7 %)	Experimental	32708182
DrugRepV_8149	Cytarabine	NA	Leukemia	Vaccinia virus	NA		NA	Decrease (99.8 %)	Approved	32708182
DrugRepV_8151	Cyclocytidine Hydrochloride	NA	NA	Vaccinia virus	NA		NA	Decrease (99.8 %)	NA	32708182
DrugRepV_8156	Triapine	NA	Leukemia, Lung Cancer, Kidney Cancer, Prostate Cancer, and Pancreatic Cancer	Vaccinia virus	NA		NA	Decrease (99.9 %)	Investigational	32708182
DrugRepV_8158	Apigenin	NA	NA	Vaccinia virus	NA		NA	Decrease (54.8 %)	Experimental	32708182
DrugRepV_8159	Avasimibe	NA	Peripheral vascular disease	Vaccinia virus	NA		NA	Decrease (50.9 %)	Investigational	32708182
DrugRepV_8160	Cyclosporin A	NA	Bone marrow transplant rejection	Vaccinia virus	NA		NA	Decrease (67.2 %)	Approved, Investigational, Vet approved	32708182
DrugRepV_8161	ML130	NA	NA	Vaccinia virus	NA		NA	Decrease (35.9 %)	NA	32708182
DrugRepV_8162	PAC-1	NA	Lymphoma, Melanoma, Solid Tumors, Breast Cancer, and Thoracic Cancers	Vaccinia virus	NA		NA	Decrease (95.5 %)	Investigational	32708182
DrugRepV_8163	ABT-263	NA	Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies	Vaccinia virus	NA		NA	Decrease (33.1 %)	Investigational	32708182
DrugRepV_8164	ABT-737	NA	NA	Vaccinia virus	NA		NA	Decrease (26.6 %)	NA	32708182
DrugRepV_8165	PF-2545920	NA	NA	Vaccinia virus	NA		NA	Decrease (33.7 %)	NA	32708182
DrugRepV_8168	TPCA-1	NA	NA	Vaccinia virus	NA		NA	Decrease (78.5 %)	NA	32708182
DrugRepV_8170	PTC-209	NA	NA	Vaccinia virus	NA		NA	Decrease (90.7 %)	NA	32708182
DrugRepV_8171	Selisistat	NA	NA	Vaccinia virus	NA		NA	Decrease (30.5 %)	NA	32708182
DrugRepV_8172	Salinomycin	NA	NA	Vaccinia virus	NA		NA	Decrease (92.5 %)	Vet approved	32708182
DrugRepV_8173	Dapivirine	NA	Acquired immunodeficiency syndrome	Vaccinia virus	NA		NA	Decrease (41.7 %)	Investigational	32708182
DrugRepV_8174	CCG 50014	NA	NA	Vaccinia virus	NA		NA	Decrease (35.8 %)	NA	32708182
DrugRepV_8175	Mocetinostat	NA	Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma	Vaccinia virus	NA		NA	Decrease (46.9 %)	Investigational	32708182
DrugRepV_8177	UK 383367	NA	NA	Vaccinia virus	NA		NA	Decrease (17 %)	NA	32708182
DrugRepV_8178	Lonafarnib	NA	Solid tumors, leukemia (unspecified), and lung cancer	Vaccinia virus	NA		NA	Decrease (36.2 %)	Investigational	32708182
DrugRepV_8179	BX-912	NA	NA	Vaccinia virus	NA		NA	Decrease (42.3 %)	NA	32708182
DrugRepV_8180	URB597	NA	NA	Vaccinia virus	NA		NA	Decrease (21.7 %)	NA	32708182
DrugRepV_8181	Anagrelide HCl	NA	NA	Vaccinia virus	NA		NA	Decrease (58.4 %)	NA	32708182
DrugRepV_8185	Ganetespib	NA	BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome	Vaccinia virus	NA		NA	Decrease (99.7 %)	Investigational	32708182
DrugRepV_8186	PF-04929113	NA	Cancer/tumors	Vaccinia virus	NA		NA	Decrease (99.4 %)	Investigational	32708182
DrugRepV_8187	NMS-E973	NA	NA	Vaccinia virus	NA		NA	Decrease (99.1 %)	NA	32708182
DrugRepV_8188	XL888	NA	NA	Vaccinia virus	NA		NA	Decrease (99.6 %)	NA	32708182
DrugRepV_8189	Tanespimycin	NA	Leukemia (myeloid) and solid tumors.	Vaccinia virus	NA		NA	Decrease (99.4 %)	Investigational	32708182
DrugRepV_8190	VER-49009	NA	NA	Vaccinia virus	NA		NA	Decrease (98.9 %)	NA	32708182
DrugRepV_8191	SNX2112	NA	NA	Vaccinia virus	NA		NA	Decrease (99.4 %)	NA	32708182
DrugRepV_8192	BIIB021	NA	Tumors and Lymphoma	Vaccinia virus	NA		NA	Decrease (99.8 %)	Investigational	32708182
DrugRepV_8194	NVP-BEP800	NA	NA	Vaccinia virus	NA		NA	Decrease (98.8 %)	NA	32708182
DrugRepV_8195	AUY922	NA	Lymphoma, Breast Cancer, Metastatic Disease, Advanced Solid Tumors, and Hematologic Neoplasms	Vaccinia virus	NA		NA	Decrease (99.8 %)	Investigational	32708182
DrugRepV_8196	KW-2478	NA	NA	Vaccinia virus	NA		NA	Decrease (92.7 %)	NA	32708182
DrugRepV_8198	ABT-751	NA	Lung Cancer	Vaccinia virus	NA		NA	Decrease (81.5 %)	Investigational	32708182
DrugRepV_8199	Epothilone A	NA	NA	Vaccinia virus	NA		NA	Decrease (27.3 %)	NA	32708182
DrugRepV_8200	Amygdalin	NA	NA	Vaccinia virus	NA		NA	Decrease (58.3 %)	NA	32708182
DrugRepV_8201	Kaempferol	NA	NA	Vaccinia virus	NA		NA	Decrease (64.7 %)	NA	32708182
DrugRepV_8202	ENMD-2076	NA	Breast cancer, leukemia (unspecified), lung cancer, and solid tumors	Vaccinia virus	NA		NA	Decrease (72.3 %)	Investigational	32708182
DrugRepV_8203	AMG-900	NA	NA	Vaccinia virus	NA		NA	Decrease (50.4 %)	NA	32708182
DrugRepV_8204	MLN8054	NA	Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies	Vaccinia virus	NA		NA	Decrease (36.2 %)	Investigational	32708182
DrugRepV_8205	Ibrutinib	NA	Mantle cell lymphoma	Vaccinia virus	NA		NA	Decrease (74.9 %)	Approved	32708182
DrugRepV_8206	CNX-774	NA	NA	Vaccinia virus	NA		NA	Decrease (70 %)	NA	32708182
DrugRepV_8207	AR-A014418	NA	NA	Vaccinia virus	NA		NA	Decrease (47.9 %)	Experimental	32708182
DrugRepV_8208	CGP 57380	NA	NA	Vaccinia virus	NA		NA	Decrease (58.1 %)	NA	32708182
DrugRepV_8210	HMN-214	NA	NA	Vaccinia virus	NA		NA	Decrease (58.9 %)	NA	32708182
DrugRepV_8211	TG003	NA	NA	Vaccinia virus	NA		NA	Decrease (46.7 %)	NA	32708182
DrugRepV_8212	Skepinone-L	NA	NA	Vaccinia virus	NA		NA	Decrease (47.1 %)	NA	32708182
DrugRepV_8213	TAK-632	NA	NA	Vaccinia virus	NA		NA	Decrease (65.2 %)	NA	32708182
DrugRepV_8214	YM201636	NA	NA	Vaccinia virus	NA		NA	Decrease (56.3 %)	NA	32708182
DrugRepV_8215	MK-2461	NA	NA	Vaccinia virus	NA		NA	Decrease (57 %)	NA	32708182
DrugRepV_8217	SP600125	NA	NA	Vaccinia virus	NA		NA	Decrease (50.5 %)	NA	32708182
DrugRepV_8218	SKI II	NA	NA	Vaccinia virus	NA		NA	Decrease (65.1 %)	NA	32708182
DrugRepV_8219	PKI-402	NA	NA	Vaccinia virus	NA		NA	Decrease (44.9 %)	NA	32708182
DrugRepV_8220	BEZ235	NA	Cancer, Solid Tumor, Renal Cancer, Breast Cancer, and Cowden Syndrome	Vaccinia virus	NA		NA	Decrease (37.4 %)	Investigational	32708182
DrugRepV_8221	WYE-125132	NA	NA	Vaccinia virus	NA		NA	Decrease (67.6 %)	NA	32708182
DrugRepV_8222	OSI-027	NA	NA	Vaccinia virus	NA		NA	Decrease (68.3 %)	Investigational	32708182
DrugRepV_8223	Torin 1	NA	NA	Vaccinia virus	NA		NA	Decrease (57.3 %)	NA	32708182
DrugRepV_8224	Ku-0063794	NA	NA	Vaccinia virus	NA		NA	Decrease (55.3 %)	NA	32708182
DrugRepV_8225	AZD2014	NA	Advanced Gastric Adenocarcinoma	Vaccinia virus	NA		NA	Decrease (70.3 %)	Investigational	32708182
DrugRepV_8228	KX2-391	NA	Colon cancer | Pancreatic cancer | Prostate cancer | Breast cancer	Vaccinia virus	NA		NA	Decrease (65.1 %)	Investigational	32708182
DrugRepV_8230	PP1	NA	NA	Vaccinia virus	NA		NA	Decrease (35.8 %)	NA	32708182
DrugRepV_8231	AZ 960	NA	NA	Vaccinia virus	NA		NA	Decrease (82.1 %)	NA	32708182
DrugRepV_8232	LY2784544	NA	Myelofibrosis, Polycythemia Vera, Primary Myelofibrosis, Thrombocythemia, Essential, and Myeloproliferative Disorders	Vaccinia virus	NA		NA	Decrease (65.7 %)	Investigational	32708182
DrugRepV_8233	WHI-P154	NA	NA	Vaccinia virus	NA		NA	Decrease (66.3 %)	NA	32708182
DrugRepV_8234	Cyt387	NA	Polycythemia Vera, Primary Myelofibrosis, Post-Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis (PMF)	Vaccinia virus	NA		NA	Decrease (45.2 %)	Investigational	32708182
DrugRepV_8235	KPT-276	NA	NA	Vaccinia virus	NA		NA	Decrease (27.6 %)	NA	32708182
DrugRepV_8236	KPT-185	NA	NA	Vaccinia virus	NA		NA	Decrease (26.2 %)	NA	32708182
DrugRepV_8237	Phloretin	NA	NA	Vaccinia virus	NA		NA	Decrease (-27 %)	Experimental	32708182
DrugRepV_8242	SC144	NA	NA	Vaccinia virus	NA		NA	Decrease (98.4 %)	NA	32708182
DrugRepV_8243	Daidzein	NA	Dietary supplement	Vaccinia virus	NA		NA	Decrease (32.2 %)	Experimental	32708182
DrugRepV_8244	Delanzomib	NA	Solid Tumors, Multiple Myeloma, and Lymphoma, Non-Hodgkin.	Vaccinia virus	NA		NA	Decrease (99.7 %)	Investigational	32708182
DrugRepV_8245	MLN9708	NA	Multiple myeloma	Vaccinia virus	NA		NA	Decrease (99.6 %)	Approved, Investigational	32708182
DrugRepV_8246	Oprozomib	NA	NA	Vaccinia virus	NA		NA	Decrease (99.5 %)	Investigational	32708182
DrugRepV_8247	MG-132	NA	NA	Vaccinia virus	NA		NA	Decrease (98.9 %)	NA	32708182
DrugRepV_8248	MLN2238	NA	Multiple myeloma	Vaccinia virus	NA		NA	Decrease (99.7 %)	Approved, Investigational	32708182
DrugRepV_8249	ONX-0914	NA	NA	Vaccinia virus	NA		NA	Decrease (99.5 %)	NA	32708182
DrugRepV_8250	Amonafide	NA	Breast cancer, ovarian cancer, and prostate cancer	Vaccinia virus	NA		NA	Decrease (99.3 %)	Investigational	32708182
DrugRepV_8253	Golvatinib	NA	Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck	Vaccinia virus	NA		NA	Decrease (79.8 %)	Investigational	32708182
DrugRepV_8255	AG 1296	NA	NA	Vaccinia virus	NA		NA	Decrease (53.2 %)	NA	32708182
DrugRepV_8256	NVP-TAE226	NA	NA	Vaccinia virus	NA		NA	Decrease (91.5 %)	NA	32708182
DrugRepV_8257	Cabozantinib malate	NA	Metastatic medullary thyroid cancer	Vaccinia virus	NA		NA	Decrease (79.3 %)	NA	32708182
DrugRepV_8258	XL-184	NA	Thyroid cancer	Vaccinia virus	NA		NA	Decrease (64.2 %)	Approved, Investigational	32708182
DrugRepV_8259	Linifanib	NA	NA	Vaccinia virus	NA		NA	Decrease (60.5 %)	NA	32708182
DrugRepV_8260	TKI-258	NA	Multiple myeloma and solid tumors	Vaccinia virus	NA		NA	Decrease (67.6 %)	Investigational	32708182
DrugRepV_8261	AZD4547	NA	Cancer	Vaccinia virus	NA		NA	Decrease (81.5 %)	Investigational	32708182
DrugRepV_8262	AG-1024	NA	NA	Vaccinia virus	NA		NA	Decrease (71.8 %)	NA	32708182
DrugRepV_8263	BMS-754807	NA	Solid Tumors	Vaccinia virus	NA		NA	Decrease (61.8 %)	Investigational	32708182
DrugRepV_8265	Butein	NA	NA	Vaccinia virus	NA		NA	Decrease (62.6 %)	NA	32708182
DrugRepV_8266	CO-1686 (AVL-301)	NA	Nonsmall Cell Lung Cancer, Non-small Cell Lung Cancer, and Locally Advanced or Metastatic Non-small Cell Lung Cancer	Vaccinia virus	NA		NA	Decrease (74.3 %)	NA	32708182
DrugRepV_8267	PD168393	NA	NA	Vaccinia virus	NA		NA	Decrease (67.2 %)	Experimental	32708182
DrugRepV_8268	PD153035 HCl	NA	NA	Vaccinia virus	NA		NA	Decrease (74.7 %)	NA	32708182
DrugRepV_8270	Desmethyl Erlotinib	NA	Cancer	Vaccinia virus	NA		NA	Decrease (75.5 %)	Approved, Investigational	32708182
DrugRepV_8271	OSI-420	NA	NA	Vaccinia virus	NA		NA	Decrease (46.7 %)	NA	32708182
DrugRepV_8274	WZ8040	NA	NA	Vaccinia virus	NA		NA	Decrease (96.4 %)	NA	32708182
DrugRepV_8282	1-(2-fluorophenyl)-3-(4-(4-isopentyl-1H-1,2,3-triazol-1-yl)phenyl)urea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8283	1-(3-fluorophenyl)-3-(4-(4-isopentyl-1H-1,2,3-triazol-1-yl)phenyl)urea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8284	1-(4-(4-(ethoxymethyl)-1H-1,2,3-triazol-1-yl)phenyl)-3-(3-fluorophenyl)urea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8285	1-(3-fluorophenyl)-3-(4-(4-(3-oxobutyl)-1H-1,2,3-triazol-1-yl)phenyl)urea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8286	1-(4-(4-butyl-1H-1,2,3-triazol-1-yl)phenyl)-3-(3-fluorophenyl)urea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8287	N-(2-(3-(4-(4-butyl-1H-1,2,3-triazol-1-yl)phenyl)ureido)phenyl)methanesulfonamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8288	1-(4-(4-isopentyl-1H-1,2,3-triazol-1-yl)phenyl)-3-o-tolylurea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8289	1-(4-(4-hexyl-1H-1,2,3-triazol-1-yl)phenyl)-3-(2-(trifluoromethyl)phenyl)urea)	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8290	3-(4-(ethoxymethyl)-1H-1,2,3-triazol-1-yl)-N-(2-morpholinophenyl)benzenesulfonamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8291	ethyl 3-((3-(4-(ethoxymethyl)-1H-1,2,3-triazol-1-yl)phenyl)sulfonamido)benzoate	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8292	3-((3-(4-(ethoxymethyl)-1H-1,2,3-triazol-1-yl)phenyl)sulfonamido)benzoic acid	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8293	3-(4-butyl-1H-1,2,3-triazol-1-yl)-N-(2-(methylsulfonamido)phenyl)benzenesulfonamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8315	Tenatoprazole	NA	NA	Human immunodeficiency virus	NA		Western blot	Decrease (50 %)	NA	32132561
DrugRepV_8317	Roscovitine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31866007
DrugRepV_8318	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Investigational	31866007
DrugRepV_8319	Kenpaullone	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31866007
DrugRepV_8320	SB743921	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31866007
DrugRepV_8321	3-Deazauridine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31866007
DrugRepV_8322	2’-C-Methylcytidine	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	31866007
DrugRepV_8323	Alisporivir	NA	Hepatitis C virus	SARS Coronavirus-2	Experimental	NA	Viral RNA reduction assay	Decrease (50 %)	Investigational	32376613
DrugRepV_8324	Alisporivir	NA	Hepatitis C virus	SARS Coronavirus-2	Experimental	NA	Viral RNA reduction assay	Decrease (90 %)	Investigational	32376613
DrugRepV_8327	4-ethynyl-2-fluoro-2-deoxyadenosine	NA	NA	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	32429580
DrugRepV_8328	Alovudine	NA	HIV	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	32429580
DrugRepV_8329	5-O-(12-thioethydodecanoyl)FLT	NA	NA	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	32429580
DrugRepV_8331	5-O-(tetradecanoyl)3TC	NA	NA	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	32429580
DrugRepV_8333	5-O-(tetradecanoyl)FTC	NA	NA	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	32429580
DrugRepV_8335	Nafamostat	NA	Blood vessel coagulation | Hemorrhagic lesions	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Investigational	32596694
DrugRepV_8337	Gabexate	NA	Cancer, ischemia-reperfusion injury, and pancreatitis	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Investigational	32596694
DrugRepV_8339	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8340	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8341	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8342	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8343	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8344	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8345	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8346	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8347	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8348	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8349	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8350	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8351	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8352	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8353	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8354	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8355	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8356	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8357	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8358	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8359	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8360	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8361	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8362	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8363	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8364	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8365	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8366	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8367	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8368	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8369	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8370	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8371	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8372	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8373	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8374	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8375	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8376	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8377	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8378	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8379	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8380	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8381	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8382	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8383	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8384	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8385	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8386	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8387	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8388	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8389	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8390	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8391	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8392	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8393	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8394	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8395	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8396	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8397	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8398	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8399	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8400	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8401	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8402	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8403	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8404	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8405	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8406	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8407	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8408	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8409	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8410	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8411	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8412	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8413	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8414	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8415	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8416	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8417	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8418	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8419	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8420	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8421	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8422	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8423	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8424	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8425	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8426	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8427	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8428	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8429	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8430	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8431	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8432	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8433	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8434	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8435	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8436	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8437	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8438	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8439	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8440	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8441	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8442	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8443	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8444	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8445	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8446	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8447	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8448	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8449	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8450	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8456	Berberine Chloride	NA	NA	Zika virus	NA	NA	NA	Decrease (50 %)	NA	29844387
DrugRepV_8457	Berberine	NA	Parasitic and fungal infection	Zika virus	NA	NA	Plaque assay	Decrease (50 %)	Approved	30641880
DrugRepV_8458	Emodin	NA	Polycystic Kidney	Zika virus	NA	NA	Plaque assay	Decrease (50 %)	Investigational	30641880
DrugRepV_8459	Berberine	NA	Parasitic and fungal infection	Enterovirus	H	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28081706
DrugRepV_8460	Berberine	NA	Parasitic and fungal infection	Enterovirus	SHZH98	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28081706
DrugRepV_8461	Berberine	NA	Parasitic and fungal infection	Enterovirus	JS-52	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28081706
DrugRepV_8462	Berberine	NA	Parasitic and fungal infection	Enterovirus	BrCr	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28081706
DrugRepV_8463	Pirodavir	NA	Picronavirus infection	Enterovirus	H	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	28081706
DrugRepV_8464	Pirodavir	NA	Picronavirus infection	Enterovirus	SHZH98	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	28081706
DrugRepV_8465	Pirodavir	NA	Picronavirus infection	Enterovirus	JS-52	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	28081706
DrugRepV_8466	Pirodavir	NA	Picronavirus infection	Enterovirus	BrCr	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	28081706
DrugRepV_8467	Berberine	NA	Parasitic and fungal infection	Influenza virus	NA		XTT assay	Decrease (50 %)	Approved	32245183
DrugRepV_8468	Berberine	NA	Parasitic and fungal infection	Influenza virus	NA		XTT assay	Decrease (50 %)	Approved	32245183
DrugRepV_8469	Berberine	NA	Parasitic and fungal infection	Influenza virus	NA		XTT assay	Decrease (50 %)	Approved	32245183
DrugRepV_8470	Berberine	NA	Parasitic and fungal infection	Influenza virus	NA		XTT assay	Decrease (50 %)	Approved	32245183
DrugRepV_8471	Berberine	NA	Parasitic and fungal infection	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Approved	21295891
DrugRepV_8472	Berberine	NA	Parasitic and fungal infection	Influenza virus	NA		NA	Decrease (50 %)	Approved	30099043
DrugRepV_8473	Ebselen	NA	Meniere Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Investigational	23850693
DrugRepV_8474	2-Phenylbenzo[d]isothiazol-3(2H)-one	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8475	2-Phenylbenzo[d] isoxazol-3(2H)-one	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8476	2-Phenyl isoindolin-1-one	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8477	Chelerythrine chloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8478	Nitidine chloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8479	Berberine chloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8480	Sanguinarine chloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8481	Norsanguinarine chloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8482	R-Apomorphine hydrochloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8483	S-Apomorphine hydrochloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8484	R(?)-Propylnorapomorphine hydrochloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693
DrugRepV_8485	R(?)-Apocodeine hydrochloride	NA	NA	Human immunodeficiency virus	NA		NA	Decrease (50 %)	NA	23850693